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Preface
This thesis emerged from Paulo Refinetti’s interest in understanding tumor growth. He had done
projects on this topic during his Master’s studies, in particular for his Master’s thesis, supervised
and hosted by Prof. William G. Thilly from MIT. During his stay at MIT Paulo Refinetti learned
key ideas and methods and also was introduced to Dr. Per Ekstrom who would become his
co-supervisor and laboratory host during his Ph.D. studies. After some initial experiments and
wide-ranging discussions, a Ph.D. project focussing on investigating the interaction between
stromal cells and tumor cells was decided on. This interplay is generally believed to play a
major role in cancer growth and progression. His Master’s projects had prepared Paulo Refinetti
for working with mutations both in the theoretical sense of mathematical biology and in the
biological sense of detecting, characterising and quantifying them. Observing the spread of
mutations in mitochondrial DNA is particularly attractive. Because there are many copies of
the mitochondrial DNA present in each cell, the somatic mutational process is accelerated and
it should thus be easier to find tumors with such mutations. Determining the multiplicity of
mitochondrial DNA in cells was one of the questions Paulo Refinetti tackled and it led him to
propose and develop a novel mathematical model for analysing the results of an rtPCR run. The
first part of the thesis describes the adaptation of the CDCE method to human mitochondrial
DNA and resulted in a low cost and highly effective tool. Paulo Refinetti also wrote software
that can automatically analyse and score the output from CDCE runs. The effectiveness was
demonstrated in an application to samples taken from many tumors, a comparison with next
generation sequencing and in two clinical applications. The analysis of tumor samples showed
that in some cases, somatic mutations in mitochondrial DNA that are present in high fractions are
found. The second part of the thesis covers the application to samples taken from tumors. At
the beginning, the traditional method relying on staining was believed to be able to distinguish
stromal cells from tumor cells. This would have allowed to take samples from either source and
score them separately. In the available samples, this turned out to be inconclusive. Taking small
patches of cells that cover the whole of a tumor slice, and thus sample it systematically, turned
out to be a better idea. In tumors, where a mutation in the mitochondrial DNA is present, the
analysis of the patches gives a fairly precise picture of the spatial distribution of the mutation
within the slice. The final step is taken by slicing a three dimensional tumor tissue into layers.
Paulo Refinetti demonstrated the feasibility of this approach and applied it in two examples. The
graphical representation of this data shows the spread of a mutation via the growth of a tumor.
Lausanne, 17 January 2017 Stephan Morgenthaler
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Abstract
Lineage tracing is a basic concept in developmental biology, as well as diseases related to organ
development. A reliable method to track cell lineages in human tissues has the potential to greatly
contribute to the fields of oncogenesis, tissue renewal, ageing as well as wound healing.
Inherited mitochondrial mutations have been a successful tool in the understanding of human
lineage and migrations throughout history. Similarly, somatic mitochondrial mutations have been
used to study the patters of cell division and renewal in some human tissues. Each cell has many
copies of the mitochondrial genome, a mutation can therefore be present in any fraction of the
total number of mitochondrial DNA copies. To study somatic mitochondrial mutations therefore
requires mutations to detected, and the mutant fraction to be quantified. This requirement makes
the use of most sequencing techniques very difficult.
The first step in the development of lineage tracing methods using somatic mtDNA mutations
as a marker, is a quantitative, fast and high throughput detection method. A two step PCR was
designed to amplify first the whole mtDNA in large fragments without nuclear DNA amplification.
Second, a set of small fragments that can be scanned for mutations using cycling temperature
capillary electrophoresis. In the end 76% of the mitochondrial genome could be scanned for
mutations. Test showed that mutations present at a fraction as low as 1% of the total copy numbers
could be detected and accurately quantified. Furthermore, the method could be applied to analyse
micro-anatomical samples taken by laser capture micro dissection.
Lineage tracing in human tumors was achieved by scanning the mitochondrial DNA for mutations
in samples extracted from macro-anatomical samples taken across surgically removed and freshly
frozen tumor pieces. Tumors in which a mutation was detected at a sufficient fraction of the
extracted DNA were finely sampled. The first attempt consisted in taking 286 samples across a
slice of a Leydig cell tumor, in which two separate mutations were identified at a high enough
fraction to justify further investigation. Both mutations strongly correlated suggesting a single
lineage. Since no discernible pattern emerged, the results were validated by taking 96 samples on
another slice of tissue, slightly deeper, and observing that in similar positions, similar mutant
fractions could be reproduced.
The natural evolution was to take multiple successive slices of tissue. On each slice 96 sam-
ples,arranged in an 8× 12 grid are then taken. Analysing the results from 19 layers gave the
three dimensional reconstruction of a tumor lineage in a tissue volume. The results show that the
lineage followed is quite diffused through the volume and does not occupy its majority.
A three dimensional reconstruction of a cell lineage was then established for two more tumors,
and three metastasis. Under the assumption that a metastasis is seeded by a single tumor cell, the
v
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presence of the same mtDNA mutation in both primary tumor and metastasis guarantees that only
cells carrying the mutation are tumor-derived. The three dimensional reconstruction of a primary
tumor lineage through a metastasis is therefore the reconstruction of the patters of metastasis
growth in its host tissue. Observing that most of the metastasis volume is not composed of tumor
derived cells suggests that metastatic cells grow by diffusing through their host tissue, or by
recruiting host organ cells, as well as conditioning them to assume its abnormal morphology.
Lineage tracing in humans has many further applications both inside the field of oncology and
outside. Further study of primary tumor and metastasis will increase the data on the morphology
of tumors growing in their host tissue. A large amount of data might allow the deduction of the
underlying principles governing the tumor-environment relationship. Lineage tracing can also be
applied to the study of other fields such as wound healing or arteriosclerosis. Most importantly, it
has the potential to improve our understanding of human developmental biology.
Key words: Mitochondrial DNA, Lineage Tracing, Cycling Temperature Capillary Electrophore-
sis, Oncogenesis, Metastasis
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Résumé
Le tracement de lignage est un concept de fondamental en biologie du développement ainsi que
dans l’étude des maladies du développent. L’introduction d’une méthode capable d’identifier et
de suivre les lignages cellulaires à l’intérieur de tissu humains bénéficierait l’étude du cancer, de
la cicatrisation ainsi que du vieillissement.
Les mutations mitochondriales héréditaires, ont permis l’étude des migrations humaines au travers
de l’histoire. Un parallèle existe entre les populations humaines dans le monde et les lignages
cellulaires dans un tissu. En faisant ce parallèle, les mutations somatiques mitochondriales, ont
été utilisées pour étudier les mécanismes de divisions cellulaires dans certains organes. Dans
chaque cellule se trouvent plusieurs copies d’ADN mitochondrial. Une mutations, peux donc être
présente dans une, plusieurs, ou toutes les copies d’ADN mitochondriales d’une cellule. Il en
suit, que pour étudier les mutations somatiques mitochondriales, il n’est pas seulement nécessaire
de les détecter, mais de quantifier les fractions auxquels elles sont présentes. Cette contrainte
rend la plupart des techniques de séquençage génétique inutilisables.
Pour permettre l’étude de tracement de lignages en utilisant les mutations somatiques mitochon-
driales come marqueur, a fallut développer une méthode quantitative, rapide et avec un haut
débit. Une PCR en deux étapes a été mise au point pour, dans un premier temps, amplifier
l’ADN mitochondriale dans son ensemble. En un deuxième temps, amplifier une série de petites
séquences optimiser pour l’utilisation de électrophorèse capillaire avec température variable
(CTCE). Cette méthode permet de détecter et quantifier des mutations présentes dans 76% de
l’AND mitochondriale. Des tests de précision ont démontré qu’il est possible de détecter et
quantifier les mutations jusqu’à une fraction de 1%. De plus, il est possible d’analyser des
échantillons difficiles comme ceux prélever par « Laser capture microdissection »
La première étape dans le tracement de lignages dans un un tissu cancéreux est d’identifier
des mutations qui peuvent être utilisées comme marqueur. Pour cela, l’AND extrait de larges
coupes au travers de l’échantillon est étudier pour découvrir telles mutations dans le genome
mitochondrial. L’analyse est poursuite dans les tissu ou une mutations a été trouve. Dans un
premier essai, 286 échantillons micro-anatomiques ont été prélevés sur une coupe histologique
d’un cancer des cellules de Leydig, où 2 mutations de l’AND mitochondrial avaient étés détectées.
Une forte corrélation a été mesurée entre les deux mutations, ce qui indique qu’il existe un seul
lignage. Aucune morphologie n’as pu être reconnue. Pour valider les résultats, 96 échantillons
micro-anatomiques ont donc été prélevé sur une coupe histologique successive du même tissu.
L’étape suivante a été de prendre plusieurs coupes histologiques successives, et de prélever 96
échantillons sur chacune. Les échantillons ont été place selon une grille 8×12, placée, autan que
vii
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possible, au dessus de la précédente. En analysant de cette façon 19 coupes histologiques, il a été
possible d’observer la disposition tridimensionnel d’un lignage à l’intérieur d’un tissu cancéreux.
L’observation de ces résultats montre que le lignage suivit n’occupe qu’une minorité du volume
tumoral total.
De cette façon, une reconstruction tridimensionnel de lignage cancéreux a été réaliser pour deux
autres cancers primaux et 3 métastases. Sous l’hypothèse que les métastases ont pour origine une
seule cellule cancéreuse, la présence de la même mutation mitochondrial dans le cancer primaire
et la métastase garantie que seule les cellules ayant la mutation sont issue du cancer.
Les résultats montre que la majorité du volume des métastases n’est pas composée de cellules
issues du cancer. Il est donc possible de conclure que les métastase grandissent en s’infiltrant
dans le tissu environnante ou en recrutant les cellules de l’organe ou elles se trouvent. En même
temps, les cellules issues du cancer conditionnent les cellules du tissu environnant pour assumer
une morphologie anormal.
L’habilité à tracer des lignages cellulaires a plusieurs applications dans l’études des cancers et
ailleurs. Une succession d’études sur des tumeurs primaires et des métastases a le potentiel
d’élucider comment les tumeurs interagissent avec leur environnement. C’est une technique qui
peut aussi être utilisé pour étudier l’artériosclérose e la cicatrisation. Surtout, c’est une technique
avec laquelle il sera possible de mieux comprendre la biologie du développement.
viii
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1 Introduction
1.1 Motivation
Every organism is, at its beginning a single cell. Development is how this cell divides, differenti-
ates, and ultimately gives rise to a complete organism. Once the organism is born, development
is not finished. The organism must grow, develop new function sometimes, and must self-repair,
renew itself to continue functioning. Sometimes development fails, resulting in death, or dis-
function in the adult organism. To understand these processes is the goal of developmental
biology.
All cells in the human body have a common ancestor. However, at one point during development,
a groups of cells acquire characteristics that sets them apart from others, forming lineages. The
characteristic that identifies a cell lineage and sets it apart from others is a marker. Understanding
the behaviour of cell lineages as they grow to form tissues, is lineage tracing.
Lineage tracing requires the ability to detect the presence of a marker in a tissue, and then
identifying its distribution through the tissue volume. Somatic mitochondrial mutations are
potentially a very good marker for lineage tracing. Distinguishing the cells that carry a mutation
from the others, a cell lineage can be defined. The objective of this thesis was to develop
the methods to use somatic mtDNA mutations as a marker for lineage tracing. This requires
first, the ability to detect the presence of mutations in a tissue volume. Second, to follow the
mutation through the volume and identify areas that are part of the same lineage. Once developed,
these methods will enable lineage tracing in human tissues. In doing so, improve scientific
understanding of human developmental biology and carcinogenesis.
1.2 There are many copies of mitochondrial DNA in each cell
The core proteins of the oxidative phosphorylation chain are synthesised inside the mitochondria,
and encoded in the mitochondrial DNA. Inside each cell, there is a large number of copies of
1
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the mitochondrial DNA. The number seems to vary according to the specific needs of cells. For
example, cardiac muscle cells have roughly 7000 mtDNA copies per cell, twice as many copies
as skeletal muscle cells [1]. Since there are many copies of mtDNA in each cell, a mitochondrial
mutation can be present in only one copy, all copies, or any fraction in between. A mutation
present in all the copies of mtDNA in a cell is called homoplasmic. A mutation that is present in
a fraction of the mtDNA copies in a cell is called heteroplasmic. There are few reliable estimates
of mtDNA copy number in different cell types in humans and the turnover process of mtDNA in
cells is poorly understood [2, 3]. Consequently the process through which mtDNA mutations
arise and reach (or don’t) homoplasmic levels is subject to speculation [4, 5, 2, 6].
1.3 Lineage Tracing
Lineage tracing is the study of the ancestry of the cells composing a multi-cellular organism.
The current understanding of biology is that a single cell gives rise, via multiple divisions
and differentiation steps, to a whole organ, organism or tumor. To investigate this process
we require lineage markers, which are retained in the lineage of an original cell, and can be
followed, or traced back. The earliest lineage marker used was a form of ink [7], which could
be injected directly in cells of a developing embryo. If the embryo is transparent, the ink can be
seen to propagate as the cells divide [7, 8, 9]. This technique has as a first drawback, that ink
concentration decreases as cells divide, resulting in the signal being lost after some generations
of cell division [8]. The second disadvantage is that it requires the embryo to be transparent to
be followed. The organisms to which it can be applied are limited, and include the Xenopus
[7] and the Zebra-fish. From the experiments with ink, the importance of developing perennial
markers, that are not diluted as the cells divide, became apparent. The chimeric organisms
were developed to answer that need. Chimeras were made using similar species of which the
cells could be differentiated under the microscope. One of the best-known historical examples
is the Chick-Quail chimera realized by Waddington [10]. Other examples include mouse-rat
chimera [11, 12]. In these experiments, the different cells from different organism "randomly"
distribute over the lineages of development. The observation of the born animal can then allow
the determinations of common ancestry [8]. Among the major disadvantages of this technique are:
the random distribution of cells in the lineages and the difficulties involved in making chimeras.
With the development of fluorescent proteins (such as GFP), genetically inserted markers rapidly
took the center stage. The expression of fluorescent proteins can be induced in a transgenic
organism. Better understanding of molecular biology has given researchers the possibility of
putting the expression of GFP under the control of specific promoters [13, 14]. Lineage tracing
is then done by assuming that the activity of a transcription factor marks specifically a single
cell lineage, which is often a strong assumption. Consequently ways to increase the selectivity
of the marker’s expression have been developed. A powerful tool is the Cre-Lox system. Cre
recombinase has the ability of recombining together two Lox sites [9, 15, 16, 17]. The activity
of Cre, can itself be put under the simultaneous control of a transcription factor and an external
stimuli. External stimuli include tamoxifen or estrogen [18]. Many comprehensive reviews on
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the subject exist (e.g. Kretzschmar et al. [8]). The important thing about the inducible Cre-Lox
system for gene expression is that it will cause the marker to be constitutively expressed in all
cells, that at the time of external activation, expressed the transcription factor under which the Cre
recombinase expression was put under [9, 19]. This constitutive expression will then be passed
on to all the progeny of that cell. Thus selectively marking the lineage. The descendants of the
marked lineages can then be seen under fluorescence microscopy.
Markers mentioned up to now are an evolution of ink. They all rely on inserting in a group of cells
of interest, something that can be seen later on. It is also possible to decide to follows a marker
that arises spontaneously in cells. These "internal" markers present the great advantage of being
applicable to human studies. Most internal markers are genetic markers. A lot of the development
of internal markers has been motivated by the study of populations. Tracking populations
throughout history is not so different from following stem cells throughout organogenesis. In
both cases, the only available information is the final state, and in both cases there is a common
ancestor a certain number of divisions back. An example of a successful marker is X chromosome
inactivation in women heterozygous for the glucose-6-phosphate dehydrogenase (G6PD) gene.
Two variants of the gene, both active, that produce G6PD type A and B respectively exist. The two
protein variants of the enzyme can be easily distinguished by electrophoresis [20, 21, 22]. Tissues
that are clonal, will have only one type of the protein, whereas if there is a polyclonal origin, the
probability of having only one variant is small. This technique has been used successfully to
establish the clonal origin of atherosclerotic plaque [22]. It does however have its limitations,
the X chromosome carying the B variant of G6PD is rare and found general only in women of
african origin. Furthermore, it is not applicable in men. Thus limiting greatly its applicability to
tissue from the general population.
1.4 Mitochondrial DNA
Mitochondrial DNA (mtDNA) is composed of a single circular chromosome of 16569 base pairs
(hg38, GRCh38, Dec. 2013). It encodes for 22 tRNA, 13 protein subunits and two ribosomal
RNA subunits. In each cell, many copies of the mtDNA are present. The number per cell is
believed to vary according to cell type. Estimates of mtDNA copy number vary between a few
hundreds to several thousands, also depending on the cell type in question [23, 24, 4](with highest
recorded numbers of 8000 for cardiomyocytes) Mitochondrial DNA encodes the core proteins
of the oxidative phosphorilation chain, as well as the tRNA and ribosome subunits required to
synthesise them. Mitochondrion are supposed to be responsible for most of the intracellular ATP
production [25, 26]. The study of mitochondrial DNA is key in understanding the principles of
cellular metabolism, as it is responsible for a disproportionate part of the energy production for
its length. Also, mtDNA is involved in mitochondrial diseases, and is thought to be involved
in the process of ageing, as well as tumor development and possibly Alzheimer [27, 28, 29].
The importance of mtDNA can be seen in the cases where it is dysfunctional: Mitochondrial
diseases. Mitochondrial diseases are diseases due to mitochondrial disfunction, most often due to
mutations in mtDNA. They have an estimated prevalence in the order of 1 person in 10 000. The
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severity of the symptoms is dependent on the affected tissue and degree of heteroplasmy of the
deleterious mutation [30, 31, 32, 33]. The diagnosis of mitochondrial mutation is often difficult.
An individual affected by a mitochondrial mutation, can have the mutation present at a very low
fraction throughout the body, and only reaching a mutant fraction high enough to cause harm
in a specific tissue. This will make diagnosis through sequencing of mtDNA taken from blood
particularly difficult. Furthermore, the detection of the mutation does not characterise the disease.
Mitochondrial diseases often affect muscle and nerve tissue, examples are MERF and LHON
[33, 31, 30, 34, 35].
mtDNA has been a very successful research tool to understand the patterns of human migration
throughout the world [36, 37, 38]. Being maternal inherited only, and having a mutation rate
slightly higher than nuclear DNA, it provides an ideal tool for the purpose. Understanding human
migration involves determining the time in history when the last common ancestor happened
between two human populations. Then reconstructing the migration patterns by filling in the gaps
with genetic information from archeological remains. The main difficulty when using nuclear
DNA to study human populations, is in the process of mixing that happens at each generation.
Only one out of each pair of chromosomes is transmitted from parent to children, and each time
a chromosome is not passed on, the line that it identifies becomes broken. Furthermore, there
are the possibilities of crossover. mtDNA does not suffer from this drawback, and unbroken
maternal lines of mtDNA can be traced back. Mutation rates per generation are also an important
factor in the suitability to be a marker. Too low a mutation rate, will give too little temporal
resolution, and separation in the populations will not be localisable in history. Whereas too high
a mutate rate will give very good resolution, but will prevent the history to be extrapolated far
back in time. High mutation rate means that the probability of identical independent mutations
becomes too high for lineage to be uniquely identifiable. mtDNA is estimated to acquire between
0.3 and 1 mutation in the whole genome, each generation [39, 40]. Under the assumption that
mutation rates are uniformly distributed, the probability of an identical, independent mutation
is in the order of 10−4. If generation times are in the order of 20 years, the hypothesis can
be made that they are unlikely in the period of 50 000 to 100 000 years of human history that
are of interest for the study of migrations. A further advantage is that with this high mutation
rate, separations between populations can be localised in history with the precision of a few
generations. Lineage tracing in developmental biology essentially works on the same principles
as the study of human populations. Differences are found and last common ancestors identified.
For very much the same reasons as for human lineages, mtDNA has proven an effective tool for
lineage tracing inside human tissues. In most cases, humans are born with only one variant of
mtDNA. Thus all the differences present can be hypothesised as having arisen due to somatic
mutations. There are currently no reliable estimates of the mutation rate per cell division for the
mtDNA. Measurements have been performed in cell lineages [41, 5, 42, 43]. They are either
limited or difficult to translate to human tissue. However, it does seem to be low enough to justify
the assumption of no independent identical mutation arising at a high fraction. The first problem
faced when using mtDNA mutation as a marker for clonality is the mutant fraction. The presence
of many copies of mtDNA in a cell, mean that a quantitative measure of the mutant fraction is
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required to identify a cell clone. A successful example is the use of cytochrome-C-oxidase (COX)
gene inactivation mutations. If more than 90% of the mtDNA in a cell carry a gene inactivating
mutation on the COX gene, it will lead to an accumulation of cytochrome C that can be detected
by IHC [44, 45, 6, 46, 4]. With this method, it has been possible to identify colon crypts as a
single clonal unit [4], as well as to study the turnover patterns of human airway epithelium. The
main advantage of this technique, is that it can be used directly on human tissue, and requires no
"mutation discovery" a-priori. It does have a limitation in that COX gene inactivating mutations
are quite rare, requiring the study of many tissues. Furthermore, no visible mutation can be
defined as "neutral" and the question arises whether selective pressure is applied for or against it.
1.5 Tumor Lineages
Oncogenesis, the process through which cancers arise is still poorly understood. There seems
to be a general consensus that cancers are a clonal disease, and therefore arise from a single
cell [47, 48, 49, 50, 51, 52]. The idea could be traced originally to Boveri at the beginning of
the 20th century. The idea then gained ground with the modelling and theories of Armitage and
Doll [53, 54], according to which, the age specific incidence could be explained by a multi stage
disease progression model. Using the X chromosome inactivation method, the clonal origin of
Burkitt’s cell lymphoma, myeloid leukaemia was established [55]. In most carcinomas, evidence
to support a clonal origin of tumors seem scarce. Studies of cervical cancer, were inconclusive,
and encountered the difficulty of being unable to select cancer cells from the tumor mass [20].
Clonal origin was claimed for head and neck tumor [56], although the study also suffers from
difficulty in quantifying the fraction of tumor cells. Even though tumors are supposed to have
a clonal origin, they form heterogeneous structures [50, 57, 58, 59]. Histologic analysis of
tumors shows that they are composed of different tissue type with cells of different morphology
[57]. Also, they form very heterogeneous populations [60], with tumors of the similar tissue,
showing marked differences. The observation of heterogeneity is not a contradiction to clonal
origin. It does however require either differentiation of tumor lineages during oncogenesis, or the
recruitment of different cell types from the host tissue. If tumor lineages could be traced, then it
would be possible to identify which portions are tumor derived, and thus what differentiation do
tumor cells undergo, as well as which cells are recruited from the host tissue. Cancer lineage
tracing has been investigated in the mouse using a wide variety of external markers. Example
are fluorescent proteins inserted using recombinant viruses [58], or activated with the Cre-lox
system [8, 15, 61, 62]. Since cancer is extremely rare in the mouse, most of the mouse cancer
studies rely on the induction, or insertion of a tumor. It is possible to graft mice with a human
tumor, which might have been labeled beforehand [63, 64, 65, 59]. Alternatively, many strategies
have been proposed to induce a tumor in the mouse. Some recently used are the modification
of gene expression, such as TP53 [66, 67, 15] or other tumor suppressor genes. Often activated
using Cre-lox system [15, 8], or under the regulation of a particular transcription factor. A tumor
often arises from these manipulations, but the similarity of these "induced mouse tumours" with
a normally occurring human tumor is not clear.
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Internal markers are most often genetic markers [68, 2, 69, 70]. They present the advantage of
being applicable to the study of human tumors. The most successful is again the use of X chromo-
some inactivation [71, 55, 72, 73, 56, 74, 52]. Internal marker rely on the genetic heterogeneity
intra-tumor or or between the tumor and its surrounding tissue. Genetic heterogeneity can be
of many different types, such as allelic instability[47], chromosomal aberrations [51], single
nucleotide polymorphism [75]. somatic mtDNA mutations have also, to a more limited extent
been used to trace cell lineages in tumors [76, 77]. Although, to my knowledge, no extensive
study using the labelling of COX inactivating mutation has been attempted in tumors.
Taken together, these results point to a general misunderstanding of the nature of solid tumors.
There does not seem to be many methods that allow the direct study of human tumor tissue. The
two most accurate ones, X chromosome inactivation and labelling of COX inactivation, very
successful in the study of normal tissue, have had their difficulties being used on human tumors.
Possible explanations might be that the X chromosome inactivation method can only be used
on a small fraction of women from African descent. Whereas COX inactivation requires the
presence of a very rare set of mtDNA mutations to occur at a high fraction. There does not
seem to be a clear demonstration of the clonal origin of carcinomas in humans. In fact, there
does not seem to be a clear consensus of what constitutes tumor tissue. Which was the main
difficulty faced by the studies that used X chromosome inactivation to test the clonality of tumors.
Any successful method, to analyse tumor lineages, therefore has to work under the assumption
that it is impossible to select tumor areas a-priori. It requires the ability to analyse sufficiently
small samples, in sufficient numbers, to allow systematic sampling of a tissue volume. This way,
the patterns of tumor lineages could be reconstructed directly from the acquired data, without
requiring a histological analysis of the sample. In doing so, it would be possible to reconstruct
the patterns of clonal growth in tumor volume.
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2.1 Homoplasmic mutations are less frequent than expected
The project started with the idea that carcinomas, were composed of two distinct parts, a
mesenchymal and an epithelial part [78, 66]. The question still existed whether the mesenchymal
portion is related to the tumor cells, or a reaction of the surrounding "normal" tissue. Reviewing
the literature, we made the hypothesis that roughly 80% of all tumors would carry a mitochondrial
mutation at a homoplasmic, or near-homoplasmic level [79, 80, 81, 76]. If a tumor is a clonal
group of cells, then a mtDNA mutation present at the tumor origin would be present in all
tumor cells. Taking samples across a tumor sample would therefore detect mutations with a
high frequency. The first experiment performed, attempted to determine whether the epithelial
and mesenchymal portion of a tumor were clonal related. To do so, 8 large LCM samples were
selected based on histological examination, for 10 tumors. Using a first round amplification from
the literature and the first CTCE primer set of our design, 60% of the mtDNA was scanned across
those samples. Results were inconclusive, as no mutations were detected in the tumor samples.
Not only had the initial question not been answered, but the observation frequently reported in the
literature had not been reproduced. If homoplasmic mutations were common in human tumors,
how come we had found none? One possibility is that homoplasmic mtDNA mutations are rarer
than initially supposed. One of the possible explanations is that most published results, are
measured in mixed samples, in which the tumor fraction is estimated by histological observation.
2.2 Design a reliable primer set
The first primer set used [82], to amplify mtDNA was unreliable on LCM samples. DNA
extracted from laser capture micro-dissection (LCM) samples is low in concentration, and
sometimes difficult to amplify. We therefore needed to develop a new primer set that would prove
more reliable. From our experience in primer design, a length of around 800bp seemed optimal.
It was also important that the PCR result could be checked using capillary electrophoresis, instead
of gel electrophoresis. This is when the idea came of placing a tail at the end of each primer. The
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tail can then be amplified by a highly efficient "tail primer", which could also be labeled with a
fluorophore for detection using capillary electrophoresis. The second round primer set was then
modified and augmented to amplify on the new set of pre-amp and achieve a higher coverage.
In the end we had a reliable set of primers, with less than 1% failure rate, that could be used on
DNA extracted from LCM samples.
2.3 Tumor cells cannot be distinguished by histology alone
Trying to understand what could be defined as "tumor cells," epithelial and mesenchymal portions
within a tumor, we were able to identify no consensus. A problem that had already been identified
by Fialkow. Philip J. Fialkow in the 60’s and 70’s was trying to do something strikingly similar to
us, and encountered similar problems. He was trying to demonstrate the clonal origin of tumors,
as well as the origin of the different tissues present in a tumor mass [83, 55, 84, 72, 73, 20, 56,
85, 86, 87, 88]. He also came up against the difficulty of defining which parts of a tissue was
tumor and which was not. His results from having multiple independent pathological examination
of the same samples, seem to suggest that no clear consensus exists. In fact, there does not
seem to be a way to define, based purely on morphology, which cells are tumor in origin and
which are not, even when they all are part of the "anomalous mass" that constitutes the tumor.
Imuno-histochemistry (IHC) does not offer an adequate solution. If it is impossible to define
which areas in a tumor sample, are tumor in origin, and which are normal in origin, then any
attempt at selecting structures based on morphology is bound to fail. This was one of the possible
explanations for our earlier failures to identify mutations. Our observations also seem to point
in the direction that there is no clear understanding of what tumor cells are. In the chapter 5,
the difficulties of imaging tumor tissues are described. Trying different types of staining we
were unable to obtain specific tumor staining or to recognise clear structures within the tumors.
Furthermore the results from 2 dimensional lineage tracing, shown in chapter 9, demonstrate
that the mtDNA mutations used as markers can be found across a slice of tumor tissue without
apparent correlation to tissue morphology, further strengthening the hypothesis that in a tumor
mass, cells of tumor origin cannot be distinguished by histology alone.
2.4 Sampling needs to be unbiased
There is no method that allows us to distinguish between tumor cells and non-tumor derived
cells simply through observation. Any attempt to select structures when picking LCM samples is
therefore bound to introduce biases. Tests with the LCM equipment were therefore performed to
determine the size of sample that could be consistently taken: a circle of around 25000µm2. A
standard 8×12 grid was then designed with 96 such samples. Sampling a tumor slice was then
conducted by placing these grids and taking samples close by. An example of such a sampling
pattern can be seen in figure 9.1, in which a large portion of the slice is covered in identical
samples taken in a grid formation. Observation of these scans revealed that the mutations seem to
be distributed across the surface without a discernible correlation with observable structures. The
8
2.5. Lineage tracing must be in three dimensions
test that ultimately verified that indeed we were tracing lineages, was the ability to reproduce
the results in another slice. These results can be seen in the chapter 9 and form the main results
presented in the paper described in section 9.2. These results allowed us to conclude that any
attempt to select samples based on tissue morphology is going to be of little benefit and likely to
introduce biases. It is therefore important to have a systematic sampling of the tissue analysed.
2.5 Lineage tracing must be in three dimensions
The paper described in section 9.2 shows that it is possible to find the same mutations in a separate
slice of tissue, in similar position.The next logical step, is to sample consecutive slices. Sampling
the same location in consecutive slices of the tissues, it would be possible to reconstruct the three
dimensional patterns of cell lineages in human tumors. The first attempt was the Leydig cell
tumor, which had already been subject to two dimensional scanning. At first all consecutive slices
were taken, sampling and analysing them, we realised that the sampling in the z (depth) axis, was
too fine in comparison to the sampling in the x and y directions. So after taking 12 consecutive
slices of tissue, only one every 3 was placed on membrane. The result of the experiment was a
success. Once the analysis was done and the first three dimensional plot of mutations made, we
observed that there was a strong correlation of mutations in the z axis as well. Having proven it
was possible, we decided to make more three dimensional analysis of human tumors, as described
in chapter 10. They confirm that markers followed seem to form three dimensional structures that
would not be recognised only by a two dimensional analysis. This confirms that to trace a cell
lineage through a volume of tissue, a three dimensional study of the tissue is needed.
2.6 Following a marker is following a lineage, not all lineages
The first three dimensional analysis of tumor tissue for mtDNA mutations proved that it was
possible to follow a tumor lineage throughout a volume of tissue. The presence of the marker
guarantees tumor origin (if the basic assumptions of oncogenesis are true). The absence of a
marker does not guarantee "non-tumor" origin. The mutation could have arisen at the beginning of
the tumor development, and be present in the first tumor cell that gave origin to all the successive
ones. In this case, cells without the mutation would be derived from non-tumor cells. In the
other case, mutation identified and followed could have arisen at a later stage of oncogenesis, and
only mark one of the many tumor lineages. The problem was solved by finding tumors and the
corresponding metastasis carrying the same mutation. If the metastasis is started by only one,
or a small number of tumor cells, then the presence of the same lineage as the primary tumor,
guarantees that the original cell was carrying the mutation. Consequently, all tumor derived cells
in the metastasis are identifiable by the presence of the mutation. The three dimensional analysis
of tumor cell lineages in a metastasis is the reconstruction of the patterns of metastatic growth in
the host tissue.
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2.7 Tumors and metastatic growth are mostly made up of
non-tumor cells
What is left to do is still very much work in progress, understanding the results. The observed
patters do not seem to validate any known model of tumor genesis. If tumors are clonal, then
the observed results seem to indicate that the majority of the tumor volume, is not composed of
tumor derived cells. The same is true for metastasis. This would contradict the beliefs that tumor
grow as a cell colony, by expanding and pushing the remaining cells out. It would seem that very
few tumor cells diffuse through the tissues in which they grow and re-condition it. The process
and mechanisms involved in this process are not yet understood.
2.8 Automate what you can, keep improving your methods
Possibly the main reason the work presented here was possible, was that all the methods used,
and analysis performed were improved and automated along the way. This shared belief between
my supervisors and myself, as well as the dedication to optimise each step, proved crucial in the
increase in throughput we achieved. For example, a software made to design the primers, which
allowed a very large number of primer pairs to be designed, and then optimised, thus enabling us
to reach the coverage we have. When the LCM capture system was becoming the limiting factor
in the analysis, Per Ekstrom designed and built a collector to increase the throughput, from 100
samples a day to 800. Then came the problem of analysing the electropherogram, for which an
automated solution was also designed. Towards the end of the work, the combination of all the
improvements made, allowed us to make a complete three dimensional analysis of a tissue in one
week, from mutation discovery, microtome, sampling, PCR, CTCE and data analysis.
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3.1 Cycling Temperature Capillary Electrophoresis
Cycling temperature capillary electrophoresis (CTCE) is a method for detecting and quantifying
DNA variations within a sample. DNA is a double stranded helix where each strand is comple-
mentary to the other. If a sample containing two variants is denatured (i.e. the double strands are
separated into single-strands), and then allowed to anneal (i.e. reform the double-strand), homod-
uplexes and heteroduplexes will form, see figure 3.1. Homoduplexes and heteroduplexes have
different melting temperature. CTCE exploits this difference in melting behaviour to separate
them and quantify the relative fraction. The melting behaviour of double stranded DNA affects
its migration speed through a gel filled capillary. Electrophoresis is used to force DNA migration.
Since the charge of DNA is only dependent on its length, it is equal for variants of the same length.
The resistance of the gel to the migration depends on the melting status. Coupling temperature
variations with capillary electrophoresis, it is possible to force the different fragments of double
stranded DNA to migrate at different speeds through the capillary. Since heteroduplexes have
a lower melting temperature, they will spend more time in an open configuration than homod-
uplexes, and cause them to move slower. The separation allows for the relative quantity to be
measured, which leads to the mutant fraction.
For CTCE to be effectively used, DNA fragments need to respect three conditions:
1. Length smaller than 180 base pairs
2. Monotonous (only increasing or decreasing) melting profile as a function of position.
3. A GC clamp at the warmer (presence ensured by condition 2) end of the fragment that will
prevent complete separation of the strands of DNA analysed.
To separate mtDNA into fragments satisfying these conditions, a specific set of primer has been
designed. The detailed description of the design and PCR conditions are described in section 6.1.
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Figure 3.1: Schematic representation of heteroduplex formation. In the a solution containing two
variants of a double stranded DNA sequence, denaturing the DNA will cause the formation of
homoduplexes and heteroduplexes. The heteroduplexes will have a lower melting temperature
than the homoduplexes, and can be therefore separated using CTCE
Figure 3.2: Comparison of electropherograms from two samples analysed on the same fragment.
The top one contains no mutation, and a single peak is visible. The bottom sample contains a
mutation, and the typical four peak configuration is visible.The first two peaks represent the two
possible homoduplexes, whereas the second two peaks represent the two heteroduplexes.
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3.2 Primer Design
3.2.1 Pre-amps
To selectively amplify the mtDNA without amplifying the nuclear genome, a set of 23 primer
pairs was designed. They amplify overlapping fragments of lengths between 421 to 1030 base
pairs. Together these fragments amplify with a slight overlap the whole mtDNA. Designing
the fragments required the selection of areas with mismatches between the mtDNA and NUMT.
Using BLAST (ncbi) the mtDNA was aligned to the human nuclear DNA. Manualy inspecting
the alignment results, areas with as many mismatches as possible were selected for as primer
target. To check for PCR success, as well as to increase PCR efficiency, a 3-primer strategy was
used. The idea is to add a short tail at the 3’ end of each primer. The PCR is then performed with
the forward and reverse primer, as well as with a third primer that amplifies on the tail. The tail
primer is highly efficient, and can be labeled with a fluorophore. Labelling the tail primer, allows
the PCR success to be checked using capillary electrophoresis instead of gel electrophoresis.
Which highly increases the throughput.
3.2.2 Second Round
The second round fragments are amplified on the product of the first round PCR. There is
therefore no risk of nuclear amplification even in the case of compatible primers. The second
round fragments need to satisfy the requirements for efficient separation of mutants by CTCE.
An automated algorithm was designed to select the fragments over the pre-amps. The output
was a set of primers that could be amplified over each of the pre-amps. A clamp "GC-clamp"
is attached to the primer that amplifies on the side of the fragment with the highest average
melting temperature. PCR conditions were then optimised for each of the designed primer pairs.
Primers that failed to amplify were shifted a couple of base pairs up or down on the pre-amp, and
optimised again. The result was a set of 192 primers that covers 76% of the mtDNA.
3.3 Electropherogram Scoring
The output of CTCE is an electropherogram, a typical example of which can be seen in figure
3.2. As the figure shows, the presence of a mutation can be readily identified by the presence of
multiple peaks. In the case of a single peak, an internal standard is needed to determine which
allele is the one present. The mutant fraction can be estimated by measuring the relative peak
heights, or areas (height and area are related). Manually identifying and measuring the peaks is a
laborious process. A user interface has therefore been developed using Matlab. The interface also
contains various functions for the automatic recognition and measurement of the peaks. It also
allows manual selection of peaks after automated scoring. The development of automated tools,
has dropped the analysis time by over 20-fold, thus making it possible to analyse the results from
three dimensional tissue sampling.
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Figure 3.3: Custom built cap holder. Caps strips are placed on the holder and filled with lysis
buffer. Samples fall into the caps by gravity. Only one sample is captured in each cap. The caps
can then be placed on 96-wells plates and quickly centrifuged to drop the content into the well.
3.4 Laser Capture Microdissection
The objective of Laser Capture Microdissection (LCM) is to combine tissue capture with micro-
scope imaging. The equipment used throughout for all the experiments mentioned here was a
Leica LDM 6000. Samples are placed on thin PET membranes that can can be cut by the laser.
The Leica software allows for shapes to be drawn on the microscope camera output. The laser
will then cut the shapes, cutting through both samples and membrane, which will drop by gravity
into collector caps. To increase the throughput, we built our own cap holder, shown in figure 3.3.
A holder that could be fitted with two 8-caps strips at a time. Which allowed for the collection of
16 samples with only one loading. The strips were filled with lysis buffer, and after collection
could be directly transferred to a 96-well plate for incubation.
3.5 Real Time PCR
Real time PCR is considered a standard way to quantify DNA copy number. Coupled with
reverse transcription it can also be used to quantify mRNA copy number, which relates to gene
expression. The principle of the method is to perform a PCR in the presence of a fluorophore
that is fluorescent when bound to double-stranded DNA. Fluorescent level is then measured after
each PCR cycle. The output is a measure of DNA amount in the sample at each cycle, which can
be used to estimate the relative copy number between two samples. The details can be found in
the paper described in section 8.1.
There are various theories as to how the output of rtPCR should be analysed. The ∆CT method
is generally considered to be the standard. However, it still has major drawbacks. For example
requires identical PCR efficiency between two samples being compared, which means that the
PCR efficiency and fragments must be optimised. It has the considerable advantage of being
implemented in a fully automated form in most software for rtPCR analysis, whereas most other
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methods rely on the isolation of the exponential portion of the rtPCR signal. The alternative
proposed is to use a robust regression to isolate the exponential portion of the signal. This
allows the efficiency of the rtPCR to be estimated, and removes the requirement that two samples
compared have the same efficiency. It also permits the measurement of PCR efficiency without
cumbersome dilution curves, which could also introduce bias in the measurement.
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4 First Experiment
4.1 Motivation
The project started with the idea that carcinomas, were composed of two distinct parts, a
mesenchymal and an epithelial part [78, 66]. The question still existed wether the mesenchymal
portion was related to the tumor cells, or was a reaction of the surrounding "normal" tissue.
Reviewing the literature, we made the hypothesis that roughly 80% of all tumors would carry a
mitochondrial mutation at a homoplasmic, or near-homoplasmic level [79, 82, 80, 81, 76]. If a
tumor is a clonal group of cells, then a mtDNA mutation present at the tumor origin, would be
present in all tumor cells. Taking tumors, and sampling the epithelial and mesenchymal portion
of them, scanning the mtDNA for mutations, it would be possible to answer the initial question.
4.2 Experiment
We took 10 samples of colon tumors from a bio-bank, for which either normal tissue (taken from
the colon a few centimetres away from the tumor) or blood from the same patient was available.
The tumor samples were cut in 50µm slices and placed on membranes for LCM. The reason for a
50µm cut was to have at least one cell layer on the membrane, therefore guaranteeing DNA for
the analysis. With the help of a pathologist from the Norwegian Radiumhospital, three samples
that could be identified as mesenchymal and four samples that could be identified as epithelial
were chosen for each tumor, an example of which can be seen in figure 4.1. In order to detect the
presence of a mutation present in the whole tumor, an 8th sample was constructed for each tissue,
namely an even mix of DNA extracted from each tumor sample and DNA extracted from normal
tissue (or blood). We considered the possibility that all samples taken in the tumor area would
carry a mutation at a homoplasmic level. To identify it as a mutation, comparison was needed
agains normal tissue or blood, thus motivating the construction of the 8th sample.
Scanning the mitochondrial DNA requires its selective amplification. I then had the idea of
looking for a set of primer to amplify the mtDNA and then design the CTCE primers to amplify
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Figure 4.1: Example of a LCM sample from the first experiment. This specific sample was
considered to be an epithelial sample. The sample is very large, and the thickness of the slice
makes the image blurry
on the product of the first round. The idea was not novel, and a primer set was found in the
literature, that was guaranteed to amplify only the mtDNA [82]. The second round primers were
designed automatically, using a software of my design, and the POLAND algorithm for the
melting profile of a DNA fragment. After test and optimisation, roughly 60% of the mtDNA
could be scanned for mutations using this initial set-up. At the time, we still held onto the belief
that, frequently enough, a tumor is a bulk of clonal cells which regularly contains a homoplasmic
mutation present in the whole of its mass. In which case, we should observe no mutation in the
tumor samples, nor in the normal tissue. A mutation should however, be detected in the mixed
sample of tumor and normal tissue.
4.3 Results
Results were inconclusive. No mutations were identified in the mixed samples, and only two mu-
tations were detected in the individual LCM tumor samples. Not only had the initial question not
been answered, but the observation frequently reported in the literature had not been reproduced.
If homoplasmic mutations were common in human tumors, how come we had found none?
4.4 Conclusions and Reflections
The first observation was the relative high failure rate of PCR, one of the 9 first round reactions
failed and only about 60% of the mtDNA was scanned. The PCR on extracted DNA was
more consistent, but there was a reasonable frequent failure in the LCM samples which raised
questions about the reliability of the primers to amplify in difficult situations. An explanation
was that the fragments were too long, which made it too susceptible to variations we could
not control. The results of the experiment were inconclusive. No mutations were found in the
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LCMD sample, or in the mixed samples. Having scanned 80 samples, and found no mutations,
forced a re-evaluation of the method used to detect them, as well as our assumptions about
mutation rates in tumors and normal tissue. Furthermore, it was clear that the distinction between
epithelial and mesenchymal portion of a tumor was not obvious, as could be inferred from the
literature. There does not even seem to be an easy way to define what constitutes tumor cells
when histologically analysing a sample, it is at all possible. Figure 4.1 shows an example of
an epithelial sample taken for this experiment. The preparation of the sample was delegated to
the histology department of the Radiumhospital, which made the sectioning and staining. As
is shown in figure 4.1, the sample is difficult to interpret, as the contrast is poor. It was then
clear that better sample preparation was therefore needed. We still believed that somehow it was
possible to distinguish tumor cells from non-tumor cells in a sample just by observation. It was
then decided to attempt various experiments with histology. Then came the question of how
frequent are mtDNA mutations in tumors. A better review of the literature available of mtDNA
in tumors revealed a few inconsistencies in the results. Most of the claims of homoplasmy, relied
on a pathological examination [79]. Furthermore, they were performed with methods that would
not allow the quantification of the mutant fraction in a sample [89, 79]. In order to have a good
estimate of the mutational spectra in human tumors, the experiment would have do be done
"in-house." There was a high degree of failure in this experiment. One of the reasons seemed to
be the high rate of PCR failure of the first round. A better primer set for first round PCR would
need to be found.
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5 Sample Preparation and Staining
5.1 Introduction
To be imaged with a microscope, tissues need to be stained. A concept that goes back to the
beginning of microscopy and analysis of tissues with it. If the first cells were observed in 1665
by Robert Hooke, the first documented stain for tissues can be found less then a decade later,
in 1673 by Antonie van Leeuwenhoek. Van Leeuwenhoek used saffron extract as a dye, later
experimented with other known pigments such as carmine and madder. Even so, some attribute
the first histological stain to Joseph von Gerlach, who in 1858 successfully used ammoniacal
carmine to stain cerebellum. The objective of dying tissues is to create contrast. Some parts
of cells will absorb some dyes, but not others. The unabsorbed dye can then be washed away
leaving only some areas stained, thus forming patterns. Another consequence of differential
dye absorption is the possibility of counter-staining, or staining with more than one dye. Since
different stains attach to different chemical compounds, the staining choice will greatly impact
what can be observed on the sample. Consequently, many applications have their own traditional
stain.
One of the main shortcomings described in chapter 4 was the difficulty to interpret the images
acquired of the samples. In order to improve the quality of our imaging, a variety of sample
preparation protocols had to be tested. Also, if it was possible to reliably distinguish tumor cells
and therefore select them, we needed to know. A variety of staining protocols were therefore
experimented with, and applied to both normal and tumor tissue. Since different applications
require different staining, it was important for us to develop a stain that suited our purpose.
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5.2 Staining protocols
5.2.1 SYBR Green
SYBR green is a DNA marker, used mostly gel electrophoresis and for rtPCR. It binds to double
stranded DNA and has a fluorescence peak around 520nm. It can therefore be visualised with
a green fluorescent protein type microscope configuration. its main advantage is being easy to
use, and supposedly specific for DNA. Fresh frozen samples were placed on LCM membranes or
glass slides, then fixed by immersing in a 50% methanol and 50% acetone mix for 10min then
air-dried. Staining with SYBR was obtained by immersing samples for 5 min in a 2X SYBR mix
(diluting the original 10 000X SYBR 5000 times in water). SYBR staining is also possible in
combination with IHC.
5.2.2 Giemza
Giemza is an traditional way of staining. Currently in use as standard in laboratories, and is also
considered the reference technique for diagnosing the presence of the Plasmodium parasite[90].
Slides are fixed by 10min immersion in methanol, then air-dried. Staining is obtained by placing
the slides 30min in a solution of Giemza (Meyer Hematoxylin) diluted 20 times in H2O . It is then
immersed in a solution of 1% acetic acid in H2O for 30 seconds, a step known as differentiation.
Then washed in H2O and air-dried.
5.2.3 H&E
Hematotoxylin and eosin were purchased at Sigma Aldrich in their ready to use solution. Samples
were fixed in methanol for 10 minutes and then air dried. Samples were placed in Hematoxylin
for 30 min, then rinsed in 95% ethanol solution. Then dipped 8 times in Eosin, then rinsed again
in 95% ethanol, then air-dried.
5.2.4 DAPI
DAPI is a blue fluorescent stain most often used to image live cells. DAPI stock solution with a
concentration of 5mg/ml was diluted 1000 times in H2O to create the staining solution. Samples
were immersed for 5 min DAPI staining solution and then washed with H2O and allowed to
air-dry.
5.2.5 Ethidium Bromide
Ethidium Bromide (EthBr) is an intercalating agent that emits a strong fluorescence when bound
to DNA. It is a standard tool for staining DNA when performing gel electrophoresis. It can also
be used as a DNA stain in histological preparations. Our protocol consisted in fixing the samples
22
5.3. Results
for 10 in methanol. Then the samples were incubated in a solution of 0.5µg /ml of EthBr in
H2O for 5 min and then washed with H2O and allowed to air-dry
5.2.6 Pan-cytokeratins
Pan-cytokeratins (Pan-K) are a class of antibody that binds to a large amount of the known
cytokeratins. It is reported as a marker of epithelial tissue. Cytokeratins antibody was purchased
from Dako (Cytokeratin antibody, Clone AE1/AE3, Dako by Aligent, Santa Clara, CA), and
protocol was optimised according to manufacturer’s instructions. Samples were double fixed,
by immersion 10 minutes in Ethanol at -20◦C, then again 10 minutes in Acetone at -20◦C, then
allowed to air-dry. Samples were then washed with PBS and incubated with Block V (blocking
solution supplied with the antibody by supplier) for 5 min. Washed with PBS and the again with
PBS containing 0.5% bovine serum albumin (BSA) as well as 0.3% Triton-X100 (a detergent).
Samples were then incubate with antibodies diluted 100 times, for 1h at room temperature in
humid conditions. Washed with PBS and then incubated with HRP binding polymer for 30
minutes at room temperature in humid conditions then washed with PBS. Samples were then
incubated for 12 min at room temperature with DAB chromogen (supplied with antibody by
manufacturer) then washed with H2O . Last, samples were counter-stained with SYBR for
nucleus imaging.
5.3 Results
The first question is the thickness of the samples that was best for imaging. Figure 5.1 shows
H&E staining of colon with varying thicknesses. If the thickness is too low, the amount of
material deposited on the slide is too insubstantial. On the other hand, too thick slices cause
the image to loose focus, most likely due to the small depth of focus of the microscopes used.
10µm was still seen as too thin and 15µm as too thick, the best compromise was chosen to be
12µm .
5.3.1 Compatibility
Not all counter stains are compatible with an original stain. H&E is incompatible with any other
stain. EthBr cannot be used for LCM, as the fluorescent emission required for imagined, burns
through the PET membrane. Giemza has an autofluorescence similar to the one by DAPI, which
makes them incompatible. SYBR is well compatible with Giemza, as well as with the antibodies
protocols.
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Figure 5.1: Varying thickness of colon tissue, stained with H&E. Thicknesses shown: 5, 10, 15,
20 and 25 µm
(a) Normal human colon, 12µm cuts, stained using standard staining techniques. From left to right:
Ethidium Bromide, DAPI, Giemza
(b) Normal human colon, stained using pan-K antibody and counterstained with SYBR. On the left, is the
staining produced by the antibody. The crypts are clearly labeled as epithelial tissue, by the red-brown
colouring given by the fluorophore associated with the antibodies. In the middle, is the fluorescent image
showing SYBR staining. Crypt formations can be clearly distinguished by their ring-like structure of
nucleus. On the right, the merged image of SYBR and antibody. Confirms that both method permit the
clear distinction of epithelial and mesenchymal portions.
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(a) Rectal cancer
(b) Prostate Cancer
Figure 5.3: Rectal and prostate cancer, 12µm slices, stained using pan-k antibody and counter-
stained with SYBR. Pictures taken during LCM experiment, the same area is imaged in both
bright-field and in fluorescence, showing the IHC staining as well as the SYBR staining. The
shapes visible were drawn using the LCM software for sample acquisition. They represent
another attempt at selecting tumor areas.
5.3.2 Observing colon structure
The typical morphology is the crypt morphology. In all of the preparations shown, the crypts
can easily be distinguished. The IHC clearly labels the epithelial cells of the crypts and does not
mark the others. It is however very easy to distinguish the crypt formations in all of the staining.
However, as can be seen in Figure 5.3, tumors showed no clear marking by IHC, neither are the
clearly identifiable structures of the normal tissue visible.
5.4 Conclusion
In a normal tissue, such as the human colon, structures formed by the tissue are clearly identifiable,
independently of the stains. As long as the slide preparation has been done carefully, all the stains
will allow a careful observer, to recognise the tissue morphology and the defining structures, such
as the colonic crypts. In tumors, these morphologies are lost. None of the stains experimented
with here allowed a clear recognition of any structure bearing resemblance to normal tissue
classification. Observing tumor tissues, it is observable that a sample is "not normal," however,
no structures bearing clear resemblance to normal tissue features is observable. Also, if a tumor
sample is composed of tumor cells and normal cells infiltrating it, no distinction seems to be
clearly visible from histologic analysis. This observation seems counter-intuitive and to go
against what is generally though in the litterature. However, it was already observed by Fialkow
[56], that estimating the fraction of tumor cells in a sample is very difficult. The observations in
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his article suggests that there is no consistency between different pathological examinations of
the same sample. Observations that validate the ones described here.
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6 Detecting Mutations in the Mitochon-
drial Genome
The primer set used for the first round PCR was unreliable. To address the problem, we scanned
the literature and looked for a series of primer sets and methods that could be used to amplify
mtDNA. After trying a series of protocols, and not being able to have a reliable amplification of
mtDNA on laser capture samples [91, 92], we decided to design our own pre-amp set. From our
experience, a length of around 800bp seemed optimal. Furthermore, it was important that the
PCR result could be checked using capillary electrophoresis, instead of gel electrophoresis. This
is when the idea came of placing a tail at the end of each primer. A large portion of the second
round primers that failed in the first attempt also needed to be re-designed. The results of this
improvement are explained in [93]. The new set of primers consisted of 23 pre-amps (first round
primers) and 192 second round primers, and allowed the scanning of 76% of the mtDNA.
6.1 Resulting Publication: Cycling temperature capillary
electrophoresis: A quantitative, fast and inexpensive method to
detect mutations in mixed populations of human
mitochondrial DNA
6.1.1 Short description
This article describes CTCE as a method for the detection and quantification of mutations in
mtDNA. It contains an in-depth description of the method with pre-amps, second round primers
and cycling conditions. To validate the method, a sample containing multiple mutations is
artificialy created by mixing the DNA from 30 persons in equal amounts. The performance of the
method is compared to next generation sequencing (NGS), using a standard protocol. The results
clearly show that NGS is not quantitative, and is incapable of detecting mutations at a fraction
below 30%. Also challenges involved with alignment of sequencing results are highlighted.
In contrast, CTCE is shown to be able to accurately detect and quantify mutations present at
fractions as low as 1%. The throughput and cost of CTCE for the detection of mtDNA mutation
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is shown to be at least an order of magnitude better than NGS.
6.1.2 Significance
This is a methods paper. It describes and validates a method to detect and quantify mitochondrial
mutations. CTCE is applicable in various situations, not limited to lineage tracing. Other
researchers in the field of human mitochondrial DNA could benefit from a fast, quantitative
and inexpensive way of detecting mutations. Possible applications include the diagnostic of
mitochondrial diseases, forensic applications as well as tumor related questions. Furthermore,
the performance of CTCE is often questioned, when compared to other methods such as NGS.
Comparing the performance of the two methods, and showing the greater precision, throughput
and lower cost of CTCE justifies our method choice. Successive papers can therefore make
reference to this one.
6.1.3 Personal Contribution
In this article, I was responsible, together with Per Ekstrom, for the experimental design. I
designed the primers, tested them and optimised them. Per Ekstrom came up with the idea of
attaching a tail to the pre-amp primers. I designed the sequencing strategy and performed all the
downstream data analysis. The interpretation of the results was a joint effort of all three authors,
as was writing the paper.
6.1.4 Status
Published on 7th of May 2016, in Mitochondrion.
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Cycling Temperature Capillary Electrophoresis: A
quantitative, fast and inexpensive method to detect
mutations in mixed populations of human mitochondrial
DNA
Paulo Refinettia, Stephan Morgenthalera, Per O. Ekstrømb
aE´cole Polytechnique Fe´de´rale de Lausanne, EPFL FSB STAP, Station 8, Lausanne, Switzerland
bDepartment of Tumor Biology, Norwegian Radiumhospital, Oslo, Norway
Abstract
Cycling temperature capillary electrophoresis has been optimised for mutation
detection in 76% of the mitochondrial genome. The method was tested on a mixed
sample and compared to mutation detection by next generation sequencing. Out of
152 fragments 90 were concordant, 51 discordant and in 11 were semi-concordant.
Dilution experiments show that cycling capillary electrophoresis has a detection
limit of 1-3%. The detection limit of routine next generation sequencing was in
the ranges of 15 to 30%. Cycling temperature capillary electrophoresis detect and
accurate quantify mutations at a fraction of the cost and time required to perform
a next generation sequencing analysis.
Keywords: mitochondrial DNA, heteroplasmy quantification, cycling
temperature capillary electrophoresis, quantitative biology, High throughput
1. Introduction
1.1. Mitochondrial DNA
Mitochondrial DNA (mtDNA) is composed of a single circular chromosome
of 16569 base pairs (hg38, GRCh38, Dec. 2013). It encodes for 22 tRNA, 13
protein subunits and two ribosomal RNA subunits. In each cell, many copies of
the mtDNA are present. The number per cell is believed to vary according to cell
type, however, few accurate estimates exist. Mitochondrial DNA is maternally
inherited, which makes it well suited to study human migration. Quantitative
mutational spectra of mtDNA are of great utility in medicine and biology. In
Preprint submitted to Elsevier January 14, 2017
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the following we briefly address a few of the applications, namely mitochondrial
diseases, lineage tracing and tumour biology.
Mitochondrial diseases are prevalent in the order of 1 in 10 000 of the human
population, with more or less severe symptoms depending on the affected tissue
and degree of heteroplasmy of the deleterious mutation [1, 2, 3, 4]. this example
shows the importance of having a quantitative mutation assay, because knowledge
of the existence of a mutation will not characterise the disease.
There is currently much interest in using somatic mtDNA mutations as a
marker for lineage tracing [5, 6, 7, 8]. Cytochrome C oxidase inactivation muta-
tions have been successfully used as markers. The few attempts with sequencing,
however, have been hampered by the slow speed and the excessive cost.
Since it is a generally accepted that mtDNA mutations hold the answer to im-
portant biological questions, many methods have been developed to study them.
Most require the isolation of mtDNA from nuclear DNA to prevent the amplifi-
cation of pseudogenes (or NMUTs). This can be achieved by performing PCR
selectively on mtDNA, and amplifying large portions that can then be analyzed
[9, 10, 11, 12, 13, 14]. Methods range from whole mtDNA amplification using
one primer pair [15, 14] to splitting it in many pieces [11, 12, 13]. Once the
mtDNA has been amplified, it can be sequenced. Alternative methods to sequenc-
ing include temporal temperature gel electrophoresis [16], or restriction enzyme
length polymorphism to detect insertions/deletions [17]. Sequencing, even after
recent advances, remains expensive and slow if one has to analyse hundreds of
samples.
To detect and quantify mutations double stranded DNA containing no mis-
match (homoduplexes) from those containing one or more mismatches between
the strands (heteroduplexes) can be separated with the use of denaturing capillary
electrophoresis. Homoduplexes can be separated from heteroduplexes because of
different melting temperatures [18, 19, 20]. Denaturing capillary electrophoresis
was successfully used to quantify the error rates of DNA polymerase β, Taq DNA
polymerase and Pfu DNA polymerase [21, 22, 23, 24]. Denaturing capillary elec-
trophoresis was also used in its early forms to analyse mutations in the human
mtDNA [25, 26], by scanning a 100bp portion for mutations. Recent advances on
the denaturing capillary electrophoresis gave rise to cycling temperature capillary
electrophoresis (CTCE). The use of CTCE omits stringent temperature control
and fragments design [22]. Thus, allowing for analysis of many fragments simul-
taneously [27, 28, 29] .
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2. MATERIALS AND METHODS
2.1. General protocol
First, an initial round of PCR is performed using 23 primer pairs (Figure 1).
An additional primer is used to increase efficiency and label the product. To check
the presence of a product, capillary electrophoresis can be used. The second step is
a second round of PCR using 193 primer pairs and cover 76% of the mitochondrial
DNA (see supplementary material). If the optimised annealing temperature is
used for each of the 193 fragments, the sensitivity is sufficient to detect mutations
present at fractions of 1-2%. For the analysis of a single sample it is convenient
to use the same annealing temperature on all 193 fragments. We used an average
annealing temperature of 55◦C which works on 152 fragments, which cover 62%
of the total mtDNA. After the second round PCR has been performed, the resulting
products are analysed using CTCE. We use a MegaBace1000 instrument, (GE
Healthcare Life Sciences, CT, USA). The software was modified to that the built-
in oven could cycle the temperature. The temperature is switched from high to low
every 30 seconds during a period of 20 minutes. For optimal separation between
the products, each fragment needs to be cycled at specific temperatures. If the
fragments are set on the same support, it is possible either to make several runs
at different cycling temperatures, or to use a single run with a larger temperature
amplitude and slower switching frequency (see [22]).
For the purpose of comparing with modern sequencing methods, the whole
mtDNA was amplified in nine fragments using the protocol described in Ramos et
al. [11]. The resulting products were sent for library preparation and sequencing
on an Illumina Hi-seq2000 at the University of Lausanne Integrated Genomics
Facility. The results were then mapped using Bowtie2. All of the computations
were performed on the EPFL basic science cluster.
2.2. Primer Design
2.2.1. Primers for the selective amplification of mtDNA without nuclear contam-
ination
There are many regions of homology between mtDNA and nuclear DNA (nDNA).
To prevent the amplification of these regions in the nuclear DNA (NMUTs or
pseudogenes), the primers are designed not anneal to nDNA but only on mtDNA.
Using the Cambridge reference sequence rCRS (NC 012920.1) for the mtDNA
and BLAST (http://blast.ncbi.nlm.nih.gov/, 2015), the regions of homology were
determined. Primers were selected in a way that would maximise the mismatches
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between the nDNA and the mtDNA in the primer area. The length of the result-
ing amplicons was between 421 and 1156 bp. No attention was paid to possible
secondary structures formed by the primer. A total of primer pairs were designed.
The resulting fragments are shown in Figure 1. A short tail (CGC CCG CCG
CGC CCC GCG) was added on the 5’ end of all primers (both forwards and re-
verse). This addition allows the use of a third primer in the PCR reaction. The
third primer anneals to the tail and carries a fluorescent ATTO 523 molecule. The
consequence is an increase efficiency and the labelling of the product for detection
using capillary electrophoresis. The primers are given in Table 1.
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Figure 1: PCR primer layout and coverage. On the outside are the 23 fragments of first round
PCR. Each fragment was selected to have a length of around 800 and as many mismatches between
their annealing site in the mtDNA and homologous nDNA sites. The final result are fragments of
between 421 and 1156 base pairs. On the inside is shown the effective coverage achievable by
using the optimised annealing temperature for each second round PCR fragment (shown in grey).
2.2.2. Second Round PCR: amplification of fragments for analysis using CTCE
The design of the second round PCR fragments had to take into account the
melting profile. As is described in [22], the fragments are required to have a mono-
tone melting profile. Since the second round is performed on the PCR product of
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the first round, the fragments can be designed without concern for homologies
in the nDNA. An automated software was used to scan through the first round
fragments to select sub-fragments with length between 50bp and 150bp and with
monotone melting profile. Once the sub-fragment is selected, a complete GC-
clamp is added to the 5’ end of the ”warm-end” primer (i.e. the primer located at
the end of the fragment with the higher melting profile, whose existence is guaran-
teed by the monotonicity of the melting profile). The second round primers were
all tested, and those found not to work were shifted two base pairs up or down in
the sequence and optimised. This resulted in193 fragments for whom PCR works.
Together they cover 98% of the mtDNA. However, the portions of mtDNA in the
primer cannot be scanned for mutations, thus the portion effectively analysed is
reduced to 76% of the total human mitochondrial DNA. The table containing the
list of second round primers and annealing temperature is in the supplementary
materials.
2.3. PCR Conditions
As PCR buffer we use a 10X Thermopol buffer, which has the following com-
ponents: 200mM Tris-HCl, 100mM (NH4)2SO4, 100mM KCl, 20mM MgSO4
and 1% Triton- X100. It is stabilised at pH 8.8 at 25◦C .
2.3.1. First round PCR
First round samples were amplified using the following recipe.1X Thermopol
Buffer, 0.15µM forward primer, 0.15µM reverse primer, 0.15µM fluorescently la-
beled primer, dNTP 800µM , DNA template 0.3ngµl and Taq DNA polymerase
0.07U/µl . The PCR temperature cycling conditions were as follows, 4 minutes
initial denaturation at 94◦C, then 38 cycles of 94◦C, 15 seconds, 40 seconds an-
nealing temperature (specific to each fragment) and extension time at 72◦C for 150
seconds. All samples and amplified product were stored at −20◦C until analysis.
Element Concentration
10X Thermopol Buffer 0.1
Forward and reverse primer 0.3µM
”Short-GC” Primer 0.15µM
all dNTP 800µM
DNA template 0.3ng/µl
Taq DNA polymeraze 0.07U/µl
Table 2: Protocol for first round of PCR in a final volume of 10µl
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2.3.2. Second Round
Second round PCR was performed for all fragments using the recipe shown
in Table 3. The following PCR cycling were used for all fragments; 94◦C for 60
seconds followed by 30 cycles of 94◦C for 15 seconds, 55◦C for 30 seconds and
72◦C for 60 seconds. All samples and amplified product were stored at −20◦C.
Element Concentration
10X Thermopol Buffer 0.1
Primer without ”GC-clamp” 0.3µM
Primer with ”GC-clamp” 0.15µM
Labeled ”GC-clamp” Primer 0.15µM
all dNTP 500µM
Bovine Serum Albumine at 10mg/ml 1%
200 times diluted 1st round of PCR 0.05µl/µl
Cloned Pfu DNA polymeraze 0.1U/µl
Table 3: Protocol for second round of PCR in a final volume of 10µl
2.4. Capillary Electrophoresis
The PCR product after the first round was analysed using capillary electrophore-
sis (CE). Using the a MegaBace 1000, sample were injected at 5kV during 90
seconds. A DNA ladder for estimating the size of the PCR product is co-injected.
We then run the electrophoresis for 200mins at 9kV with a constant temperature
of 28◦C.
2.4.1. Cycling Temperature Capillary Electrophoresis (CTCE)
CTCE was performed with a MegaBACE1000 DNA sequencer (GE Health-
care Life Sciences, CT, USA)). The instrument software was modified by replac-
ing the ”tmpr.nxe” file with an updated version obtained from Molecular Dynam-
ics (now part of GE Healthcare). The update controls the cooling fan, and tem-
perature limits in the registry. Cycling temperature changes and intervals (cycles)
were specified in the ”macro.ini” file under the section ”Inject Samples and Run”.
Files and detailed descriptions are available upon request. The separation prin-
ciple and general protocol of CTCE has previously been published [22]. The
Polymer used to fill the capillary was obtained from The Gel Company (San Fran-
cisco, CA, USA) The electrophoresis buffer used in the anode and cathode side
was a 1:10 dilution of a 10X running buffer. The 10X electrophoresis buffer was
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made with the following components, 300mM tris, 1.0M TAPS, 10mM EDTA,
pH adjusted to 8.00 and sterile filtered.
Before CTCE, samples are thawed at room temperature. Injection time is 25
seconds, at 10kV. The electrophoresis potential is 9kV and it takes between 30 and
50 mins. In the case where all 193 fragments are organised in 96 well plates with
varying melting profiles, each plate was run six times with six different cycling
temperatures for 20 cycles. The running temperatures are: Run 1 at 44-41◦C ; Run
2 at 47-44◦C; Run 3 at 50-47◦C; Run 4 at 53-50◦C; Run 5 at 56-53◦C; Run 6 at 59-
56◦C. Using this strategy, it is possible to analyse simultaneously fragments with
varying melting temperatures It also has the added benefit of allowing a clearer
identification of double stranded PCR products as they can be seen to shift in time
as the temperature increases.
2.5. Next Generation Sequencing
The preparation of the sample for sequencing was performed using the method
described by Ramos et.al.[11]. The DNA from the 30 subjects was amplified sep-
arately using the PCR condition as described in [11], for a total of 30× 9 = 270
PCR. One µl of product resulting from each of the PCR results was then taken
and pooled together. The library preparation and sequencing was performed at
the Integrated Genomics Facility of UNIL (Lausanne Genomic Technologies fa-
cility, http://www.unil.ch/dafl/home.html). A single library was prepared from the
sample and sequencing was performed using a Hi-seq2000 instrument from Illu-
mina (Illumina Inc, San Diego, CA). Output from sequencing was aligned to the
rCRS (NC 012920.1) using Bowtie2. For a complete description of the options of
Bowtie2, please refer to the manual at http://bowtie-bio.sourceforge.net/bowtie2/manual.shtml.
In brief, Bowtie2 can run in two ways: local and end-to-end. The local mode
aligns only the better matching portions or reads, while the rest are discarded.
The end-to-end mode on the other hand forces the whole read (from end to end)
to be aligned to the sequence. The local mode has higher computational cost.
Bowtie2 contains pre-set options, for both the local and the end-to-end mode.
These present options vary in their degree of selectivity and sensitivity. The more
sensitive ones make use of longer seeds (ie: a sample from the read used to iden-
tify possible alignent areas). These are the following:
• very-fast (Same as: -D5-R1-N0-L22-iS,0,2.50)
• fast (Same as: -D 10 -R 2 -N 0 -L 22 -i S,0,2.50)
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• sensitive (Same as: -D 15 -R 2 -L 22 -i S,1,1.15 the default in –end-to-end
mode)
• very-sensitive (Same as: -D 20 -R 3 -N 0 -L 20 -i S,1,0.50)
• very-fast-local (Same as: -D 5 -R 1 -N 0 -L 25 -i S,1,2.00)
• fast-local (Same as: -D 10 -R 2 -N 0 -L 22 -i S,1,1.75)
• sensitive-local (Same as: -D 15 -R 2 -N 0 -L 20 -i S,1,0.75 the default in
–local mode)
• very-sensitive-local (Same as: -D 20 -R 3 -N 0 -L 20 -i S,1,0.50)
The alignment was attempted with each of the eight preset options, four local and
four end-to-end. The result of the mapping was then used to generate a pileup.
The final result of the analysis was the number of times each base was read, as
well as total coverage and quality score.
2.6. Sample Description and Peparation
The method described in this paper is optimised for the detection and quantifi-
cation of mtDNA mutations in mixed samples. Consequently a sample containing
a large number of variations in the sequence was created. DNA from 30 subjects
was pooled together. For each sample, the starting point was frozen tissue from
which a needle biopsy was taken. DNA was extracted using the Quiagen Mag-
Attract system according to the manufacturer’s instructions. The samples were
digested using Proteinase K and then inserted in the instrument for DNA extrac-
tion. One µl of extracted DNA was taken from each sample and pooled together.
The samples used were taken between 1997 and 2005 at the Norwegian Radium
Hospital, as part of routine care with patient’s informed consent to store surgical
discards for research purpose. Samples were anonymised with respect to patient
information. The exact haplogroups of the individual samples is not known. How-
ever, all patients were Norwegians, and can therefore be expected come mainly
from the H and U happlogroup[30]. Under Norwegian legislation, technical and
methodological development work that uses anonymised biological material does
not require approval by a research ethics committee.
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3. RESULTS
3.1. First round amplification
To verify the effectiveness of the first round PCR, both capillary and gel elec-
trophoresis were used. The resulting amplification are shown in Figure 2, which
demonstrates PCR effectiveness.
3.2. Second round amplification
The 152 fragments cover 12496bp, or 75.4% of the total, this includes the
primers. Since mutations in the primer area are not detectable, only 62% of the
total mtDNA is effectively scanned for mutations. If all the fragments are ampli-
fied separately using the optimal annealing temperature, all of the 193 fragments
will amplify, for a final coverage of 98% of the whole mtDNA thus resulting in
an effective analysis of 76% of the total for the purpose of mutation discovery
(see Figure 1). The primer set has so far been tested on individuals from North
European populations.
Figure 2: Gel Electrophoresis of the first round PCR. On the rightmost and leftmost lane is a
GeneRuler 100 bp DNA Ladder from ThermoScientific. The sizes of the bands are indicated on
the left. The intermediate lane contain the PCR products ordered from the first to the 23rd from
left to right.
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Figure 3: CTCE output example. The electropherogram display mutation detection of the frag-
ment amplified between base pairs 13322 and 13401 of the human mtDNA. The mutant fraction
is calculated by comparing the area under the heteroduplex peaks to the total area.
3.3. Precision of CTCE
To check the precision of CTCE, an experiment with serial dilutions was per-
formed. The starting point is the DNA from two sources, one with a mutations at
an appreciable level in one of the fragments and the other without any mutations
in that fragment. A series of twelve wells is then prepared. The first well contains
only the sample from the mutated DNA. The subsequent wells were constructed
by mixing equal volumes of the previous well with the non mutated sample. This
experiment was performed separately for two different samples with mutations in
different fragments of the mtDNA. Figure 4 shows the logarithm of the mutant
fraction as a function of the well number or the dilution. The mutant fractions ob-
tained by CTCE cluster around a line, which demonstrates the precision of CTCE
in determining mutant fractions down to a detection limit of around 1%. Note that
the two regression lines do not have slope −1. The slope would be −1 only if the
DNA concentration in the initial two DNA extraction were identical. Differences
in DNA extraction efficiency as well origin of the samples could accounts for the
different concentration of mtDNA in the initial samples.
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Figure 4: Precision of CTCE. The computed mutant fraction is shown as a function of dilution
number. The two colours show the two different samples for which the dilution series of mixed
samples into homogeneous sample was performed. How well the samples adhere to a straight
line is a measure of the precision of CTCE when it comes to quantifying the mutant fraction in
a mixed sample. The slopes are the result of the serial dilution series by a constant factor. We
diluted the mixed sample by a factor 2 in volume, but since the initial mtDNA concentration in
both samples is unknown, the slope is expected to be different from one. One might calculate the
ratio of mtDNA concentration between both samples using the present figure.
3.4. Mutations
The use of CTCE allows the detection and quantification of mutations in any
of the fragments. It does not, however, identify the nature of the mutation. The
data from sequencing is thus arranged in a manner to make it comparable with
CTCE by counting in each of the CTCE fragments the number of mutations found.
Restricting the analysis to the 152 fragments in which mutations can be found
using CTCE when processing the samples in parallel (Table 5).
Out of the 152 fragments analysed, 90 were perfectly concordant (same num-
ber of mutations identified), 11 were semi concordant, and 51 were discordant
(see Figures 5 and 6).
3.5. Concordance of CTCE and sequencing
Figures5 investigate the concordance and discordance between CTCE and se-
quencing. Figure 5 shows a good concordance in both presence and number of
mutations in each fragment between the methods. Also clearly visible are frag-
ments where CTCE finds mutations that are not validated by sequencing or vice
versa. Table 5 shows an overall summary
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Sequencing Parameter
Reads ∼ 339×106
Mapped reads ∼ 60% (alignment dependent)
Average number of times a base was read 596000
Minimum number of times a base was read 87000
Table 4: This table describes the output of sequencing with Illumina Hi-Seq 2000 and read align-
ment. The low percentage of mapped reads has been confirmed by another experiment where a
100bp homogeneous sample was sequenced (Per Ekstrom, currently unpublished results)
CTCE Sequencing
Total Mutations Identified 89 79
Fragments with mutations 59 51
Table 5: This table compares CTCE and sequencing in terms the mutations found and the number
of fragments where a mutations was identified
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Figure 5: Mutations in each Fragment. For each fragment, the numbers of mutations found by
CTCE and by Hi-seq. The positions are the fragment numbers. Each vertical line is a fragment,
so a position without a bar is an fragment where no mutation was found. The top part of the
plot shows the mutations detected using sequencing, and the lower panel (in negative) shows the
mutations detected using CTCE in the same fragment.
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4. DISCUSSION
4.1. Discordance of CTCE and sequencing
Figure 6 shows that there are clear discordance between sequencing and CTCE.
Three problematic areas can be distinguished in the plot. There are two groups
of fragments where sequencing detects five or more mutations and CTCE detects
two or more. In this case the explanation could be an underestimation of the mu-
tant number by CTCE. In fact, the complexity of the electropherogram increases
exponentially with the number of mutations present in the fragment. The second
problem concerns fragments where sequencing detects two or more mutations
whereas CTCE finds none. These areas are most likely due to sequencing noise
introduced in sequencing or post-processing of results. The third area of discor-
dance are the cases where sequencing finds two or less mutations and CTCE finds
more mutations. Since the detection limit of sequencing is in the order of 15%
(Figure 8) this is to be expected.
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Figure 6: Sequencing results as a function of CTCE results. This plot correlates the number of
mutations found by sequencing and by CTCE. The size of the dot represents the number of times
that specific configuration has occurred. All the sequencing results shown here are those mapped
using the ”very-sensitive-local” method.
43
4.2. Alignment of sequencing results
The raw output from the Illumina Hi-Seq2000 are a series of short reads
(roughly 100bp long). In the order of 108 reads are created in a sequencing run.
Alignment is the process of determining which portion of the analysed sequence
each read represent. The interpretation of sequencing results is heavily dependent
on the alignment procedure. It is clear that low rate of alignment errors will create
a background of apparent mutant fraction across the sequence. Figure 7 shows
the spread of mutations and mutant fractions as detected using different alignment
procedures on the same output. There are inconsistencies, with discordant mu-
tant fractions for most mutations. There are also several cases of an alignment
procedure detecting a mutation, even at a high fraction that is not confirmed by
other alignment results. Inspection of the data reveals the alignments cluster into
two groups with roughly similar behaviour. The end-to-end alignments, which are
the Bowtie2 defaults, and the local alignments. Within the two groups, increasing
stringency does not make a visible difference. It is not possible to decide which
alignment method, local or end-to-end is more accurate using the observed output
alone. Local alignment is a more conservative approach as it contain fewer mu-
tations at lower fractions. Comparison of sequencing results with CTCE results
shows a greater similarity between CTCE and local alignment than with end-to-
end alignment. The different alignment procedures also succeed in aligning a dif-
ferent number of reads. End-to-end alignment typically aligns around 58% of the
reads, whereas the local alignment reaches around 60%. We do not have enough
data to test the significance of this finding. These results corroborate doubts about
the usability of sequencing methods for the detection of low frequency mutations
put forward in Taylor et al. [13] and Hancock et al. [31, 32], which suggests
that the detection limit of mutant fractions by sequencing is somewhere between
20 and 30%. Though more accurate analyses are possible[33, 34, 35], they in-
volve higher complexities and costs. The error rate estimate of 30% therefore
reflects what is possible in routine analysis. Figure 8 shows the number of muta-
tions found in the whole mtDNA when applying different thresholds per base pair.
Assuming the number of mutations present in the sample is in the order of 100,
the threshold for local alignment can be placed slightly below 5%, whereas the
threshold for end-to-end alignment (used in [13]) would be slightly below 10%.
Since the threshold is for each base pair, the total noise level is three times the
threshold, thus roughly 30% for end-to-end alignments and 15% for end-to-end
alignment. If the sample analysed is known to contain few mutations (in the order
of one or two), the detection limit can be significantly reduced by applying more
stringent alignment methods[33, 34, 35].
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Figure 7: Variations between alignment results. The mutations found by next-generation se-
quencing as reported by different alignment methods are shown in this plot. The graphs shows for
each position, the spread of mutant fraction found by the eight alignment method tested. The line
covers the interval of the minimum fraction to the maximum fraction. A line that touches the x
axis means that at least one method of alignment did not find a mutation at that position.
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Figure 8: Mutations found as a function of baseline. For each position in the mtDNA we have
a number of reads that result in an A, T, G and C. If any of these number is less than the baseline
times the number of total reads at that position it is set to zero. To justify our choice of baseline,
we show here the number of mutations found as a function of the baseline chosen. High baseline
detects too few mutations, and inversely for low baseline. The chosen level of baseline was 5%
for local alignment and 10% for end-to-end alignment.
4.3. Cost analysis
Once a method to cover a desired sequence of DNA is established, the cost of
performing a CTCE analysis is many orders of magnitude smaller than sequenc-
ing. For the analysis of 62% of mtDNA of a single sample, as we performed here,
we calculate that the total cost of the procedure is around 75 USD. A more de-
tailed explanation is given in Table 6. The time it takes to perform the complete
analysis is 20 hours, of which 4 hours are work and the rest is waiting time. The
costs involved with next generation sequencing are much higher. For a detailed
evaluation of the cost please refer to one of the many reviews [36, 37]. The cost of
library preparation and sequencing by the facility at University de Lausanne was
1920 CHF ( 2200 USD at the time). All other costs are not taken into account as
they are much smaller.
4.4. Conclusion
This paper proposes a fast, quantitative and inexpensive method of analysing
mutations in a sample containing a mixed population of mtDNA. The method
clearly performs better than sequencing in terms of cost, speed and precision, with
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Experimental Step Materials used Approximate Cost
First round PCR, 23 re-
actions
General PCR reagents 5 USD
Second round PCR, 193
reactions
General PCR reagents 20 USD
CTCE Capillary depreciation,
Gell and Buffer
50 USD
Table 6: The table shows the cost of running a CTCE analysis on a single sample. It excludes
the value or depreciation of the equipment and electricity. PCR thermocycler and capillary elec-
trophoresis machinery should be available. We include all consumables.
the drawback of not identifying the mutation. It detects mutations at fractions as
low as 1% and it furthermore determines their fraction accurately. Coupled with a
cost below 100 USD per sample, high throughput and fast results, it can be applied
in various areas of biology. For example in the quantification of mutant fractions
in a large number of samples taken using Laser capture micro dissection.
Appendix A. Additional file — Second Round Primer list
An excel file containing the list of all second round primers complete with
GC-clamp. The file show the set of primer sequences as well as which first round
PCR template the primer amplifies on.
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7 Clinical Applications
After writing and submitting the paper [93] it was clear we had a solid method in hand. It had
been designed tried and tested, as well as proven superior to the standard NGS approach. The next
logical step was to answer the question raised by the first experiment, and find out the frequency
and distribution of mutations in tumors. We already had a large amount of DNA extracted from
tumor samples, and many tumor samples in the freezer. Scanning the mtDNA in a large number
of DNA samples, extracted from human tumors, could give us a much better understanding to the
distribution and frequency and distribution of mtDNA mutations. The details of this work can be
found in the paper [94].
7.1 Resulting Publication: Scanning the mitochondrial genome for
mutations by cycling temperature capillary electrophoresis
7.1.1 Short description
The article describes the result of applying the method described in our first paper to 94 different
human tumors. 12 tumors of 8 types are scanned for the presence of mitochondrial mutations,
which would also alert us to significant differences between tumor types. The results show
that a majority of tumors carry a mutations on the mitochondrial DNA, although often at low
fractions. Also, the mutations are not uniformly distributed throughout the mtDNA. Around 20
out of 192 fragments contain almost 80% of all detected mutations. All mutations that were
present at a fraction above 30% in the samples, were Sanger sequenced (SS), and the base pair
substitution identified (mutations at a fraction below 30% cannot be identified in SS). No two
identical mutations were found. The position, nature and amount of mutation does not depend on
the cancer type. mtDNA mutations therefore happen in a process that is independent of cancer
type.
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7.1.2 Significance
The results that Christian Arstad obtained did not show any detectable difference in mtDNA
mutations between various tumors. Also, it allowed us to better understand the mutational
spectra of mtDNA in tumors. Finding that most mutations occur in only a small fraction of
the genome, greatly streamlined the mutation discovery phase in lineage tracing. Scanning the
hots-spots only gives a good chance of identifying markers, without scanning the whole mtDNA.
A scanning of the hot-spots only represents 30 CTCE fragments, compared to 192 fragments
for the whole mtDNA. This greatly increased the number of samples scanned, or reduced the
necessary time. Furthermore, sequencing mutations identified with CTCE also offered another
independent validation of the method. Last, it reinforced the validity of one of the hypothesis
made in lineage tracing: "No independent occurrence of identical mutations." The fact that not a
single one of the sequenced mutations was identical (even when many of them where on same
fragment), greatly increased our certainty in the hypothesis.
7.1.3 Personal Contribution
Christian Arstad arrived in the lab shortly after we were certain we had a solid method to analyse
and detect mutations. My supervisors and myself already were wondering about the distribution
of mutations in the mitochondrial genome, so his arrival and proposition to take up the challenge
came at a perfect time. Having designed the method, I assisted him to set up the experimental
plan, and perform some of the original mtDNA scanning. I also contributed to analysing some of
the data and writing the paper.
7.1.4 Status
Published on the 11th October 2016, in Mitochondrial DNA Part A. [94]
7.2 Resulting Publication: Intraperitoneal exfoliated tumor cells
detected after surgical resection of rectal cancer. A prognostic
factor on survival?
7.2.1 Short description
Intraperitonealcancer cells (IPCC) can be found in the peritoneal cavity following surgical
removal of colon and rectal cancer. Part of the standard operating procedure, is to wash the
peritoneal cavity with saline solution following surgical removal of the tissue. The fluid is then
removed and can be used for analysis, a procedure known by its french name:"lavage". There
is general debate in the community as to the effect of IPCC in cancer relapse, for example by
being the source responsible for local metastasis or regrowth (a detailed literature review is
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7.2. Resulting Publication: Intraperitoneal exfoliated tumor cells detected after surgical
resection of rectal cancer. A prognostic factor on survival?
given in the paper Arstad et al, currently in press). In a previous paper by my co-supervisor
Per Ekstrom, an attempt was made to detect IPCC using Kras mutations [95]. The results were
difficult to interpret due to the low prevalence of Kras mutations. I was using mtDNA as a marker
of tumor lineages, and so the idea came that they could also be used for the detection of IPCC.
The material and extracted DNA was already available from the previous Kras study, and the
method to perform the experiment existed. Furthermore, the hot-spots of mtDNA in cancers were
known from the previous application, which meant that only the hot-spots could be scanned for
markers. DNA extracted from primary tumors and from lavage fluid was available for 191patients.
Out of these191patients analyzed, 138 (72%) had mtDNA mutations in their primary tumors, out
of which 45 (33%) had the same mutation detected in the lavage fluid, Thus guaranteeing the
presence of IPCC. No relationship was found between the presence of IPCC and cancer survival,
with an observation time of 5 years. The conclusion was that, we could well detect the presence
of IPCC using a linear tracing approach, but IPCC has no effect on survival. Metastasis and local
recurrence are therefore not a consequence of the presence of IPCC after surgery.
7.2.2 Significance
This paper demonstrated how CTCE and lineage tracing can be applied to clinical questions and
applications. If the presence of IPCC was a prognostic factor for post-surgery survival, then
the lineage tracing method we developed would have an immediate clinical application. In the
other case, an important question of cancer metastasis would be answered: "Wether IPCC are
responsible for the seeding of metastasis." In detecting the presence of the same mutation in
both primary tumor and lavage fluid, the ability of our CTCE method to detecting IPCC was
established. The results obtained did not support the theory that IPCC presence was a prognosis
factor for tumor development. This invalidates theories that would see IPCC involved in the
development of metastasis. An important finding that shows the ability of mtDNA mutations
based lineage tracing methods to answer important questions of oncology.
7.2.3 Personal Contribution
Christian Arstad was at this point fully confident in the use of CTCE to detect and quantify
mtDNA mutations. He therefore performed all of the experimental work himself. I contributed
to the experimental design, statistical analysis of results and results interpretations. I also
significantly contributed to writing the manuscript and responding to reviewers.
7.2.4 Status
Published on the 7th of June 2017, in BMC cancer [96].
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8 Measuring Mitochondrial DNA Copy
Number
The number of mtDNA copies in cells is currently unknown for most cell types. There is also
speculation that the copy number could change in cancer tissues [97, 98]. Mathematical modelling
of how mutations arise and become homoplasmic place a major emphasis on the importance of
copy number [5, 4]. A significant variation in copy number from normal tissue to tumor tissue,
could change the probability of mtDNA mutations becoming homoplasmic, or reaching a high
fraction of the total number. In the interpretation of the mutational analysis, it was therefore
important to have approximations of the copy number in our sampled tissue. We also needed
to answer the concern that the areas that were found to carry a mutation at a homoplasmic level
had a much lower copy number of mtDNA per cell than the other areas. A result that would
compromise our hypothesis of lineage tracing that independent identical mutation at high fraction
is a very rare event. The standard way in which relative copy number is quantified is real time
PCR (rtPCR). When we first attempted to use rtPCR, we noticed high variations in the results. It
was therefore decided that more investigation in the precision of rtPCR was needed if we wanted
estimates of mtDNA copy numbers in our samples. The results of this research can found in
section 8.1.
8.1 Resulting Publication: Quantifying mitochondrial DNA copy
number using robust regression to interpret real time PCR
results
8.1.1 Short description
This is a technical note, which describes an improved method to analyse rtPCR output data. The
standard way to analyse rtPCR data is using the ∆CT method which suffers from two major
drawback: assuming that the efficiency is the same for all samples compared, and requiring
cumbersome dilution series to estimate PCR efficiency. The first assumption is either wrong, or
requires optimisation and cumbersome dilution series to validate. The robust regression method
proposed in this note automatically isolates the exponential portion of the rtPCR output, and
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therefore measures PCR efficiency. This permits easy measurement of efficiency, without dilution,
as well as the comparison between samples with different efficiencies.
8.1.2 Significance
The robust regression method was used to estimate mtDNA copy number in tumor and normal
tissue. A possible explanation for the mtDNA mutations found in tumors could have been a
much smaller number of mtDNA, and thus a much higher probability of a mutation reaching
a high fraction. Verifying that there was no significant difference in mtDNA copy number
between normal tissue and tumor tissue invalidated that explanation. In doing so, the hypothesis
of no independently occurring high fraction mtDNA mutation was reinforced. The method
described, allows the comparison of fewer samples than the ∆CT method, which made possible
the estimation of mtDNA copy number in LCM samples. The technique was therefore used to
compare a sample with a homoplasmic mutation with wild type samples in the paper described
in section 9.2. In a more general sense, the availability to the community of an R package that
can make the analysis ad-hoc. Increased use of robust regression to analyse rtPCR results would
result in a general improvement in the accuracy and simplicity of rtPCR as a method for research
or diagnostic.
8.1.3 Personal Contribution
Per Ekstrom and myself designed the primers for rtPCR. I was then responsible for optimising
them and performing the experimental work. Stephan Morgenthaler had the Idea of using a robust
regression. I did all the implementation, testing and optimisation of the Data analysis method, as
well as most of the writing.
8.1.4 Status
Accepted with minor revisions the 7th of Jully 2017, in BMC Research Notes.
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Abstract
Background Real time PCR is a widely used method to quantify relative
DNA copy number. The data analysis of rtPCR output is still left with
challenges. The most widely used method is the ∆Ct method, which requires
all of the compared DNA fragments analysed to have the same PCR efficiency.
An alternative method, that relies on fitting a robust regression to the rtPCR
signal is proposed. The robust regression automatically fits the exponential
portion of the curve. This methods reduces potential biases and allows the
comparison of DNA fragments with different PCR efficiencies.
Findings The results from robust regression and ∆Ct methods are sim-
ilar. The spread of results when the same PCR is performed 96 times is
similar and can be approximated by a normal distribution in both cases.
Estimating the efficiency with the ∆Ct method requires a dilution series,
which is not required for the robust regression method. rtPCR is the used to
quantify mtDNA copy number in three different tissues types: breast, colon
and prostate, as well as associated tumors taken from the same patient, for a
total of six tissues (from three patients). The mitochondrial copy number per
cell is estimated between 200 and 300 copies per cell. When analysing the
same tissue with the robust regression and the ∆Ct method, similar results
are obtained, although the confidence ratio is slightly better for the robust
regression.
Conclusion Using a robust regression to identify the exponential phase
does not identical PCR efficiency when computing relative DNA concentra-
tion. This removes the requirement of optimising the reaction before as well
as remove a source of potential bias. The method used has been implemented
Preprint submitted to Elsevier January 18, 2017
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as an R package for convenient use.
Keywords: , rtPCR, robust regression, mitochondrial DNA
1. Background
Mitochondrial DNA (mtDNA) is composed of a single circular chromo-
some of 16569 base pairs (hg38, GRCh38, Dec. 2013). It encodes for 22
tRNA, 13 protein subunits and two ribosomal RNA subunits. The proteins
are key proteins of the oxidative phosphorylation chain. The tRNA and ribo-
somal subunits are required to process the genes and synthesize the proteins.
Better measurements of mtDNA copy numbers would improve the under-
standing of mtDNA mutagenesis [1, 2, 3]. Furthermore, it is important to
understand the growth and distributions of somatic mutations in mtDNA,
which is crucial for gaining insights into the transition from heteroplasmy
to homoplasmy in tumor cells, cell lineage in normal tissue and questions
relating to metabolic changes in tumor development [4]. The symptoms
and severity of mitochondrial diseases depends on the mutant fraction and
on the tissue [5, 6, 7, 8]. Mitochondrial mutations also appear to be in-
volved in cancer development [9, 10, 11, 12, 4], and aging [13, 14, 15, 16].
Somatic mitochondrial mutations are an important tool for lineage tracing
[2, 17, 18, 19]. Most methods depend on the detection of mutation that have
achieved homoplasmy or are very close. Accurate copy number estimates
are important in the cellular mitochondrial dynamics, and therefore in the
process through which cells become homoplasmic. The standard method for
quantifying DNA copy number is real time PCR (rtPCR)[20, 21, 22]. Most
methods rely on amplifying a mitochondrial and a nuclear fragment in sep-
arate reactions, with the template from the same sample[22, 12]. There has
been much development in the analysis of rtPCR output, however, there are
still challenges [23, 24].
Problem
The output of rtPCR reaction is the fluorescence measured at the end
of each PCR cycle, which is proportional to the amount of double stranded
DNA in the sample. It is a measure of the PCR reaction progression. Three
phases can be observed:
Phase I: Lag phase: The signal is too low for the detector, only the noise
is visible.
60
Phase II: Exponential phase: Signal grows exponentially with the number
of cycles.
Phase III: Saturation phase: Signal increases sub-exponentially, or not at
all as the PCR reaction saturates.
The dynamics of the PCR reaction can only be observed during Phase II.
The signal can be modelled by an exponential function: S = αNEc. In this
equation, N is the number of DNA copies at the start of the experiment,
S is the signal, α is an unknown constant relating the copy number to the
signal intensity and c is the cycle number. The constant α is related to
parameters such as detection efficient or fluorescence per base pair, and it is
assume that this value is constant and does not depend on the sample. The
standard method to analyse rtPCR is the ∆CT method. A signal threshold
T is chosen, a little above the noise level. The CT value is defined as the cycle
number at which the signal crosses the threshold. It is calculated by taking
a linear interpolation between the first signal value above the threshold and
the one immediately below, then taking as CT the value at which the line
intersects the chosen threshold. If there are two samples, A and B, for which
rtPCR signal have been obtained, threshold yields an equation relating the
initial copy numbers of the two samples.
T = αNAE
CA
T
A
= αNBE
CB
T
B
or
NA
NB
=
E
CB
T
B
E
CA
T
A
Assuming equal efficiency for both reactions, EA = EB = E, the equation
becomes
NA
NB
= E∆CT
Where ∆CT = C
A
T
−CB
T
. The ∆CT method has a few clear flaws, which have
already been pointed out and demonstrated by Karlen et al [23]. The first
one is the assumption of equal efficiency which is essential to this method. If
the fragments used are not the same, as is the case for the quantification of
mtDNA, the reaction needs to be optimised to have equal efficiency. If PCR
efficiency depends on initial DNA concentration, as some results suggests
[22], this would introduce errors in the measurements.
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Proposed Solution
The objective of rtPCR is to measure the relative initial copy number NA
NB
between two samples. The exponential phase is linear in the cycle number,
taking the logarithm results in:
log2 S = c log2E + log2(αN), log2(αN) = I the Intercept of the curve
The logarithm is taken to be in base two unless indicated otherwise. If
based on several consecutive values of (c,S), we determine the coefficients of
this linear equation, the intercept term (the value at c=0) measured for two
samples A and B yields the formula.
NA
NB
= 2IA−IB
The above formula relies only on the constancy of α and does not require the
efficiency to be the same. It was shown that methods that rely on observed
values of (c,S) during the exponential phase and a regression fit to obtain the
constants perform much better than the ∆CT method [23]. Furthermore, the
slope of the regression determines the logarithm of the efficiency without re-
lying on diluting the sample. The same exact mix could be analysed multiple
time and the efficiency measured with greater precision. Because unequal ef-
ficiencies are permissible, the fitting of a regression line reduces the difficulties
in optimising the PCR reactions and improves precision. Previous methods
relied on the manual selection of the exponential phase [23, 24, 25, 26], or
on cumbersome mathematical models. The solution proposed is to use a
highly robust linear regression on the log of the signal. The robust regression
minimises the median of the square residuals, instead of the mean squared
residuals (Least squared method). Results show it reliably identifies the ex-
ponential phase of the rtPCR signal and gives a good measurement of the
efficiency E and intercept I for each reaction. Using multiple replicas of the
same experiment and taking averages, the precision of the estimates can be
increased.
2. Materials and Methods
Tissue and DNA extraction
Anonymous surgical discharges were obtained after standardised informed
consent. Tissue was stored at the surgical department at -70◦C until DNA
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extraction. According to Norwegian Law, technical and methodological de-
velopment work that uses anonymised biological material does not require
approval from research ethics committees (Web page, last access November
2016). Normal and tumor tissue was obtained from three different patients
with 3 different tumor types (breast, prostate and colon). The normal tissue
was taken at a distance of 10 to 15cm from the location of the tumor. A few
milligrams were taken from each sample and subjected to DNA extraction.
DNA extraction
Samples were digested with proteinase K for 4 hours at 57◦C in 300µl
of digestion Buffer (Qiagen, Hilden, Germany) according to manufacturer’s
instructions. DNA was extracted from them using the Qiagen MagAttract
DNA Mini-M48 Kit with a dedicated automatic solution also provided by
Qiagen. The result is a DNA solution containing approximately 50ng of
DNA per µl .
Primers
Primers were designed using the rtPCR primer design tool of IDT (Inte-
grated DNA technologies). The tool designs primers with similar efficiency,
annealing temperature, and attempts to avoid the formation of tertiary struc-
tures. The nuclear and mitochondrial primer pairs were designed for simul-
taneous amplification. Table 1 shows the primer pairs.
Primer amplification conditions were then optimised to allow the same
PCR conditions to be used for both pairs simultaneously. When designing the
primers, attention was paid to homologies between nuclear and mitochondrial
DNA sequences. The mitochondrial primer was chosen so that it could not
amplify in the nuclear genome (and vice versa).
rtPCR condition
Real time PCR was performed using a BioRad CFX connect Real-time
PCR detection System. PCR recipe was 2X Perfecta SYBR Green SuperMix
for iQ (QuantaBio, Beverly, MA, USA), 0.2 µM of each primer, for a final
volume of 20µl . The PCR temperature cycling used: Initial denaturing
at 94◦C for 4min, followed by 45 cycles of denaturing at 94◦C for 30 sec,
annealing at 60◦C for 30 sec and extension at 72◦C for 1min.
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Experiment
For both the mitochondrial and the nuclear primers, 96 replicas (a whole
plate) of the same identical rtPCR are produced. A 2ml PCRmix was created
(as described the section ”rtPCR Condition”), to which 4µl of extracted DNA
was added. The mix was spread on a PCR plate adding 20µl of it into each
well. Serial dilutions for both primers were used to estimate PCR efficiency
with the ∆CT method, testing for changes in PCR efficiency and give an
indication of precision. For both primers, the initial rtPCR mix is serial
diluted into rtPCR mix without DNA, by a factor 5, for 6 steps. There are
16 replicas for each dilution for a total of 16×6 = 96 reactions As an internal
consistency check, the mtDNA copy numbers is measured for each tissue on
extracted DNA and extracted DNA diluted 10. Each tissue therefore has 4
different rtPCR reactions: Nuclear DNA, mitochondrial DNA, nuclear DNA
diluted by 10, and mitochondrial DNA diluted by 10. Each rtPCR reaction
has 24 replicas, thus the total number is 4 × 24 = 96 (a complete 96 well
plate).
Data analysis
Data analysis is performed using an R package developed specifically for
the analysis of rtPCR results. The package, together with the codes used to
generate the graphs and tables are included in the supplementary materials.
The efficiency and intercept associated with each rtPCR reaction is estimated
by fitting a robust linear regression on the base two logarithm of the signal.
First the middle point is determined as the couple (cm, logSm), where log Sm
is closest to max logS+min logS
2
. Forcing passage through the middle point en-
sures the regression fits the exponential phase. This only requires the fitting
of the slope.
The relative copy number between two experiments is defined as NA
NB
=
2IA−IB which is estimated by taking the difference in the mean intercept,
estimation of (
NA
NB
) = 2(IA−IB) = 2∆ˆI
The intercept is assumed to follow a Normal distribution, which is justified
by inspection of the results from 96 replicas. The 95% confidence interval for
∆I can therefore be estimated as:
C.I. = ∆ˆI ±W ;W = q0.975(tnA+nB−2)×
√
V ar[IA]
nA
+
V ar[IB]
nB
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Where q0.975 is the 97.5% quantile function, tν is the t distribution with ν
degrees of freedom, and nA and nB are the number of replicas for A and
B respectively and the variances are estimated from the replicated values.
From this confidence interval, one derives an interval for the relative copy
number of the form of NA
NB
× 2±W , which is in fact a confidence ration. 2W is
the maximal relative error in the copy number due to statistical uncertainty.
One can interpret the C.R as follows:
P (Crelative ⊂ [
NA
NB
− C.R.,
NA
NB
× C.R.]) = 95%
In sum, the boundaries for confidence interval of the actual relative concen-
tration, can be calculated by multiplying and dividing the estimated relative
concentration by the C.R.. The baseline noise in a rtPCR reaction is esti-
mated by taking the highest point for which the first derivative of the signal
as a function of the cycle number is negative. The threshold to calculate
the CT value is chosen by taking the highest value for the baseline in an
experiment. When relative concentrations are calculated between 2 samples,
the same threshold was used to calculate the CT value.
3. Findings and Discussion
Figure 1 shows the results of repeating 96 times the same reaction. The
efficiency and intercept, calculated using the robust regression, as well as
the CT values are shown. In all three cases, the values group together with
5 outliers. These outliers are not PCR failures. They represent genuine
variation in PCR performance on identical rtPCR mix. These results justifies
the use of a normal approximation.
Figure 2 shows the result of the dilution series. For both nuclear and
mitochondrial DNA, the measured concentration relative to the first point
was calculated using the ∆CT method and the robust regression method.
The vertical axis is the logarithm base five of the relative concentration. The
slope of the curve should be −5, by construction.
It can be seen that the robust regression gives, in both cases, a slightly
better slope than the CT method. This difference does not appear to be
significant. The dilution series can be used to estimate the efficiency of the
PCR using the CT method. If the efficiency is assume identical in all samples:
NA
NB
= E∆CT ⇒ log5
NA
NB
= ∆CT log5E
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The logarithm of the dilution factor, is linearly related to the ∆CT , and the
slope is the log of the Efficiency. Results can be seen in figure 3.
The estimates of mtDNA copy numbers can be seen on table 2. The
estimates of mtDNA copy number are constant, ranging from 100 to 150
copies of mtDNA to nuclear DNA. The values need to be multiplied by 2
to obtain the number of mitochondria per cell. The confidence ratios are
around 1.3. The ratio between the measured concentrations of mtDNA,
and diluted mtDNA should be 10, by construction. The same is true for
nuclear DNA. Taking into account the confidence ratios associated with the
measurement, the diluted samples have indeed a copy number 10 times below
their un-diluted counter-parts. Observing a CR of 1.3 is and a mitochondrial
copy number of 200, corresponds to having a 95% certainty that the real
value lies from 150 and 260. This precision was achieved with 24 replicas.
The CR decays very slowly as a function of the number of samples. Using
a robust regression to analyse rtPCR data presents major advantages over
the ∆CT method. First, it does not make the assumption of identical PCR
efficiency between two samples. This reduces potential biases, and allows for
the comparison of fragments/samples with clearly different efficiencies. It also
allows the estimation of PCR efficiency without performing dilution series.
There is reason to suspect that the efficiency and the initial concentration
are not independent. To illustrate this point, the efficiency of the dilution
series is shown in figure 3. If indeed the efficiency depends on the initial copy
number, it would be a major flaw in the estimates made with the ∆CT value.
For comparison, the prostate tumor tissue is analysed using the ∆CT method,
and the results can be seen in table 3. The results are slightly different than
those estimated using the robust regression. They are, however, coherent, if
the larger confidence ratio is taken into account. It might also explain that
the result measured, is much higher than the one observed using the robust
regression. Karlen et al [23] also shows that the ∆CT method performs well in
the case of identical efficiencies, but perform poorly in other circumstances.
The robust regression method offers an alternative way to analyse rtPCR
data. It’s major advantage is not requiring identical efficiency between sam-
ples. This removes the necessity of PCR optimisation as well as remove a
potential source of bias.
List of abbreviations used
• rtPCR: real time polymerase chain reaction
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• DNA: deoxyribonucleic acid
• mtDNA: mitochondrial DNA
• tRNA: transcription ribonucleic acid
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Figure 1: Histograms showing the distribution of Efficiency, intercept and CT . Data shown
from 94 replicas. For each reaction, the robust regression method is used to compute the
efficiency and intercept.
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Figure 2: Dilution series: DNA concentration in the PCR mix is serialy diluted by a factor
5, six times. The DNA concentration is measured using the robust regression method and
the ∆CT method. Each concentration is prepared in 16 replicas. The same procedure is
reproduced for both nuclear and mitochondrial DNA. Regression lines are fitted using the
least squared method. The data has been shifted slightly left and right of the true value
for illustration purposes.
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Figure 3: Calculating the efficiency using the ∆CT method. The measured CT values for
each dilution are plotted. The slope of the fitted line can be used to estimate the efficiency.
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Tables
Primer Sequence (5’ to 3’) Genome region
Mitochondrial Forward ACA CCC TCC TAG CCT TAC TAC chrM: 10087 - 10192
Mitochondrial Reverse GAT ATA GGG TCG AAG CCG C
Nuclear Forward AGG GTA TCT GGG CTC TGG chr11: 2170993-2171170
Nuclear Reverse GGC TGA AAA GCT CCC GAT TAT
Table 1: Primer sequences used to amplify nuclear and mitochondrial DNA sequences.
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Tissue Sample Type Efficiency Concentration Relative Error
Breast Tumor
mtDNA 2.08 129.3 1.29
mtDNA/10 2.13 6.87 1.47
Nuclear 2.02 1 1
Nuclear/10 1.99 0.16 1.4
Breast Normal
mtDNA 2.19 132.13 1.4
mtDNA/10 2.02 38.54 1.36
Nuclear 2.03 1 1
Nuclear/10 2.02 0.09 1.38
Colon Tumor
mtDNA 2.13 132.72 1.35
mtDNA/10 2.1 12.95 1.32
Nuclear 2.01 1 1
Nuclear/10 2.01 0.09 1.45
Colon Normal
mtDNA 2.11 219.19 1.5
mtDNA/10 2.11 20.82 1.56
Nuclear 2.05 1 1
Nuclear/10 1.99 0.2 1.51
Prostate Tumor
mtDNA 2.17 134.14 1.41
mtDNA/10 2.11 15.79 1.39
Nuclear 2.04 1 1
Nuclear/10 2 0.16 1.47
Prostate Normal
mtDNA 2.12 172.65 1.49
mtDNA/10 2.08 22.21 1.47
Nuclear 2.02 1 1
Nuclear/10 2.01 0.13 1.55
Table 2: Relative concentration of samples for each tissue type. The nuclear DNA con-
centration is taken as reference, and is therefore 1. The relative error (confidence ratio) is
also 1 as there is no uncertainty associated with it. The other concentrations are relative
to nuclear DNA and the relative error associated with is. The values for the efficiency are
the average efficiency over the replicas.
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Concentration Relative Error
mtDNA 288.33 1.52
mtDNA/10 23.45 1.44
Nuclear 1.00 1.00
Nuclear/10 0.11 1.52
Table 3: Concentrations calculated using the ∆CT method in Prostate Tumor sample.
The confidence ratio is estimated using the t-interval.
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9 Two-dimensional Lineage Tracing
At this point, we had a solid protocol for the analysis of mtDNA mutations in micro-anatomical
samples. We understood the need to sample macroscopically beforehand, to identify the fractions
that contained mutations that could be used as marker in the tumors. Our PCR reactions and
CTCE conditions were optimised, as was our sample processing technique. However, we still
held on to the idea that somehow, tumor areas could be identified. To identify tumor areas, we
believed that a better sample preparation was needed. We still believed that one of the reasons that
we failed in our first experiment was poor sample selection. Various tests with different staining
were then made, and are described in the chapter 5. After many experiments and testings, no
conclusive way of separating tumor cells from normal cells in the neighbourhood of the tumor was
found. If it is impossible to define which areas in a tumor sample, are tumor in origin, and which
are normal in origin, then any attempt at selecting structures based on morphology is bound to
fail. The samples taken in the first experiment (chapter 4), were selected areas of the tumor mass,
which together represented only a small fraction of the total area of a slice. Even if a mutation
was present, it is possible we did not detect it. Also, the size of the sample was too large, as later
results show. After coming up with an acceptable slice preparation protocol, experiments were
made to characterise the behaviour of our LCM equipment. In previous experiments, samples
were often lost due to miss falls. A 16 caps holder, sample collection was built and the protocol
for collecting the samples and extracting the DNA was streamlined. Allowing 96 samples to be
collected in 30min. Small samples often do not fall after being cut by the laser, possibly due to
static electricity, or simply insufficient weight. Also, smaller samples contain less DNA, which
results in a higher rate of PCR failure in the first round. A compromise therefore had to be found
between sample size and resolution. Circles of 25000µm2 were selected as a good compromise.
The same sample size was used from there onwards in all the LCM sampling.
Without ways of identifying tumor areas in samples, we decided to take slices across larger pieces
of tissue, in which some portion of the tissue could be identified as normal. Scanning the whole
mtDNA for each small LCM sample was deemed too time consuming. To identify pieces of
tissues that were potential candidates for LCM analysis, slices of tissue were taken using the
microtome. DNA extracted from a slice of tissue, contains a mix of mtDNA from all the cells in
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Figure 9.1: Results from the two-dimensional analysis of a liver adenoma. The mutant fraction
in each sample is represented by fraction of black in each circle. The size and position of each
sample taken is accurately represented by the circles.
that slice. Scanning the mtDNA mutation hotspots (identified in the paper 7.1) in the slice DNA
identified the tissues that were potential candidates for LCM analysis. One example is the Leydig
cell tumor, described in section 9.2. Two mutations were identified while scanning the mtDNA in
the macroscopic slice, then almost 300 small samples were taken with LCM across the whole
slice of tissue.
9.1 Liver tumors
Normal tissue can be identified as such from histologic analysis, when it is far removed from
the tumor area. The non-normal area that includes the tumor can also be identified by histologic
observation. The natural question is then what happens at the border. From a collaboration
with the University hospital in Bologna, Italy, samples of liver tissues were obtained. These
samples were large 2cm long samples, taken to cover the border between the tumor mass and
the surrounding normal tissue. LCM sampling was then done across the section in order to see
if any "border-phenomenon" could be observed. Using the same display syntax as in the paper
shown in 9.2, an example of a currently unpublished result can be seen in figure 9.1. A total of 10
tumors have been analysed, and the analysis of the results is still in progress. Two other examples
of liver analysis are shown in the paper described in section 9.2. They serve as a proof of concept
to show that the method described in the article is applicable to other tissues.
The two dimensional lineage tracing method is being coupled with IHC analysis, and applied to
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cholangiocarcinoma (bile duct cancer), hepatocellular carcinomas, adenomas of the liver, and
focular nodular hyperplasia. Lineage tracing results might also reveal differences in the patterns
of all three tumors. So far the results have not shown any clear border phenomenon, nor any clear
differences between the tumor types.
9.2 Resulting Publication:Tracing mitochondrial mutation in
tumors
9.2.1 Short description
This is the first major paper where lineage tracing results are published. It describes the two-
dimensional analysis of a Leydig cell tumor. Two independent mutations are identified in a Leydig
cell tumor by analysing the mtDNA hotspots on a macroscopic sample. 281 micro-anatomical
samples are then taken scattered across a slice of the tissue. The same two fragments, in which a
marker was identified, are then analysed in each of the fragments. The mutant fraction information
is then displayed on top of the histologic image of the tissue. All mutant fractions were observed
for both markers, ranging from wild type to homoplasmic mutant. There was a strong correlation
between the mutant fraction of the two markers, where samples homoplasmic for one marker,
were found to be homoplasmic for the other. Observing a high correlation between two markers
suggests the presence of one cell lineage that carries both mutations. No correlation was observed
between any identifiable structures and the presence, or absence, of mutations. In fact, the cell
lineage traced, seems scattered across the tissue with no recognisable pattern. Finely sampling
an area on another slice of the same tissue, showed a strong similarity between the position of
the mutation, establishing that the cel lineage can be found on the same position of the tissue,
slightly deeper.
9.2.2 Significance
In some ways, this is the first real lineage tracing paper. Detecting a mutation in a macroscopic
sample, and then analysing it in micro-anatomical samples, showed no recognisable patterns.
It was the observation of the same mutation in similar positions on another slice, sampled
independently, that clearly established the fact that we had indeed a method for tracing cell
lineages. Also, from reading the articles of Fialkow et al. the suspicion arose, that there was no
clear way to identify tumor cells under histologic analysis. Observing that no recognisable patters
could be observed in the results validated this suspicion. It also opened many opportunities and
asked many questions. Questions such as: "Is this pattern true for all tumors, or is it specific
to this one?" "What fraction of a tumor volume is made up of tumor cells?" With the validated
method in hand, many opportunities also arose to use it. If cell lineages can be identified on
various slices of tissue, then maybe it is possible to take successive slices, and reconstruct in
three dimensions the patterns formed by cell lineages in tumors. Maybe more data would allow a
pattern of cell growth to emerge. Last, it was these observations that established that no selective
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sampling could be performed. All successive micro-anatomical sampling was performed by
placing a standard grid of samples as small as they could be reliably taken using LCM.
9.2.3 Personal Contribution
The tissue was collected by Christian Arstad, who surgicaly removed the testicle from the patient,
and snap froze the portion that was not required for pathological examination as procedure
required. Sectioning staining and LCM was performed by myself, with the constant supervision
and collaboration of Per Ekstrom. Data analysis and writing of the article was performed by Per
Ekstrom and myself.
9.2.4 Status
Published on the 8th of April 2017 in BMC Clinical Pathology [99]
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Abstract 
Background: The growth of tumor cells is accompanied by mutations in 
nuclear and mitochondrial genomes creating marked genetic heterogeneity. 
Tumors also contain non-tumor cells of various origins. An observed somatic 
mitochondrial mutation would have occurred in a founding cell and spread 
through cell division. Micro-anatomical dissection of a tumor coupled with 
assays for mitochondrial point mutations permits new insights into this growth 
process. More generally, the ability to detect and trace, at a histological level, 
somatic mitochondrial mutations in human tissues and tumors, makes these 
mutations into markers for lineage tracing.  
Method: A tumor was first sampled by a large punch biopsy and scanned for 
any significant degree of heteroplasmy in a set of sequences containing known 
mutational hotspots of the mitochondrial genome. A heteroplasmic tumor was 
sliced at a 12µm thickness and placed on membranes. Laser capture micro-
dissection was used to take 25000µm2 subsamples or spots. After DNA 
amplification, cycling temperature capillary electrophoresis (CTCE) was used 
on the laser captured samples to quantify mitochondrial mutant fractions.  
Results: Of six testicular tumors studied, one, a Leydig tumor, was discovered 
to carry a detectable degree of heteroplasmy for two separate point mutations: a 
C ? T mutation at bp 64 and a T ? C mutation found at bp 152. From this 
tumor, 381 spots were sampled with laser capture micro-dissection. The ordered 
distribution of spots exhibited a wide range of fractions of the mutant sequences 
from 0 to 100% mutant copies. The two mutations co-distributed in the growing 
tumor indicating they were present on the same genome copies in the founding 
cell.  
Conclusion: Laser capture microdissection of sliced tumor samples coupled 
with CTCE-based point mutation assays provides an effective and practical 
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means to obtain maps of mitochondrial mutational heteroplasmy within human 
tumors.  
 
Introduction 
 
The mitochondrial genome (mtDNA) is a circular DNA molecule [1,2] of 
around 16.5 kb. Multiple copies of mtDNA are found in each mitochondrion and 
a human cell may have between 100 and 10000 copies [3], depending on cell 
type. In early studies of somatic mtDNA mutations in tumors, it was suggested 
that somatic mitochondrial mutations can grow from a low frequency of 
occurrence (heteroplasmy) to become completely dominant (homoplasmy). 
Homoplasmy was reported to be found in more than half of human tumors [4-8]. 
Later studies, however, have found this number to be significantly lower [9,10]. 
Hypothetical paths to homoplasmy, however, can be offered as mathematical 
models based on random drift linked to mtDNA replication during cell division 
and in the absence of selection [5,11,12]. The basic hypothesis is that once a 
mutation arises in an organogenic stem cell as a single copy of mtDNA, this 
mutant copy may be retained in a stem cell lineage and by random distribution 
result in some stem cells to contain a significant fraction of a particular mutant 
mtDNA copy.  If said stem cell becomes the first tumor stem cell then 
subsequent tumor stem cell divisions would be expected to continue random 
distribution of mutant copies so that after multiple divisions some descendant 
copies would contain no mutant copies (wild type homoplasmy) while others 
would have all copies carrying the mutant sequence (mutant homoplasmy) with 
most stem cells distributed with intermediate forms of mutant heteroplasmy.  
It is generally believed that most tumors are heterogeneous with infiltrations of 
non-tumor cells [13]. Sampling of only tumor-derived cells is therefore difficult. 
As non-tumor cells would not carry the mutation present in tumor cells it would 
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not be possible to distinguish between heteroplasmy and homoplasmy in a 
random tumor sample [14,15]. Pathological evaluation is often used to locate the 
tumor tissue. The success of this method depends on the experience of the 
pathologist and the quality of staining [8,16-18]. 
Somatic mtDNA mutations have been used as a marker of clonality in human 
tissues or tumors [11]. A successful method has been the immuno-histochemical 
marking of cytochrome oxidase (COX) deficient cells [19-21].  
In Taylor et al. [3], selected individual colonic crypts were sequenced and sixty 
mitochondrial mutations were detected, of which half were homoplasmic. None 
of the mutations were identical. The probability of independent identical 
homoplasmic mutations can be assumed to be very low, as is also predicted by 
the mathematical model [11]. 
Laser capture microdissection (LCM) was introduced in 1996 [22].  The method 
uses a laser to cut selected areas of tissue resting on a membrane. The area of 
interest can be collected by gravity or by adherence and is transferred to post 
processing vials. LCM has been used to capture spots of tissue for the analysis 
of proteins, mRNA and DNA [23-26]. 
This study describes a method to trace somatic mitochondrial mutations through 
a tumor slice. In a first step, DNA from a large representative piece of tissue is 
analyzed to detect the presence of mtDNA mutations. If mutations are found, 
LCM is used to obtain several small spots of the tissue. Cycling capillary 
temperature electrophoresis (CTCE) [27-30] is used to detect and quantify 
mutant fractions in each sample. In the course of this study, more than 900 LCM 
samples were analyzed for the presence of mtDNA mutations.  
 
Materials and Methods 
Tissue samples 
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Surgical discharges were collected under informed consent at the surgical 
departments of Bærum sykehus (Vester Viken, Helse sør-øst, Norway) in 2015. 
Similarly, liver samples were collected as surgical discharges under informed 
consent at the University Hospital in Bologna (Policlinico Sant'Orsola-Malpighi, 
Bologna, Italy) as part of a different study.  
According to the regional ethics comity (REC), “technical and methodological 
development work that uses anonymized biological material” does not require 
approval from REC 
(https://helseforskning.etikkom.no/ikbViewer/page/reglerogrutiner/soknadsplikt/
sokerikkerek?p_dim=34999&_ikbLanguageCode=us).   
Six samples of testicular cancer, five germ cell tumors, and one Leydig cell 
tumor were snap-frozen in liquid nitrogen and stored at –70°C until DNA 
extraction was performed. Fresh frozen samples have been shown to have better 
DNA integrity than formalin fixed, paraffin embedded samples [31]. All 
samples were anonymized with an arbitrary number. 
 
DNA extraction  
A representative sample of each tissue was obtained by inserting a blunt end 
19G 11/2 hypodermic needle (Microlance3, Becton Dickinson, Ireland) through 
the frozen tissue.  DNA was extracted from the core sample by Blood & Cell 
Culture DNA Mini Kit (Qiagen, Valencia, California USA).  DNA was eluted 
with elution buffer (as recommended by manufacturer) and stored at –20°C. The 
DNA from these samples was analyzed for somatic mitochondrial mutations.  
 
First round PCR 
Segments of mtDNA that have previously shown to contain many somatic 
mutations [32] were amplified with mitochondrial-specific primers to avoid 
amplification of homologeous regions in the nuclear DNA. Five sets of 
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mitochondrial specific primer pairs were used, resulting in amplification product 
between 714 and 928 base pair in length (see Table 1).  
 
The PCR reaction mixture contained 0.1 µl of extracted DNA (~5ng), 0.8mM 
dNTPs (0.2mM of each dNTP) (VWR, Oslo, Norway), 1X Thermopol Buffer, 
2mM MgSO4, 0.075unit Taq/ µl, 0.15 µM of each forward, reverse and 
fluorescently labeled primer (Integrated DNA Technologies, Leuven, Belgium) 
and total reaction volume of 10µl. The temperature cycling was performed in an 
Eppendorf Mastercycler ep gradient S (Eppendorf, Hamburg, Germany) with an 
initial denaturation 94 ºC for 240 seconds followed by cycling 38 times under 
the following conditions, denaturation at 94ºC for 15 seconds, annealing for 40 
seconds with temperature given in Table 1 and elongation at 72ºC for 150 
seconds.  
 
Capillary electrophoresis 
All first round amplification products were checked and visualized by capillary 
electrophoresis in MegaBACE 1000 DNA Analysis System (GE Healthcare Life 
Sciences, Pittsburgh, PA, USA). Samples were loaded into the capillaries from 
96-well plates by electrokinetic injection at 161 V/cm for 20 seconds. The 
temperature of the capillary chamber was set to 27°C and electrophoresis was 
carried out at a constant field of 145 V/cm. 
 
Second round PCR 
Template for second round PCR was 0.8 µl of a 1:200 dilution (first round PCR 
in H2O). The templates were dispensed into 96-wells plates with a syringe 
dispenser (Hydra 96, Robbins Scientific, USA). To each well 10µl reaction 
mixture was added, consisting of 1xThermopol Reaction Buffer with 2 mM 
MgS04, 0.3µM forward primer, 0.15µM 1/2GC-tailed “reverse” primer, 
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0.15µM, 6-Carboxyfluorescein-GC-clamp primer, 500µM dNTP, 100µg Bovine 
Serum Albumine (Sigma-Aldrich, Oslo, Norway) and 0.75U Cloned Pfu DNA 
polymeraze. Plates were sealed with two strips of electrical tape (Clas Ohlson, 
Oslo, Norway). The temperature cycling was repeated 25 times; 94°C for 15 
seconds, annealing temperature (given in table 2) held for 30 seconds and 
extension at 72°C for 60 seconds. 
 
Tumor analysis 
Testicular tumor samples were obtained from six patients. Apparent normal 
tissues adjacent to the tumor were marked with a suture (by the surgeon 
responsible for removing the tumor) and snap frozen in liquid nitrogen. The 
suture was used as a reference when the sample was mounted in the cryotome. 
DNA extracted from the testicular tumor samples were analyzed for somatic 
mutations in the hotspot regions of the mtDNA. The fragments selected were 
based on the results of scanning 76% of the mtDNA in 94 tumor samples from 
13 different tissues origin [32].  
 
Tissue sectioning 
Sample with somatic mitochondrial mutations was mounted to a cryostat sample 
holder with a water-soluble glycols and resins matrix (Tissue-Tek® O.C.T. 
Compound, Sakura, Finetek, USA). The sample holder temperature was set to  
-20°C and the knife temperature to -23°C. The cryostat (Leica CM1950) cut 
12µm sections. Each cut was gently transferred to either a steel framed 
polyethylene naphthalate membrane (Leica, Leica Microsystems, Wetzlar, 
Germany) or glass microscope slide (Thermo Scientific, Gerhard Menzel, 
Braunschweig, Germany). 
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Cycling temperature capillary electrophoresis 
CTCE analysis was performed for the selected fragments as previously 
described [28]. In brief; a 96-capillary DNA analyzer (MegaBACE 1000) was 
used to analyze 6-carboxyfluorescein labeled PCR products. Mutant PCR 
amplicons were separated from the wild type by cycling the temperature around 
the capillaries. The cycling temperature was based on the theoretical melting 
temperature, for each fragment, calculated by Poland's algorithm [29,33] in the 
implementation described by Steger [34,35]. The separation temperature 
proposed by the algorithms was adjusted based on the urea concentration in the 
matrix. The instrument was modified to allow for elevated temperature cycling 
[27,36].  Temperature cycling was programmed in the macro.ini file used by the 
Instrument Control Manager (ICM) software package (GE Healthcare Life 
Sciences, Pittsburgh, PA, USA). The injection and running electric fields were 
as given for the first round amplicons. 
 
Internal standard 
The two heteroplasmic mutations found in the initial sample analysis were re-
amplified with a 5’ ROX-labeled primer. These were used as internal standards 
during electrophoresis and were injected into all capillaries in all runs prior to 
sample injection. The internal standard serves as a control of the separating 
temperature and as a marker for the DNA mutations. 
 
Tissue sectioning 
 
Fixing and Staining 
The membrane and the glass slide with the 12 µm tissue section were dried at 
room temperature and fixed in pure methanol (Sigma-Aldrich) for 10 minutes, 
followed by subsequently air drying of the methanol residue. The tissue was 
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stained with Giemsa azur eosin methylene blue solution (Merck, Damstadt, 
Germany) (diluted 1/20 with H2O) for 30 minutes. Slides are then submerged 
into 1% acetic acid in H2O solution for 30 seconds (differentiation) and 
immediately rinsed in water. The stained tissue was air dried prior to imaging by 
microscope. 
 
Laser Capture Microdissection 
A Leica LDM 6000 was used to take images of tissue sections mounted on 
membrane or glass slides. The software, Leica laser microdissection 
V6.7.1.3952, was used to control the microscope when taking pictures or 
selecting areas for laser capture microdissection and cutting. A hardware 
modification was made to the collection unit allowing for samples to be 
collected into two strips of 8 PCR caps (VWR, Oslo, Norway).  
20 µl of a collection solution (1xThermopol buffer with Proteinase K, 
0.27µg/µl) was added to each cap in the inverted strips. After cutting and 
collecting the selected areas by laser capture microdissection, the strips (with 
collection liquid and tissue) were mounted onto a 96-well PCR plate (Axygen, 
VWR, Oslo, Norway). The plate was briefly centrifuged and incubated at 56°C 
for 30 minutes. Deactivation of proteinase K was achieved by raising the 
temperature to 95°C for 1 minute. One microliter of incubated solution was used 
as template for the first round PCR (see above).
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Results  
 
Of the six testicular tumors analyzed, the sample from the Leydig cell tumor 
was found to have two mutations, one in fragment 2 and one in fragment 4 
(Table 2). The two mutations were identified as base pair substitutions, C to T at 
base pair 64 and a T to C at base pair 152 (NC_012920.1). None of the other 
five tumors had any mutations in the fragments analyzed. Figure 1 shows the 
electropherograms for the fragments with a mutation. Finding only one sample 
with a mitochondrial mutation was less than expected, but is not significant 
when considering the small number of samples.  
In the first step the DNA was extracted by needle biopsy taken through the 
tumor sample. It, therefore, contains a mixture of DNA from cells across the 
tumor. The presence of a detectable mutation fraction found in this way suggests 
that sampling by LCM might identify the same mutation. In the other tumors, no 
mutations were found, which suggests that none is present or the fraction is too 
low.  
The sample with two mutations was taken to the next step in the procedure. 
Figure 2 shows an image of a section of the tissue with two mutations. The red 
circle indicates the area determined as normal by the surgeon. Ninety-three 
circular spots (~25000µm2) were dissected by LCM and dropped into separate 
caps. For each sample, fragments 2 and 4, in which a mutation was found, were 
analyzed.  
To estimate the number of cells in a LCM sample, Giemsa stained dark blue 
nuclei were counted in 48 circles, by two researchers. The average number of 
nuclei observed was 31 with a standard deviation of 13 and a range of 7 to 76 
nuclei/circle. The theoretical upper bound can be calculated assuming an 
average cell diameter of 20 µm. This gives a total of ~80 cells.  
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The mitochondrial DNA copy number in the LCM samples was determined by 
real-time PCR. LCM samples homoplasmic for both mutations (black circles) 
and wild type (white circles) were analyzed, and no difference in mtDNA copy 
number could be detected. The copy number was 300 per cell.  
Figure 3 displays the LCM spots for which the mutant fraction could be 
determined for both mutations (color-coded by white and black circles).  The 
combined LCM and PCR success rate was 86% and 76% for the two markers, 
respectively. In some samples, other mutants that do not co-elute with the 
internal standard have been marked with a different color. The inserted 
electropherograms demonstrate the allele separation and quantification of 
mutant fraction found in three different spots for each marker. The mutant 
fraction was calculated based on the peak heights and have previously been 
shown to have a linear relationship between signal and mutant fraction [29]. 
From these data, close to homoplasmic mutated regions could be identified for 
each marker.  
Following this first analysis, a further 186 LCM samples were taken from the 
remaining part of the tissue section, as shown in Figure 4. The mutant fraction 
could be determined in a large fraction of samples (89% and 91%) as shown in 
Figure 4. The location of the spots for the second part of the analysis were 
selected by a subjective assessment of visible structures in Figure 4. Subsequent 
review of the data in Figures 3 and 4 did, however, not reveal any clear relation 
between apparent tissue structure and observed mutant fraction.  
To validate the procedure, a new section approximately 50 µm below the first 
one was analyzed. To eliminate possible biases, the samples were collected as 
two fixed grids (8x6) in Figure 5. The success rate in determining the mutant 
fraction was 98% and 100%. The positions at which homoplasmic mutations can 
be observed in Figure 5, correlate with those in Figure 3. Six areas with near 
homoplasmic mutations in Figure 3, are matched to six nearby areas in Figure 5.  
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In addition, spots mostly show similar mutant fractions for both markers. The 
correlation was 0.75. It is reasonable to conclude that these mutations occur 
together, i.e., an mtDNA either contains both mutations or none. 
The method was subsequently used to analyze two independent liver samples (a 
cholangio- and a hepato- cellular carcinoma). Both tumors had known 
mitochondrial mutations (study in progress). Each sample was subjected to 
LCM and mutation analysis in the grid–like sampling scheme as shown for the 
testis sample. Figure 6 displays the results of the 288 spots cut from each tissue. 
The upper section (cholangio carcinoma) is dominated by one mtDNA type and 
has heteroplasmic spots with a low mutant fraction in some areas. Only one 
spot, indicated by the arrow, is almost homoplasmic for the mutation, but in fact, 
the electropherogram showed the presence of a third mutation at a low fraction.  
The lower section of Figure 6 (hepatocellular carcinoma) has multiple spots of 
near homoplasmic mutations as well as several heteroplasmic spots.   
 
Discussion 
This paper describes a method to sample and analyze mutations from spots of a 
tumor tissue. The novelty lies in the small size of the samples or spots (25000 
µm2 or an average of 31 cell) and the systematic distribution of the samples. 
Since each cell carries multiple mitochondria and each mitochondrion has 
multiple copies of mtDNA, dissecting such a small number of cells gives 
enough templates for PCR amplification. This would not be sufficient for 
detecting mutations in nuclear DNA. In our studies we observed that it is better 
to distribute the spots on a regular grid, rather than placing them according to 
visible structures. The results give a demonstration of the efficacy of tracing the 
distribution of mutant mitochondrial genomes across a slice from a tissue or a 
tumor. This method could be used for studies of humans or experimental 
animals.   
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Because the LCM instrument depended on gravitation, spots smaller than 25000 
µm2 resulted in a higher laser capture failure rate (data not shown). Increasing 
the size of the spots risks dilution of the mutant fraction, leading to a potential 
sampling bias.  
Because the probability of independent occurrence of an identical mutation in 
the mtDNA of a cell is very small, the observed results are consistent with a 
clonal expansion of cells. To place an upper bound on this probability, a 
fragment not having any mutation but situated in a hotspot region of the mtDNA 
(d-loop) was analyzed in 700 LCM samples. No mutations were found. The 
probability of independently acquiring a given mutation can thus safely be 
placed below 1/700. Some estimates put it much lower at around 10-30 [19]. To 
further strengthen the argument, macroscopic samples of 94 tumors were 
analyzed [32]. One hundred and forty-two high fraction mtDNA mutations were 
sequenced and none of them were identical.  
In the specific case of the testicular tumor analyzed here, two homoplasmic 
mutations 88 base pairs apart are detected and traced. Since the presence of 
these mutations is highly correlated, it suggests that one cell lineage is being 
observed, and not a series of independent events.  
The method described is sensitive and provides a quantitative way to explore 
any tissue for heteroplasmy. Under our optimized conditions, the cost of 
analyzing 300 spots is about $30 (not including the cost of a trained technician 
working for three days). Once heteroplasmy with a sufficiently large mutant 
fraction has been established, it can, for example, be used to explore the 
resection margins of a tumor. Furthermore, if a continuous stack of sections cut 
by microtome were available, investigating mitochondrial mutations in three 
dimensions becomes possible. This would advance the field of three-
dimensional lineage tracing in humans. 
 
93
 
 Refinetti et. al, page 14 of 27 
Conclusion  
The method presented in this study can be used for lineage tracing in humans. 
Its capacity was demonstrated in human tumors and can be extended to the study 
of metastasis and normal tissue. Using a regular sampling grid of LCM spots is 
shown to be essential to study tumor heterogeneity.   
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Figure 1. 
Electropherogram of mutated fragments detected by cycling temperature 
capillary electrophoresis. Electropherograms a) and c) show non-mutated 
samples, while electropherograms b) and d) show the two mutations found in 
one sample.  
2 4
a) c) 
b) d) 
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Figure 2. 
Overview of sample harboring two mutations. The red circle indicates suture 
position attached by the surgeon to indicate normal tissue. Image was taken with 
the LCM microscope by scanning the sample  
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Figure 3. 
Laser capture microdissected spots with mutants fractions. Marker detected by 
primer set # 2 is on the top and marker detected by primer set #4 is on the 
bottom. White is associated with the first peak (homoduplex) in 
electropherogram, and black is associated with the second peak (homoduplex). 
The fraction of white and black in each circle, represent the fraction of the first 
and second variant respectively in each sample. Other color presents mutants not 
aligning with the internal standard in the electropherogram. Inserted 
electropherograms represent homoplasmic regions and heteroplasmic areas (e.g 
mix of two cell population). 
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Figure 4. 
Laser capture microdissected spots with mutants fractions. Marker detected by 
primer set # 2 is on the top and marker detected by primer set #4 is on the 
bottom. White is associated with the first peak (homoduplex) in 
electropherogram, and black is associated with the second peak (homoduplex). 
The fraction of white and black in each circle, represent the fraction of the first 
and second variant respectively in each sample. Other color presents mutants not 
aligning with the internal standard in the electropherogram. Inserted 
electropherograms represent homoplasmic regions and heteroplasmic areas (e.g 
mix of two cell population). 
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Figure 5. 
Focused laser capture microdissection in a grid of 8x6 spots. Marker detected by 
primer set # 2 is on the top and marker detected by primer set #4 is on the 
bottom. Enlargement show adjacent different homoplasmic areas. Scale bar is 
178 µm long. 
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Figure 6. 
Laser capture microdissection of two liver samples. Top image is a 
cholangiocellular carcinoma, the lower is a hepatocellular carcinoma. The first 
peak in the electropherogram (homoduplex) is presented as white while second 
peak (homoduplex) is black. Other colors present represent mutants not aligning 
with the internal standard in the electropherogram (i.e. other variants). 
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Table 1 
Primers used to selectively amplify mtDNA.  
 
 Annealing
#  Start (bp)  End (bp)  Length (bp) "Forward" primer (5' - 3') "Reverse" primer (5' -  3') temperature (°C)
23 15924 201 846 *AACCGGAGACGAAAACCTTTTTC *CTTTAGTAGGTATGTTCGCCTGT 51
1 16521 880 928 *CCATAAAGCCTAAATAGCCCACA *CCAACCCTGGGGTTAGTATAGCT 54
10 6917 7671 754 *TGCTCTGAGCCCTAGGATTCATC *TGAGGGCGTGATCATGAAAGGTG  55.5  
16 10852 11566 714 *GCCTAATTATTAGCATCATCCCC *ATGCCTCATAGGGATAGTACAAG 51
22 15169 15993 824 *GAGGGGCCACAGTAATTACAAAC *TGGGTGCTAATGGTGGAGTTAAA 51
*=tail sequence (CGCCCGCCGCGCCCCGCG)  
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Table 2 
Primers used to amplify fragments suitable for detecting mutation by 
CTCE.  
Template,fragment# Annealing
# Start(bp) End(bp) fromfirstPCR "Forward"primer(5'-3') "Reverse"primer(5'-3') temperature(°C)
1 16569 25 1 *TGCATGGAGAGCTCCCGTGAGTGG CCCCTTAAATAAGACATCACGAT 52
2 42 126 1 *ATTAACCACTCACGGGAGCTCTC AGGATGAGGCAGGAATCAAAGAC 55
4 131 181 1 *CACCCTATGTCGCAGTATCTGTC CACACTTTAGTAAGTATGTTCGC 55
6 483 513 1 *GGGGTTAGCAGCGGTGTGTGTGTG TCCCACTCCCATACTACTAATCT 55
7 530 633 1 *TACCCAGCACACACACACCGCTG CAAACCTATTTGTTTATGGGGTGA 55
8 673 705 1 *TTAGAGGGTGAACTCACTGGAAC GGTTTGGTCCTAGCCTTTCTATT 58
82 7031 7134 10 *ACGACACGTACTACGTTGTAGCC AATATGATAGTGAAATGGATTTT 52
84 7340 7416 10 *CTTTCTTCCCACAACACTTTCTC TCTCAAATCATGAAAATTATTAAT 55
125 11029 11086 16 *TTAGGAGGGGGGTTGTTAGGGGGT CATCCCTCTACTATTTTTTAACC 58
127 11193 11243 16 *ACCAGCCAGAACGCCTGAACGCA GGTGTTGTGAGTGTAAATTAGTG 55
128 11283 11311 16 *TGTGCCTGCGTTCAGGCGTTCTGG TAATCATATTTTATATCTTCTTC 60
130 11437 11492 16 *TTGACCCAGCGATGGGGGCTTCGA GAGCCAACAACTTAATATGACTA 55
176 15201 15257 22 *AGAATCGTGTGAGGGTGGGACTGT AGTAATTACAAACTTACTATCCG 60
177 15274 15377 22 *AGTAGACAGTCCCACCCTCACAC GGTGATTTTATCGGAATGGGAGG 60
178 15394 15448 22 *CTAGGAATCACCTCCCATTCCGA TAATGTCATTAAGGAGAGAAGGAA 55
181 15761 15864 22 *ACCTCCTCATTCTAACCTGAATC CAGGCCCATTTGAGTATTTTGTTT 55
184 16080 16130 23 *CAAGTATTGACTCACCCATCAAC ACAGGTGGTCAAGTATTTATGGTA 57
185 16170 16272 23 *GTGGGTGAGGGGTGGCTTTGGAGT CCAATCCACATCAAAACCCCCTC 56
187 16263 16366 23 *AACTGCAACTCCAAAGCCACCCC CCCTATCTGAGGGGGGTCATCCAT 58
*=tailsequence(CCCGCCGCCCCCGCCCGGG)
GC-Clamp=(6FAM-CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCGGG)   
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10 Three-dimensional Lineage Tracing
From the results described in chapter 5, the optimal thickness of a slice was established at 12µm .
So the question was, how many consecutive samples of 12µm could be taken using a microtome.
The first attempt, performed on the cell tumor used for the paper 9.2 resulted in 24 cuts, the first
12 are successive, and the last 12 were taken with 2×12µm interval between them. The same
96 sample grid was taken on 18 of these slices. The results can be seen in the paper described
in 10.1. It confirms a certain degree of conservation of the mutant fractions across the z axis.
Furthermore, it also established that sampling every slice was oversampling, and depth was being
sacrificed for too much resolution.
Viewing the three dimensional plot of two independent markers in the cell tumor, we became
convinced that we could identify cell lineages in tumors, and trace them in 3D. The question
remained: "What cell lineage is being tracked?" In fact, no guarantee exists that the cell lineage
that carries the mtDNA mutation was the only tumor lineage. A tumor lineage is being tracked,
so the presence of the mutation marks the presence of tumor cells, but the inverse needs not be
the case. Furthermore, the majority of the scanned volume does not contain the mutation. Thus, if
the cell line followed was indeed the major tumor lineage, then it would mean that the majority of
a tumor volume would not be composed of tumor-derived cells. A condition was needed, where
the presence of the marker, would guarantee tumor origin, and its absence would guarantee it is
not tumor derived. Figure 10.1 shows a textbook illustration of how metastasis are thought to
form. If the model is true, then the metastasis has at its origin one, or very few tumor cells from
the primary tumor. We hypothesised that, a metastasis containing the same mtDNA mutation
as found in the primary tumor, would be founded by a tumor cell marked with that mutation.
Consequently, all the tumor derived cells in the metastasis would contain the mutation. The key
is to be able to identity the same mutation in both the primary tumor and the metastasis.
The sampling protocol chosen was to sample one out of each five. Ideally, 70 successive
12µm slices of tissue would be taken. Every 5th slice is placed on membrane for LCM sampling,
and the other four are be placed on glass, stained and imaged. This results in deeper the analysis
of a larger volume by increasing the depth of tissue sampled, without sacrificing the ability to
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Chapter 10. Three-dimensional Lineage Tracing
Figure 10.1: Current theory of metastasis formation. A single cell leaves a grown tumor and
"seeds" a metastasis. If true, this hypothesis means that all tumor cells in a metastasis are
descendent of a single tumor cells. Picture taken from the site johnhopkins.edu.
image the tissue continuously. Protocol and results can be seen in the paper described in 10.1.
10.1 Resulting Publication
10.1.1 Short description
The paper describes the result of our three dimensional lineage tracing. Using the method
described in the chapter 9, mtDNA mutations that can serve as marker for lineage tracing are
identified in five primary tumors, breast, bladder, colon, liver and cell (the same tissue described
in chapter 9). In the bladder tumor case, the two markers found in the primary tumor are then
also found in the lymph node metastasis. The primary breast tumor has only one marker, and
it was identified in both a lymph node metastasis and in a liver metastasis. Three-dimensional
reconstructions were not possible for the primary bladder tumor and breast tumor, due to poor
sample conditions, but were possible for their metastasis. In the end, a total of 8 three dimensional
reconstruction, for 6 tissues (2 tissues had two markers, the bladder tumor metastasis and the cell
tumor) were obtained. A strong correlation was observed between both markers followed in the
cell tumor and in the bladder tumor metastasis. Also, the majority of the volume analysed is not
made of cells that contain the mutation. An observation that is true in primary tumors and in the
metastasis and is difficult to explain using standard oncogenesis theory. A possible interpretation
is that tumor lineages grow by "percolating" through the surrounding tissue and conditioning it to
assume the abnormal morphology observed.
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10.1. Resulting Publication
10.1.2 Significance
It is probably the most significant paper of the thesis. In it is the definitive proof that it is possible
to perform lineage tracing in three dimensions. A tissue is a volume, thus to properly follow a
cell lineage it must be followed in three dimensions. Lineage tracing in two dimensions only
gives a cut across the structures formed by lineages as they grow. The result resembles a random
speckling of mutations. However, three dimensionally following mtDNA mutations revealed
some form of connection between the various areas carrying the mutation.
10.1.3 Personal contribution
Samples came from different sources. I was responsible for making the slices and preparing them,
as well as taking the LCM samples and processing them, with the almost constant supervision and
advice of Per Ekstrom. I also designed and implemented the software that was used to analyse
the electropherograms and performed the analysis. The plotting of the results was a joint effort of
Per Ekstrom and Myself, as was writing the paper.
10.1.4 Status
In preparation
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Background
Results
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Keywords:
1. Background
Tumors are thought to be clonal lesions, originating from a single cell,
that grows and goes on to create a tumor mass [1, 2, 3]. As with develop-
mental biology, the question the arises as to how a single cell gives rise to
the observed result. In other words, what are the patters of growth of cell
lineage. Since the question is similar in developmental biology and tumors,
it follows that similar techniques have been employed to study the patters of
cell lineages. Tracing cell lineages in human tissue, both normal and tumor
requires the identification of markers, that identify individual lineages and
allow their patterns of growth to be mapped. Somatic mitochondrial DNA
(mtDNA) mutation are a strong candidate to serve as markers of clonality
to study lineage tracing, and have been successfully used in normal human
tissues [4, 5, 6]. Laser capture micro dissection (LCM), is a technique that
allows the selection of small groups of cells from a histologic preparation [7].
In normal tissue, it is therefore possible to select micro-anatomical samples
that contain cells from one tissue type from an organ. The reason being
that compose an organ can be readily identified by histology and staining
Preprint submitted to Elsevier January 18, 2017
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procedures. Application of lineage tracing methods from normal tissue to
tumor tissue has been less conclusive. The first reason is the difficulty in
identifying different tissue origins within a tumor tissue. While it is possible
to recognise a tissue section as ”not normal”, it is often impossible to de-
termine which portions are tumor [8]. Attempts to selectively sample tumor
tissue can therefore only lead to a biassed sampling of the selected tissue [1].
Another often encountered issue is the presence of a signal. In normal tissue,
clones tend to be reasonably small, for example one crypt in the human colon
[6]. Consequently, even rare mutational events can be observed by sampling a
reasonably small amount of tissue, due to the number of clonal units (crypts
for the colon) that can be studied. In tumors, due to their origin as one cell
that grows, lineages tend to be fewer and larger. Attempts to detect gene
inactivating mutations in cytochrome C oxydase, in human adenomas have
been hampered by the small number of adenomas that actually develop such
mutations [9]. When a mutation was detected, it usually covered a large
portion of the total adenoma. Another difficulty when performing lineage
tracing is that tissue are a three dimensional. Studying lineage tracing on a
slice of tissues only gives a cross section of the real pattern of cell growth.
To understand the actual patters, a three dimensional analysis is required.
Sampling a volume requires a dramatically larger number of sample than
sampling a surface. Most methods that are capable of detecting and quanti-
fying mtDNA mutations do not have the throughput and precision to satisfy
this constrain [10].
In this paper, the authors propose to use a method that has been shown to
effectively detect and quantify mtDNA mutations in two dimensions, and ex-
tend it to three dimensions. In a previous work cycling temperature capillary
electrophoresis (CTCE) is used to detect and quantify mtDNA mutations in
lied cell tumor. The mutations found are then analysed over a large number
of micro-anatomical samples taken across a slice of tumor tissue (Refinetti
et al, under review). The results confirmed the initial hypothesis that it is
almost impossible to select for a cell lineage by histologic analysis. Using
CTCE as a method to detect mtDNA mutations as markers of clonality will
give the precision and throughput for a three dimensional analysis. Also,
sample will be taken on a standard grid formation at a similar position on
each successive slice of tissue. In doing so, no bias will be introduced in the
sample.
113
2. Materials and Methods
2.1. Sample description and origin
Samples were collected from 5 different patients, and are as follow:
• Patient 1: Primary breast tumor, Liver metastasis, lymph node metas-
tasis
• Patient 2: Primary bladder tumor, Lymph node metastasis, primary
tumor.
• Patient 3: Primary hepatocellular carcinoma
• Patient 4: Primary colon cancer
• Patient 5: Primary Leighdig cell tumor (also described in Refinetti et
al. under review)
Samples from Patients 1, 2 and 4 were collected at the Norwegian Radiumhos-
pital with informed consent. Sample from patient number 5 was collected
at Bærum sykehus (Vester Viken, Helse sør-øst, Norway). Samples from pa-
tient 3 was collected at the surgical department of the university hospital
of Bologna (Italy). All samples were collected with informed consent ac-
cording to local law and were anonymised prior to us using. According to
the Norwegian law, ”Technical and methodological development work that
uses anonymised biological material” does not require approval from research
ethics committee (REC) (Web page, last access November 2016). Following
surgical resections, all samples were snap frozen by immersion in liquid ni-
trogen within 10 min. They were then kept below -30◦C until sectioning. No
fixing or embedding was done before sectioning.
2.2. DNA extraction
Two consecutive 50µm slices were placed in an eppendorf tube an DNA
was extracted using the Mag-attract system by Macherey-Nagel. In brief,
samples were incubated with Proteinaze K in lysis buffer for 3h at 50◦C.
Samples were then placed in a dedicated DNA extraction robot by Macherey-
Nagel, specifically for the use of the Mag-attract system. Result is DNA at
a rough concentration go 50ng/µl .
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2.3. Tissue sectioning
Sampling of tumor tissue, is obtained by taking consecutive slices with
the microtome and using LCM to sample an 8× 12 grid on the slices. Sam-
ples were mounted to a cryostat sample holder with a water-soluble glycols
and resins matrix (Tissue-Tek O.C.T. Compound, Sakura, Finetek, USA)
and placed in a cryotome (Leica CM1950) with room temperature of -20◦C
and knife temperature of -23◦C. Small adjustments were made to those tem-
peratures if it was necessary to improve cutting performance. 2 consecutive
50µm slices were taken and placed in a Eppendorf (Eppendorf, Germany)
tube. Next, 70 consecutive 12 µm slices were then taken. Every 5th slice
(i.e. numbers 1, 6 ... 66) was placed on PET (Leica, Leica Microsystems,
Wetzlar, Germany) membrane for LCM. All other cuts were placed on glass
slide (SuperFrost by Thermo Scientific, Gerhard Menzel, Braunschweig, Ger-
many) for imaging.
2.4. Fixing and Staining
The membranes and glass slides with the 12µm tissue section were dried
at room temperature and fixed in pure methanol (Sigma-Aldrich) for 10
minutes, followed by subsequently air drying of the methanol residue. The
tissue was stained with Giemsa azur eosin methylene blue solution (Merck,
Damstadt, Germany) (diluted 1/20 with H2O ) for 30 minutes. Slides are
then submerged into 1% acetic acid in H2O solution for 30 seconds (differ-
entiation) and immediately rinsed in water. The stained tissue was air dried
prior to imaging by microscope.
2.5. Laser Capture Microdisection
A Leica LDM 6000 was used to take images of tissue sections mounted
on membrane or glass slides. The software, Leica laser microdissection
V6.7.1.3952, was used to control the microscope when taking pictures or
selecting areas for laser capture microdissection and cutting. A hardware
modification was made to the collection unit allowing for samples to be col-
lected into two strips of 8 PCR caps (VWR, Oslo, Norway). The Leyca
software was used to design a standard sampling pattern of 96 circles with
an area of about 25000µm2, placed regularly on an 8 × 12 grid. The same
grid was sampled on each membrane section. Observation of the in-between
samples placed on glass slides, allowed the grids to be placed on the posi-
tion corresponding to the previous sampling. 20µl of a collection solution
(1xThermopol buffer with Proteinase K (0.27µg /µl )) was added to each
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cap in the inverted strips. After cutting and collecting the selected areas by
laser capture microdissection, the strips (with collection liquid and tissue)
were mounted onto a 96-well PCR plate (Axygen, VWR, Oslo, Norway). The
plate was briefly centrifuged and incubated at 56◦C for 30 minutes. Deacti-
vation of proteinase K was achieved by raising the temperature to 95◦C for
1 minute. One microliter of incubated solution was used as template for the
first round PCR.
2.6. PCR conditions
2.6.1. First Round
Areas of mitochondrial DNA (mtDNA) that previously has shown to con-
tain many somatic mutations [11] were amplified with mitochondrial spe-
cific primers to avoid amplification of homology regions in the nuclear DNA
(NUMTs). Five sets of mitochondrial specific primer pairs were used, re-
sulting in amplification product between 714 and 928 base pair in length
(see table 1). The PCR reaction mixture contained 0.1µl of extracted DNA,
0.8mM dNTPs (0.2mM of each dNTP) (VWR, Oslo, Norway), 1X Ther-
mopol Buffer, 2mM MgSO4, 0.075unit Taq/µl , 0.15 µM of each forward,
reverse and fluorescently labeled primer (Integrated DNA Technologies, Leu-
ven, Belgium) in a total reaction volume of 10µl . The temperature cycling
was performed in an Eppendorf Mastercycler ep gradient S (Eppendorf, Ham-
burg, Germany) with an initial denaturation 94 ◦C for 240 seconds followed
by cycling 38 time under the following conditions, denaturation at 94 ◦C for
15 seconds, annealing for 40 seconds with temperature given in Table 1 and
elongation at 72◦C for 150 seconds.
2.6.2. Second Round
Template for second round PCR was 0.8µl of a 1:200 dilution (first round
PCR in H2O). The templates were dispensed into 96-wells plates with a
syringe dispenser (Hydra 96, Robbins Scientific, USA). To each well 10µl re-
action mixture was added, consisting of 1xThermopol Reaction Buffer with
2 mMMgS04, 0.3µM forward primer, 0.15µM 1/2GC-tailed ”reverse” primer,
0.15µM , 6-Carboxyfluorescein-GC-clamp primer, 500µM dNTP, 100µg Bovine
Serum Albumine (Sigma-Aldrich, Oslo, Norway) and 0.75U Cloned Pfu DNA
polymeraze. Plates were sealed with two strips of electrical tape (Clas
Ohlson, Oslo, Norway). The temperature cycling was repeated 25 times;
94◦C for 15 seconds, annealing temperature (given in table 2) held for 30
seconds and extension at 72◦C for 60 seconds.
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 Annealing
#  Start (bp)  End (bp)  Length (bp) "Forward" primer (5' - 3') "Reverse" primer (5' -  3') temperature (°C)
23 15924 201 846 *AACCGGAGACGAAAACCTTTTTC *CTTTAGTAGGTATGTTCGCCTGT 51
1 16521 880 928 *CCATAAAGCCTAAATAGCCCACA *CCAACCCTGGGGTTAGTATAGCT 54
10 6917 7671 754 *TGCTCTGAGCCCTAGGATTCATC *TGAGGGCGTGATCATGAAAGGTG  55.5  
16 10852 11566 714 *GCCTAATTATTAGCATCATCCCC *ATGCCTCATAGGGATAGTACAAG 51
22 15169 15993 824 *GAGGGGCCACAGTAATTACAAAC *TGGGTGCTAATGGTGGAGTTAAA 51
*=tail sequence (CGCCCGCCGCGCCCCGCG)
Table 1: First round primers used.
Template,fragment# Annealing
# Start(bp) End(bp) fromfirstPCR "Forward"primer(5'-3') "Reverse"primer(5'-3') temperature(°C)
1 16569 25 1 *TGCATGGAGAGCTCCCGTGAGTGG CCCCTTAAATAAGACATCACGAT 52
2 42 126 1 *ATTAACCACTCACGGGAGCTCTC AGGATGAGGCAGGAATCAAAGAC 55
4 131 181 1 *CACCCTATGTCGCAGTATCTGTC CACACTTTAGTAAGTATGTTCGC 55
6 483 513 1 *GGGGTTAGCAGCGGTGTGTGTGTG TCCCACTCCCATACTACTAATCT 55
7 530 633 1 *TACCCAGCACACACACACCGCTG CAAACCTATTTGTTTATGGGGTGA 55
8 673 705 1 *TTAGAGGGTGAACTCACTGGAAC GGTTTGGTCCTAGCCTTTCTATT 58
82 7031 7134 10 *ACGACACGTACTACGTTGTAGCC AATATGATAGTGAAATGGATTTT 52
84 7340 7416 10 *CTTTCTTCCCACAACACTTTCTC TCTCAAATCATGAAAATTATTAAT 55
125 11029 11086 16 *TTAGGAGGGGGGTTGTTAGGGGGT CATCCCTCTACTATTTTTTAACC 58
127 11193 11243 16 *ACCAGCCAGAACGCCTGAACGCA GGTGTTGTGAGTGTAAATTAGTG 55
128 11283 11311 16 *TGTGCCTGCGTTCAGGCGTTCTGG TAATCATATTTTATATCTTCTTC 60
130 11437 11492 16 *TTGACCCAGCGATGGGGGCTTCGA GAGCCAACAACTTAATATGACTA 55
176 15201 15257 22 *AGAATCGTGTGAGGGTGGGACTGT AGTAATTACAAACTTACTATCCG 60
177 15274 15377 22 *AGTAGACAGTCCCACCCTCACAC GGTGATTTTATCGGAATGGGAGG 60
178 15394 15448 22 *CTAGGAATCACCTCCCATTCCGA TAATGTCATTAAGGAGAGAAGGAA 55
181 15761 15864 22 *ACCTCCTCATTCTAACCTGAATC CAGGCCCATTTGAGTATTTTGTTT 55
184 16080 16130 23 *CAAGTATTGACTCACCCATCAAC ACAGGTGGTCAAGTATTTATGGTA 57
185 16170 16272 23 *GTGGGTGAGGGGTGGCTTTGGAGT CCAATCCACATCAAAACCCCCTC 56
187 16263 16366 23 *AACTGCAACTCCAAAGCCACCCC CCCTATCTGAGGGGGGTCATCCAT 58
*=tailsequence(CCCGCCGCCCCCGCCCGGG)
GC-Clamp=(6FAM-CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCGGG)
Table 2: Second round primer pairs used
2.7. Cycling Temperature Capillary Electrophoresis
CTCE analysis was performed for the selected fragments as previously de-
scribed .In brief; a 96-capillary DNA analyzer (MegaBACE 1000) was used
to analyze 6-carboxyfluorescein labeled PCR products. Mutant PCR ampli-
cons were separated from the wild type by cycling the temperature around
the capillaries. The cycling temperature was based on the theoretical melting
temperature, for each fragment, calculated by Poland’s algorithm [12] in the
implementation described by Steger [12, 13]. The separation temperature
proposed by the algorithms was adjusted based on the urea concentration
in the matrix. The instrument was modified to allow for elevated tempera-
ture cycling [14, 15]. Temperature cycling was programmed in the macro.ini
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Figure 1: Schematic representation of sampling procedure. The sampled slides are placed
on LCM membranes, and 96 samples are taken in the form of an 8 × 12 grid. One slide
every 5 is sampled, and the ones in-between are placed on glass slides for imaging. The
above schematic has been repeated for a total of 70 slides of which 14 are sample and 56
are only imaged.
file used by the Instrument Control Manager (ICM) software package (GE
Healthcare Life Sciences, Pittsburgh, PA, USA). The injection and running
electric fields were as given for the first round amplicons.
2.8. Dada visualisation
The output of the analysis is the mutant fraction in the samples taken.
Understanding these results requires the information to be plotted in three
dimensions. The hypothesis is made that the mutation analysed, marks a cell
lineage within the tissue. For each sample, the depth, within the tissue, is
known by the slice number (assuming the microtome has infinite precision).
Assuming also that the grid is positioned always in the same way on each
sampled slide, it is easy to assign a cartesian coordinate to each sample taken.
Also, the shape of the sample is constant, a disc of 25000µm2 with a height
of 12µm . A total of 21 points are then randomly distributed within each
disk of a sample, and assigned a value 0 or 1. The number of 1 assigned
is proportional to the mutant fraction measured in the sample. A mutant
fraction of 100% will be represented by 21 points with value 1, randomly
distributed in space within the volume occupied by the sample in space.
Linear interpolation is then used to obtain a surface plot of the resulting
”cloud” of points in the volume.
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Patient Tissue 3D Markers Sample
Taken
Measured
Samples
1 Primary Breast tumor no 1 672 524
Lymph node metastasis yes 1 1344 571
Liver Metastasis yes 1 1344 708
2 Primary Bladder cancer no 2 288 287, 229
Lymph node metastasis yes 2 1344 986, 611
3 hepatocellular carcinoma yes 1 1344 956
4 Colon Cancer yes 1 1344 598
5 leydig cell tumor yes 2 1824 1728,1824
Table 3: Summary of samples analysed. For each patient, the markers analysed are
the same across tissues. In some tissues, due to their states or size, it was impossible
to establish a 3D reconstruction. 3D reconstruction was only established when multiple
samples could be taken consecutively. The number of samples taken is the number of micro
anatomical pieces taken using LCM. The measured samples is the number of samples for
which a mutant fraction could be successfully calculated. In the cases with two marker,
the number of samples for each marker are separated by a coma.
3. Results
As can be seen in table 3, a three dimensional reconstruction of mutant
fraction has been possible for six tissues. Of these six tissues, two have
two markers, for a total of 8 three dimensional reconstructions. Not every
sample successfully gives information. Lack of cells in the sample (due to the
morphology of the tissue) or PCR failure, or difficult to interpret signal can
contribute to the absence of information from a sample. The total number
of samples taken, as well as the number of successful ones are also shown in
table 3. The visualisation of the mitochondrial markers in three dimensions,
gives a representation of the patters of cell lineage.
Figure 2 shows the histogram of mutant fractions for all analysed markers
and tissues. It can be observed that all distributions are heavily skewed
towards the wild type. Thus, a majority of samples taken are are mostly
wild-type. In the tissues for which 2 markers are present, both markers seem
to have a very similar distribution. Suggesting that the mutation are found
together in the same samples, thus independently marking the same lineage.
The three dimensional reconstruction of the cell lineages traced in each
tissue are online and publicly accessed in a form that allows for explo-
ration. A snap picture of each can be seen in figures 4 to 6. An interac-
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Figure 2: Histogram of mutant fraction. The mutant fractions for each tissue are sum-
marised as histograms. The colon cancer and the hepatocellular carcinoma, have only one
tissue and one marker, for which the distribution of the mutant fraction i shown. The
breast tumor, has only one marker followed, and three tissues, for an easier comparison,
the mutant fraction of the three tissues is shown in the same histogram. The tissues with
more than one marker are plotted individual, with both marker shown, this is the case for
the leydig cell tumor, as well as both tissues of the bladder tumor.
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tive plot of all the samples and all markers available can be seen online.
A page has been dedicated in the Radiumhospital website for this purpose:
http://www.ous-research.no/hovig/?k=hovig%2FEkstrom&aid=16790. The
graphs show both the reconstruction of the lineage lineage carrying the mu-
tation, and of those not carrying it. By observing the reconstruction of the
lineages carrying the mutations, the first thing that can be seen is the sparsity
of the mutations. Taking the example of the leydig cell tumor, the majority
of the volume does not carry the mutation. There is a layer in the middle of
the tissue with a higher fraction than the rest, and there seems to be some
sort of connection between the various areas carrying the mutation. Also,
a strong similarity between marker 1 and marker 2 of the leydig cell tumor
can be observed. This observation supports the theory that there is one cell
lineage that caries both markers. By observing the interactive reconstruction
go the leydig cell tumor, it can also be noted that the majority of the volume
studied is not composed by the lineage that carries both markers. Similarly,
in none of the studied tissues, was a lineage that fills the majority of the
volume found.
4. Discussion
Some of the tissues have a high percentage of failed samples. Sample
failure can be quite common since many procedures are performed in series,
and failure in one of them will compromise the final result. The most probable
source of sample failure is failure to collect it. The LCM system used relies
on gravity for the sample cut by the laser to fall in the well underneath. Due
to the small size and weight of the sample, as well as the static electricity
present on the membrane, samples sometime don’t fall. Also, high standard
of quality were kept, and only samples in which a mutant fraction could
be cleanly measured, with a precision below 3-5%, have been kept. The
automated analysis of the electropherogram require a very high quality signal
as well as internal standard, which also contributed partly to failure rate.
The ability to make a three dimensional analysis of cell cell lineages in tumor
depends on the quality of the tissue. Both primary tumors of the breast and
prostate were low quality tissues. They were small and poorly conserved. His
made the taking of 70 consecutive high-quality slices impossible. A smaller
number of samples was therefore taken for the purpose of understanding the
distribution of the mutations. Having the data available, the 3D plotting
was still made available for viewing.
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Figure 3: Snapshot of 3D reconstruction of the metastasis of the breast tumor metastasis.
Liver metastasis is on the left and lymph node metastasis on the right. The same marker
is tracked in both images
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Figure 4: Snapshot of 3D reconstruction from lymph node metastasis of bladder tumor.
On the left is the reconstruction of marker 1, and on the right marker 2.
123
Figure 5: Snapshot of 3D reconstruction of leydig cell tumor. On the left is the recon-
struction of marker 1, and on the right marker 2.
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Figure 6: Snapshot of 3D reconstruction of hepatocellular carcinoma.
One of the main hypothesis made here is that following a mtDNA muta-
tion is following a cell lineage. The presence of internal standard guarantees
that the mutation being followed is the same in each sample in which it is
found. The probability of two lineages carrying the same mutation is esti-
mated to be bellow 1/700 (Refinetti et al, under review). Other research
place the estimate much lower than that [4, 5]. Also, in the cases where two
markers are present, it is clear that they are strongly correlated, as figure
7 clearly shows. For example the leydig cell tumor, the histogram clearly
shows that the two markers have similar distributions. Also, looking at the
three dimensional reconstruction of them seem to indicate a strong similar-
ity. With areas carrying one mutation having the other one as well. The
probability of having 2 identical mutations occurring independently in two
separate cell lines would be even smaller than having just one.
Standard cancer development theory suggests that metastasis are seeded
by one, or few cells [16, 17, 18, 19, 20]. In the case of the breast tumor, two
metastasis carry the same mutation that is found in the primary tumor. If the
metastasis is necessarily seeded by a tumor derived-cell, it further reinforces
the hypothesis that the lineage marked by the mutation followed is indeed
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Figure 7: The absolute value of the difference between the mutant fraction of marker 1
and marker 2 is taken for each LCM sample of the leydig cell tumor. The histogram is
then made with the resulting values. As can be seen, the majority of the values cluster
around 0, which demonstrates a strong correlation between the two.
a tumor lineage. Furthermore, if it is true that, one, or very few cells were
at the origin of the metastasis, then the only tumor lineage present in the
metastasis, is the one marked by the mutation followed. This is true for both
metastasis. In the primary tumor, there is no guarantee that no other tumor
lineage exist. In the metastasis, however, there is reason to believe that the
only tumor lineage present is the one followed by the marker. What is being
observed in the three-dimensional reconstruction of the lineage, is therefore
the distribution of tumor cells in a metastasis. The areas without the marker
are not of tumor origin and have been recruited locally. Observing the pattern
shown in figure shows that the majority of the volume is not composed of
tumor derived cells. The cells derived from the tumor are scattered in small
clusters that are sometimes connected. It almost looks like a percolation
pattern i which the tumor cells would defuse through the tissue and then
make small local growth. The presence of these cells however, disrupt the
local tissue to assume a ”disorganised” morphology.
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5. Conclusion
Observation of three-dimensional reconstructions of tumor cell lineages
seem to suggest that the majority of the tumor volume is not composed of
tumor-derived cells. An observation that is further supported by the study
of metastasis. If a metastasis is started by a single cell, then the descendent
of this original cell must spread and diffuse (or percolate) through the host
tissue, and in doing so make condition it to adopt the observed abnormal
morphology. The spacial correlation between multiple markers strongly sup-
ports the credibility of the observations made as well as their consequence. As
does the coherence of the observed structures in three dimensions. Hallmarks
of cancer derived models of oncogenesis do not seem capable of explaining
the observations made here.
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11 Conclusion
It is possible to trace cell lineages in human tissues. A bold but accurate statement.
We were not the first to attempt studying lineage tracing in humans, and their tumors. As
mentioned in the Introduction (chapter 1), many researchers have attempted, with varying degrees
of success, to solve the problem. We are not even the first to use somatic mitochondrial mutations
as a marker. However, none of the previous approaches were completely successful in providing
a general applicable method.
The contribution of this thesis is a solution to the problem. Optimising CTCE to detect and
quantify mtDNA mutations in samples, has dropped the cost of the analysis, and improved the
throughput and the precision. We could then thus process a much higher number of samples
than anyone before, opening up the possibility of sampling a volume. Since cell lineages grow
in a volume, a three dimensional analysis is the only way to get an accurate observation of the
processes involved. Also, by taking a critical view on the histo-pathological analysis of cancers,
we deduced that selective sampling was the wrong way to proceed. Systematic sampling (grid of
identical small samples) of tumor slices showed no predictable pattern of mutations. This irregular
dispersion of mutations required an independent validation by extending the observations in
to the third dimension, the depth of the tissue. This in turn led to the visualisation of three
dimensional reconstruction of cell lineages. Possibly for the first time with good precision and
resolution in tumors. The final result is a tried and tested protocol for the analysis of cell lineages
in three dimension in human tissues. The observations clearly show that tumor lineages do not
grow in an organised fashion. It would seem from, the observations made that tumors grow by
infiltrating the local tissue. This infiltration causes the tissue to acquire its abnormal morphology.
The mechanisms and processes through which this happens are not fully understood. Another
possible explanation for the observed results, could be the seeding of metastasis by multiple
cells. It has been suggested, in a recent paper by Cheung et al. [100], that in the mouse model,
metastasis can be seeded by a cluster of cells from the primary tumor. If such was also the case
in humans, then the metastasis would contain a similar mix of lineages as the primary tumor, and
could therefore have only a small fraction of its volume filled by the lineage carrying the markers
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we followed. This explanation challenges the current understanding of how tumor metastasis
originate, while upholding the hypothesis that most of the tumor mass is composed of tumor
derived cells. It is clear that an unbiased sampling of tumor tissue in three dimensions, coupled
with a reliable analysis method, leads to surprising observations that cannot be explained by the
current oncogenesis paradigm.
11.1 Future
Among the first direct applications of the methods described in this thesis is the study of
mitochondrial mutations. Even if it is not lineage tracing per se, our CTCE based method
for the detection of mtDNA mutations could contribute significantly to the field. As has been
mentioned already, mitochondrial diseases are caused by deleterious mtDNA mutations reaching
high fraction in some tissues. Sequencing the mtDNA in the blood has no or little chance of
picking up the signal, because it is insufficiently sensitive (anything below 30% can be missed).
Our method, with 1% sensitivity, could pick it up and therefore place a definitive diagnosis on
many patients for which current methods cannot do it.
The ability to study cell lineages directly in human tissues offers many further possibilities.
There are a large number of unanswered question of human biology and medicine that could
be answered or elucidated by applying the techniques developed in this thesis. The various
observations relating to cancers we described in this thesis should already raise many questions
in the reader’s mind. What is a tumor really? Is it the bulk of the anomalous mass or the small
group of cells causing the surrounding tissue to behave as it does? Does this small group of
cells even exist? Maybe, more three dimensional reconstructions of tumor lineages can provide
answers. Our observations seem to indicate that the majority of the tumor mass, or its metastasis,
is not composed of tumor derived cells. And yet, visual observation of the sample, shows an
anomalous mass of cells. This points to a poorly understood interaction between tumor derived
cells and surrounding tissue.
A similar example could be wound healing. While cancer is an uncontrolled proliferation of
cells, wound healing is a controlled proliferation of cells, that still requires further investigation.
Mapping the lineages that compose a human scar would shed light onto the process through
which they are formed. The origin of the cells that form the scar could also lead to the better
understanding of why some wounds do not heal, a major problem in traumatology and surgery,
or inversely, why some wounds "over-heal" forming keloids. Understanding the relationship
between cell lineages in the human body would lead to understanding the process of growth
and differentiation that brings us, humans, from a single cell to a fully functional organism.
Repeating experiments similar to the ones we described, and increasing the number of samples
taken, would reconstruct the various lineages that compose human organs. In doing so, we would
better understand the differentiation paths taken by human stem cells during development.
132
Bibliography
[1] F J Miller. Precise determination of mitochondrial DNA copy number in human skeletal
and cardiac muscle by a PCR-based assay: lack of change of copy number with age.
Nucleic acids research, 31(11):61e–61, June 2003.
[2] Tariq G Fellous, Stuart A C McDonald, Julia Burkert, Adam Humphries, Shahriar Is-
lam, Nemantha M W De-Alwis, Lydia Gutierrez-Gonzalez, Paul J Tadrous, George Elia,
Hemant M Kocher, Satyajit Bhattacharya, Lisa Mears, Mona El-Bahrawy, Douglas M
Turnbull, Robert W Taylor, Laura C Greaves, Patrick F Chinnery, Christopher P Day,
Nicholas A Wright, and Malcolm R Alison. A Methodological Approach to Tracing Cell
Lineage in Human Epithelial Tissues. Stem cells (Dayton, Ohio), 27(6):1410–1420, June
2009.
[3] J L Elson, D C Samuels, D M Turnbull, and P F Chinnery. Random Intracellular Drift
Explains the Clonal Expansion of Mitochondrial DNA Mutations with Age. The American
Journal of Human Genetics, 68(3):802–806, March 2001.
[4] Robert W Taylor, Martin J Barron, Gillian M Borthwick, Amy Gospel, Patrick F Chinnery,
David C Samuels, Geoffrey A Taylor, Stefan M Plusa, Stephanie J Needham, Laura C
Greaves, Thomas B L Kirkwood, and Douglass M Turnbull. Mitochondrial DNAmutations
in human colonic crypt stem cells. Journal of Clinical Investigation, 112(9):1351–1360,
November 2003.
[5] H A Coller, K Khrapko, N D Bodyak, E Nekhaeva, P Herrero-Jimenez, and W G Thilly.
High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be
explained without selection. Nature Genetics, 28(2):147–150, June 2001.
[6] Viola Walther and Malcolm R Alison. Cell lineage tracing in human epithelial tissues
using mitochondrial DNA mutations as clonal markers. Wiley Interdisciplinary Reviews:
Developmental Biology, 5(1):103–117, August 2015.
[7] Walther Vogt. Gestaltungsanalyse am Amphibienkeim mit örtlicher Vitalfärbung. Vorwort
über Wege und Ziele. Wilhelm Roux’ Archiv für Entwicklungsmechanik der Organismen,
106(1-4):542–610, December 1925.
133
Bibliography
[8] Kai Kretzschmar and Fiona M Watt. Lineage Tracing. Cell, 148(1-2):33–45, January
2012.
[9] Margaret E Buckingham and Sigolène MMeilhac. Tracing Cells for Tracking Cell Lineage
and Clonal Behavior. Developmental Cell, 21(3):394–409, September 2011.
[10] E Zwilling. Induction of the Olfactory Placode by the Forebrain in Rana pipiens. Experi-
mental Biology and Medicine, 31(8):933–935, May 1934.
[11] ANDRZEJ K TARKOWSKI. Mouse Chimæras Developed from Fused Eggs. Nature,
190(4779):857–860, June 1961.
[12] B Mintz. Genetic Mosaicism in Adult Mice of Quadriparental Lineage. Science (New
York, N.Y.), 148(3674):1232–1233, May 1965.
[13] Cédric Blanpain and Elaine Fuchs. Epidermal Stem Cells of the Skin. Annual Review of
Cell and Developmental Biology, 22(1):339–373, November 2006.
[14] K Hatta, T Schilling, R BreMiller, and C Kimmel. Specification of jaw muscle identity in
zebrafish: correlation with engrailed-homeoprotein expression. Science (New York, N.Y.),
250(4982):802–805, November 1990.
[15] Andrew D Rhim, Emily T Mirek, Nicole M Aiello, Anirban Maitra, Jennifer M Bailey,
Florencia McAllister, Maximilian Reichert, Gregory L Beatty, Anil K Rustgi, Robert H
Vonderheide, Steven D Leach, and Ben Z Stanger. EMT and Dissemination Precede
Pancreatic Tumor Formation. Cell, 148(1-2):349–361, January 2012.
[16] Kristin Hope and Mickie Bhatia. Clonal interrogation of stem cells. Nature Methods,
8(4):S36–S40, April 2011.
[17] P C Orban, D Chui, and J D Marth. Tissue- and site-specific DNA recombination in
transgenic mice. Proceedings of the National Academy of Sciences, 89(15):6861–6865,
August 1992.
[18] Daniel Metzger and Pierre Chambon. Site- and Time-Specific Gene Targeting in the
Mouse. Methods (San Diego, Calif.), 24(1):71–80, May 2001.
[19] Alexandra Van Keymeulen and Cédric Blanpain. Tracing epithelial stem cells during
development, homeostasis, and repair. The Journal of Cell Biology, 197(5):575–584, May
2012.
[20] P J Fialkow. Clonal Origin of Human Tumors. Annual Review of Medicine, 30(1):135–143,
February 1979.
[21] R G Wiggans, P V Woolley, Tarilyn Smythe, D Hoth, J S Macdonald, Linda Green, and
P S Schein. Phase-II trial of tamoxifen in advanced breast cancer. Cancer Chemotherapy
and Pharmacology, 3(1), August 1979.
134
Bibliography
[22] E P Benditt and J M Benditt. Evidence for a Monoclonal Origin of Human Atherosclerotic
Plaques. Proceedings of the National Academy of Sciences, 70(6):1753–1756, June 1973.
[23] A Alonso. Real-time PCR designs to estimate nuclear and mitochondrial DNA copy
number in forensic and ancient DNA studies. Forensic science international, 139(2-3):141–
149, January 2004.
[24] Helen A L Tuppen, Emma L Blakely, Douglass M Turnbull, and Robert W Taylor. Mi-
tochondrial DNA mutations and human disease. Biochimica et Biophysica Acta (BBA) -
Bioenergetics, 1797(2):113–128, February 2010.
[25] Robert N Lightowlers, Patrick F Chinnery, Douglass M Turnbull, and Neil Howell. Mam-
malian mitochondrial genetics: heredity, heteroplasmy and disease. Trends in Genetics,
13(11):450–455, November 1997.
[26] Brigitte Pakendorf and Mark Stoneking. MITOCHONDRIAL DNA AND HUMAN EVO-
LUTION. Annual Review of Genomics and Human Genetics, 6(1):165–183, September
2005.
[27] Laura C Greaves and Doug M Turnbull. Mitochondrial DNA mutations and ageing.
Biochimica et Biophysica Acta (BBA) - General Subjects, 1790(10):1015–1020, October
2009.
[28] J Shoffner. Oxidative Phosphorylation Diseases and Mitochondrial DNA Mutations:
Diagnosis and Treatment. Annual Review of Nutrition, 14(1):535–568, January 1994.
[29] Manuel B Graeber and Ulrich Müller. Recent developments in the molecular genetics of
mitochondrial disorders. Journal of the Neurological Sciences, 153(2):251–263, January
1998.
[30] Salvatore DiMauro and Eric A Schon. Mitochondrial DNA mutations in human disease.
American journal of medical genetics, 106(1):18–26, 2001.
[31] Laura C Greaves, Amy K Reeve, Robert W Taylor, and Doug M Turnbull. Mitochondrial
DNA and disease. The Journal of pathology, 226(2):274–286, November 2011.
[32] Chan Bae Park and Nils-Göran Larsson. Mitochondrial DNA mutations in disease and
aging. The Journal of Cell Biology, 193(5):809–818, May 2011.
[33] M Zeviani. Mitochondrial disorders. Brain, 127(10):2153–2172, September 2004.
[34] R G Boles. Quantification of Mitochondrial DNA Heteroplasmy by Temporal Temperature
Gradient Gel Electrophoresis. Clinical chemistry, 49(1):198–200, January 2003.
[35] Michael D Brown and Douglas C Wallace. Molecular basis of mitochondrial DNA disease.
Journal of Bioenergetics and Biomembranes, 26(3):273–289, June 1994.
135
Bibliography
[36] L L Cavalli-Sforza and E Minch. Paleolithic and Neolithic Lineages in the European
Mitochondrial Gene Pool. The American Journal of Human Genetics, 61(1):247–251, July
1997.
[37] I B Colson, M B Richards, J F Bailey, B C Sykes, and R E M Hedges. DNA Analysis of
Seven Human Skeletons Excavated from the Terp of Wijnaldum. Journal of Archaeological
Science, 24(10):911–917, October 1997.
[38] Martin Richards, Vincent Macaulay, Eileen Hickey, Emilce Vega, Bryan Sykes, Valentina
Guida, Chiara Rengo, Daniele Sellitto, Fulvio Cruciani, Toomas Kivisild, Richard Villems,
Mark Thomas, Serge Rychkov, Oksana Rychkov, Yuri Rychkov, Mukaddes Gölge, Dimitar
Dimitrov, Emmeline Hill, Dan Bradley, Valentino Romano, Francesco Calì, Giuseppe
Vona, Andrew Demaine, Surinder Papiha, Costas Triantaphyllidis, Gheorghe Stefanescu,
Jirˇi Hatina, Michele Belledi, Anna Di Rienzo, Andrea Novelletto, Ariella Oppenheim,
Søren Nørby, Nadia Al-Zaheri, Silvana Santachiara-Benerecetti, Rosaria Scozzari, Antonio
Torroni, and Hans-Jürgen Bandelt. Tracing European Founder Lineages in the Near Eastern
mtDNA Pool. The American Journal of Human Genetics, 67(5):1251–1276, November
2000.
[39] B M Henn, C R Gignoux, M W Feldman, and J L Mountain. Characterizing the Time
Dependency of Human Mitochondrial DNA Mutation Rate Estimates. Molecular Biology
and Evolution, 26(1):217–230, October 2008.
[40] Ron Lundstrom, Simon Tavaré, and R H Ward. Modeling the evolution of the human
mitochondrial genome. Mathematical biosciences, 112(2):319–335, December 1992.
[41] Christine Reder. Acta Biotheoretica, 49(4):235–245, 2001.
[42] Corinna Herrnstadt, Gwen Preston, Richard Andrews, Patrick Chinnery, Robert N
Lightowlers, Douglass M Turnbull, Iwona Kubacka, and Neil Howell. A high frequency
of mtDNA polymorphisms in HeLa cell sublines. Mutation Research/Fundamental and
Molecular Mechanisms of Mutagenesis, 501(1-2):19–28, April 2002.
[43] K Khrapko, H A Coller, P C André, X C Li, J S Hanekamp, and W G Thilly. Mitochondrial
mutational spectra in human cells and tissues. Proceedings of the National Academy of
Sciences, 94(25):13798–13803, December 1997.
[44] John K Blackwood, Stuart C Williamson, Laura C Greaves, Laura Wilson, Anasta-
sia C Rigas, Raveen Sandher, Robert S Pickard, Craig N Robson, Douglass M Turnbull,
Robert W Taylor, and Rakesh Heer. In situ lineage tracking of human prostatic epithelial
stem cell fate reveals a common clonal origin for basal and luminal cells. The Journal of
pathology, 225(2):181–188, September 2011.
[45] Patrick F Chinnery, David C Samuels, Joanna Elson, and Douglass M Turnbull. Accumu-
lation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is
there a common mechanism? The Lancet, 360(9342):1323–1325, October 2002.
136
Bibliography
[46] D A Cottrell, E L Blakely, M A Johnson, P G Ince, G M Borthwick, and D M Turnbull.
Cytochrome c oxidase deficient cells accumulate in the hippocampus and choroid plexus
with age. Neurobiology of aging, 22(2):265–272, March 2001.
[47] Kenji Takahashi, Takashi Kohno, Shingo Matsumoto, Yukihiro Nakanishi, Yasuhito Arai,
Toshiyoshi Fujiwara, Noriaki Tanaka, and Jun Yokota. Clonality and heterogeneity of
pulmonary blastoma from the viewpoint of genetic alterations: A case report. Lung Cancer,
57(1):103–108, July 2007.
[48] Kornelia Polyak. Breast cancer: origins and evolution. Journal of Clinical Investigation,
117(11):3155–3163, November 2007.
[49] Wennuan Liu, Sari Laitinen, Sofia Khan, Mauno Vihinen, Jeanne Kowalski, Guoqiang Yu,
Li Chen, Charles M Ewing, Mario A Eisenberger, Michael A Carducci, William G Nelson,
Srinivasan Yegnasubramanian, Jun Luo, Yue Wang, Jianfeng Xu, William B Isaacs, Tapio
Visakorpi, and G Steven Bova. Copy number analysis indicates monoclonal origin of
lethal metastatic prostate cancer. Nature medicine, 15(5):559–565, April 2009.
[50] Douglas Hanahan and Robert A Weinberg. Hallmarks of Cancer: The Next Generation.
Cell, 144(5):646–674, March 2011.
[51] Nicholas E Navin and James Hicks. Tracing the tumor lineage. Molecular oncology,
4(3):267–283, May 2010.
[52] P Nowell. The clonal evolution of tumor cell populations. Science (New York, N.Y.),
194(4260):23–28, October 1976.
[53] P ARMITAGE and R DOLL. The Age Distribution of Cancer and a Multi-stage Theory of
Carcinogenesis. British Journal of Cancer, 8(1):1–12, March 1954.
[54] P ARMITAGE and R DOLL. A Two-stage Theory of Carcinogenesis in Relation to the
Age Distribution of Human Cancer. British Journal of Cancer, 11(2):161–169, June 1957.
[55] Philip J Fialkow. The Origin and Development of Human Tumors Studied with Cell
Markers. New England Journal of Medicine, 291(1):26–35, July 1974.
[56] Philip J Fialkow, George M Martin, George Klein, Peter Clifford, and Surjit Singh.
Evidence for a clonal origin of head and neck tumors. International Journal of Cancer,
9(1):133–142, January 1972.
[57] Douglas Hanahan and Robert A Weinberg. The Hallmarks of Cancer. Cell, 100(1):57–70,
January 2000.
[58] Brett Hall, Jennifer Dembinski, A Sasser, Matus Studeny, Michael Andreeff, and Frank
Marini. Mesenchymal Stem Cells in Cancer: Tumor-Associated Fibroblasts and Cell-
Based Delivery Vehicles. International Journal of Hematology, 86(1):8–16, July 2007.
137
Bibliography
[59] Raghu Kalluri and Michael Zeisberg. Fibroblasts in cancer. Nat Rev Cancer, 6(5):392–401,
March 2006.
[60] So Yeon Park, Mithat Gönen, Hee Jung Kim, Franziska Michor, and Kornelia Polyak.
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an
invasive phenotype. Journal of Clinical Investigation, 120(2):636–644, February 2010.
[61] Gregory Driessens, Benjamin Beck, Amélie Caauwe, Benjamin D Simons, and Cédric
Blanpain. Defining the mode of tumour growth by clonal analysis. Nature, 488(7412):527–
530, August 2012.
[62] Stewart Sell. Stem cell origin of cancer and differentiation therapy. Critical Reviews in
Oncology/Hematology, 51(1):1–28, July 2004.
[63] Thea D Tlsty. Stromal cells can contribute oncogenic signals. Seminars in cancer biology,
11(2):97–104, April 2001.
[64] Gerald R Cunha, Simon W Hayward, Y ZWang, and William A Ricke. Role of the stromal
microenvironment in carcinogenesis of the prostate. International Journal of Cancer,
107(1):1–10, August 2003.
[65] Thea D Tlsty and Patrick W Hein. Know thy neighbor: stromal cells can contribute
oncogenic signals. Current Opinion in Genetics & Development, 11(1):54–59, February
2001.
[66] Kornelia Polyak, Izhak Haviv, and Ian G Campbell. Co-evolution of tumor cells and their
microenvironment. Trends in Genetics, 25(1):30–38, January 2009.
[67] Alexander B Mohseny and Pancras C W Hogendoorn. Concise Review: Mesenchymal
Tumors: When Stem Cells Go Mad. Stem cells (Dayton, Ohio), 29(3):397–403, March
2011.
[68] Nadine T Gaisa, Trevor A Graham, Stuart Ac McDonald, Richard Poulsom, Axel Hei-
denreich, Gerhard Jakse, Ruth Knuechel, and Nicholas A Wright. Clonal architecture of
human prostatic epithelium in benign and malignant conditions. The Journal of pathology,
225(2):172–180, August 2011.
[69] Jason C Mills and Ramesh A Shivdasani. Gastric Epithelial Stem Cells. Gastroenterology,
140(2):412–424, February 2011.
[70] Yong-Gang Yao, Richard W Childs, Sachiko Kajigaya, J Philip McCoy Jr., and Neal S
Young. Mitochondrial DNA Sequence Heterogeneity of Single CD34 +Cells After
Nonmyeloablative Allogeneic Stem Cell Transplantation. Stem cells (Dayton, Ohio),
25(10):2670–2676, October 2007.
[71] Ronald D Barr and Philip J Fialkow. Clonal Origin of Chronic Myelocytic Leukemia. New
England Journal of Medicine, 289(6):307–309, August 1973.
138
Bibliography
[72] Philip J Fialkow, Robert J Jacobson, and Thalia Papayannopoulou. Chronic myelocytic
leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and
monocyte/macrophage. The American Journal of Medicine, 63(1):125–130, July 1977.
[73] P J Fialkow, S M Gartler, and A Yoshida. Clonal origin of chronic myelocytic leukemia in
man. Proceedings of the National Academy of Sciences, 58(4):1468–1471, October 1967.
[74] G L Chen and J T Prchal. X-linked clonality testing: interpretation and limitations. Blood,
110(5):1411–1419, September 2007.
[75] Maho Shibata and Michael M Shen. The roots of cancer: Stem cells and the basis for
tumor heterogeneity. BioEssays, 35(3):253–260, October 2012.
[76] B Linnartz. Comprehensive Scanning of Somatic Mitochondrial DNA Alterations in Acute
Leukemia Developing from Myelodysplastic Syndromes. Cancer research, 64(6):1966–
1971, March 2004.
[77] Douglas C Wallace. Mitochondria and cancer. Nat Rev Cancer, 12(10):685–698, Septem-
ber 2012.
[78] Michael W Klymkowsky and Pierre Savagner. Epithelial-Mesenchymal Transition. The
American Journal of Pathology, 174(5):1588–1593, May 2009.
[79] Bert Vogelstein, Kornelia Polyak, Yunbo Li, Hong Zhu, Christoph Lengauer, James K V
Willson, Sanford DMarkowitz, Michael A Trush, and KennethWKinzler. Nature Genetics,
20(3):291–293, November 1998.
[80] Pen-Hui Yin, Cheng-Chung Wu, Jin-Ching Lin, Chin-Wen Chi, Yau-Huei Wei, and Hsin-
Chen Lee. Somatic mutations of mitochondrial genome in hepatocellular carcinoma.
Mitochondrion, 10(2):174–182, March 2010.
[81] Aekyong Kim. Mitochondrial DNA Somatic Mutation in Cancer. Toxicological Research,
30(4):235–242, December 2014.
[82] Amanda Ramos, Cristina Santos, Luis Alvarez, Ramon Nogués, and Maria Pilar Aluja.
Human mitochondrial DNA complete amplification and sequencing: A new validated
primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification.
Electrophoresis, 30(9):1587–1593, May 2009.
[83] P FIALKOW. Clonal origin of human tumors. Biochimica et Biophysica Acta (BBA) -
Reviews on Cancer, 458(3):283–321, October 1976.
[84] Philip J Fialkow, A Michael Denman, Robert J Jacobson, and Mark N Lowenthal. Chronic
Myelocytic Leukemia. Journal of Clinical Investigation, 62(4):815–823, October 1978.
[85] J M Friedman and Philip I Fialkow. Cell Marker Studies of Human Tumorigenesis.
Immunological Reviews, 28(1):17–33, January 1976.
139
Bibliography
[86] P FIALKOW. CLONAL ORIGIN FOR INDIVIDUAL BURKTTT TUMOURS. The
Lancet, 295(7643):384–386, February 1970.
[87] J M Friedman and Philip I Fialkow. Cell Marker Studies of Human Tumorigenesis.
Immunological Reviews, 28(1):17–33, January 1976.
[88] Masaharu KOBAYASHI. Seals for Vacuums. SHINKU, 10(11):388–394, 1967.
[89] Khaled K Abu-Amero, Ali S Alzahrani, Minjing Zou, and Yufei Shi. High frequency
of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I
respiratory defect in thyroid cancer cell lines. Oncogene, 24(8):1455–1460, December
2004.
[90] J J Barcia. The Giemsa Stain: Its History and Applications. International Journal of
Surgical Pathology, 15(3):292–296, July 2007.
[91] Célia H Tengan and Carlos T Moraes. Detection and Analysis of Mitochondrial DNA
Deletions by Whole Genome PCR. Biochemical and Molecular Medicine, 58(1):130–134,
June 1996.
[92] K Khrapko, N Bodyak, W G Thilly, N J van Orsouw, X Zhang, H A Coller, T T Perls,
M Upton, J Vijg, and J Y Wei. Cell-by-cell scanning of whole mitochondrial genomes
in aged human heart reveals a significant fraction of myocytes with clonally expanded
deletions. Nucleic acids research, 27(11):2434–2441, January 1999.
[93] Paulo Refinetti, Stephan Morgenthaler, and Per O Ekstrom. Cycling temperature capillary
electrophoresis: A quantitative, fast and inexpensive method to detect mutations in mixed
populations of human mitochondrial DNA. Mitochondrion, 29:65–74, July 2016.
[94] Christian Arstad, Paulo Refinetti, David Warren, Karl-Erik Giercksky, and Per Olaf
Ekstrøm. Scanning the mitochondrial genome for mutations by cycling temperature
capillary electrophoresis. Mitochondrial DNA Part A, pages 1–12, October 2016.
[95] Annette Torgunrud Kristensen, Johan N Wiig, Stein G Larsen, Karl-Erik Giercksky, and
Per O Ekstrom. Molecular detection (k-ras) of exfoliated tumour cells in the pelvis is a
prognostic factor after resection of rectal cancer? BMC Cancer, 8(1):224, July 2008.
[96] Christian Arstad, Paulo Refinetti, Annette Torgunrud Kristensen, Karl-Erik Giercksky,
and Per Olaf Ekstrøm. Is detection of intraperitoneal exfoliated tumor cells after surgical
resection of rectal cancer a prognostic factor of survival? BMC Cancer, 17(1):406, June
2017.
[97] P H Yin, H C Lee, G Y Chau, Y T Wu, S H Li, W Y Lui, Y H Wei, T Y Liu, and C W Chi.
Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular
carcinoma. British Journal of Cancer, May 2004.
140
Bibliography
[98] Antonio Salas, Yong-Gang Yao, Vincent Macaulay, Ana Vega, Ángel Carracedo, and Hans-
Jürgen Bandelt. A Critical Reassessment of the Role of Mitochondria in Tumorigenesis.
PLoS Medicine, 2(11):e296, October 2005.
[99] Paulo Refinetti, Christian Arstad, William G Thilly, Stephan Morgenthaler, and Per Olaf
Ekstrøm. Mapping mitochondrial heteroplasmy in a Leydig tumor by laser capture micro-
dissection and cycling temperature capillary electrophoresis. BMC clinical pathology,
17(1):6, 2017.
[100] Kevin J Cheung and Andrew J Ewald. A collective route to metastasis: Seeding by tumor
cell clusters. Science (New York, N.Y.), 352(6282):167–169, April 2016.
141

Paulo Reﬁnetti
Proﬁle
Think, ask questions and question the answers, is my practice. Validate the Way, choose 
the goal, perfect the method, is my philosophy. Develop reasoning, add value and solve 
problems, is my Way forward. 
Education
SWISS FEDERAL INSTITUTE OF TECHNOLOGY (EPFL), LAUSANNE 
SWITZERLAND— 2011-NOW
PhD in Applied Statistics, in collaboration with MIT and Norwegian Radium Hospital. 
Most knowledge of developmental biology today, comes from animal models. Although 
instructive, they are insufﬁcient to understand pathological processes such as cancer, 
failed wound healing, atherosclerosis, etc. 
My goal is to allow the study of developmental biology in humans. Combining 
Mathematical, Engineering and Biological techniques, we develop the methods to trace 
cell lineages directly in human tissues. With my supervisors, we have developed the 
biological, mechanical and software tools to identify cell lineages in human tumors, and 
follow them in 3D both in the primary tumors and in the metastasis. The method can now 
be expanded for both diagnostic purposes and the study of organogenesis in humans. 
Supervision of Prof. S. Morgenthaler, Chair of applied statistics, EPFL. Co-supervision of 
Prof W.G. Thilly , Laboratory of epidemiology and stem cell biology, MIT. Co-supervision 
of Dr. Per Ekstrom, Department of Cancer Research, Radiumhospital, Oslo. 
Courses followed in Algorithm Design, Statistical Mechanics and Mathematical Statistics. 
Courses taught in Probability, Statistics and Analytical Mechanics. 
SWISS FEDERAL INSTITUTE OF TECHNOLOGY (EPFL), LAUSANNE, 
SWITZERLAND — 2009-2011
Masters in Bio-Engineering from the School of Life Sciences with chosen additional 
options in Biomechanics, Statistical Physics, Biophysics, Image Processing, Signal 
Processing
Master thesis at MIT in Epidemiology, supervised by Prof. William G. Thilly and Prof. 
Stephan Morgenthaler
SWISS FEDERAL INSTITUTE OF TECHNOLOGY (EPFL), LAUSANNE, 
SWITZERLAND — 2006-2009
Bachelor in Engineering from the School of Life Sciences
Bachelor project on Fractal geometry and Cancer supervised by Prof. Stephan 
Morgenthaler
SCUOLA EUROPEA VARESE, VARESE ITALY — 2002-2006
European Baccalaureat, 1st  language French, 2nd language English with chosen additional 
options in Mathematics, Physics, Chemistry, Economics and Philosophy
Finished with best Baccalaureat of the class of 2006 with a GPA of 88/100
BIRTH 
Born 26/10/1988
in Paris, France
NATIONALITY
Italian, Brazilian
CIVIL STATUS
Single, no children
PERMANENT ADDRESS
Via Rossini 2
Carnago (VA), 21040
Italy
PHONE
+41 76 222 07 95
FAX
+39 0331 98 53 77
EMAIL
pauloref@mit.edu
paulo.reﬁnetti@gmail.com
paulo.reﬁnetti@epﬂ.ch
Experience
OSLO RADIUMHOSPITAL, OSLO, NORWAY — 2011-ONGOING
Designing methods for lineage tracing in humans. Improving the methods of mutational 
spectrometry to follow mitochondrial DNA in human tissues.  
MASSACHUSETTS INSTITUTE OF TECHNOLOGY, BOSTON, USA — 2010-2011
Visiting student in the Laboratory of Epidemiology supervised by Prof. William G. Thilly
Master thesis in Epidemiology.
GERMAN CANCER RESEARCH CENTER (DKFZ), HEIDELBERG, GERMANY —2011
Working on the Swedish Family cancer database. The goal of the stay was to test the 
hypothesis of a familial risk for cancer. This included designing and implementing speciﬁc 
statistical tests.
GLOBALFOOD, SAO PAULO, BRAZIL — 2004
Internship in Laboratory practices
Assistance in product development in a leading food additives company
Languages
SPOKEN WRITTEN
French Native Language Native Language
Portuguese Native Language Native Language
Italian Native Language Native Language
English Language of Studies Language of Studies
German Good Basic Working Knowledge
Japanese Conversational Basic Knowledge
Spanish Basic Working Knowledge Basic Working Knowledge
Scientiﬁc Skills
MATHEMATICS
Mathematical Statistics, Applied Statistics, Analysis, Numerical Analysis
PROGRAMMING
Algorithm Design, Software Architecture, Database Management Systems
BIOLOGY
Quantitative Biology, Epidemiology, Molecular Biology, Genetics, Histology, Cell Culture
ENGINEERING
Image Processing, Mechanics, Material Sciences, Thermodynamics
PROGRAMMING LANGUAGES
C++, Objective C , perl, MATLAB, R, Java, HTML, CSS, Java-script, bash, SAS, python
OFFICE SOFTWARE
LaTex, Microsoft Ofﬁce, iWork, NeoOfﬁce, OpenOfﬁce
Page 2
BIRTH 
Born 26/10/1988
in Paris, France
NATIONALITY
Italian, Brazilian
CIVIL STATUS
Single, no children
PERMANENT ADDRESS
Via Rossini 2
Carnago (VA), 21040
Italy
PHONE
+41 76 222 07 95
FAX
+39 0331 98 53 77
EMAIL
pauloref@mit.edu
paulo.reﬁnetti@gmail.com
paulo.reﬁnetti@epﬂ.ch
Special Responsibilities
STUDENT COUNCIL MEMBER, HIGH SCHOOL
Member of the student council at the Scuola Europea di Varese
Responsible for communicating and representing the interests of the French speaking 
students in front of the principles
HOSTING CONFERENCES FEATURING HIGH PROFILE INDUSTRIALS, EPFL
Member of SV-Industry, an association responsible for inviting leading professionals in the 
ﬁeld of Life Sciences to share experiences with students 
Special Interests
SPORTS
Ski, Golf (hcp 6.5), Water-ski, Kendo, Judo, Diving (Rescue Diver), Dancing
HOBBIES
Cooking, Go (5 kyu), History, Traveling, Wine tasting, Ancient arts, Playing piano
Awards
PRIX SSV DU MEILLEUR PROJET DE MASTERS EN BIOSCIENCES 
COMPUTATIONELLES
Prize for best master project in computational biosciences. Discerned by the School of Life 
Sciences, EPFL. 
BEST POSTER PRESENTATION AT KYOTO BREAST CANCER CONSENSUS 
CONFERENCE 2016
Prize for best poster presentation at the Kyoto breast cancer consensus conference, in 
March 2016. Hosted by The Lancet. 
Page 3
BIRTH 
Born 26/10/1988
in Paris, France
NATIONALITY
Italian, Brazilian
CIVIL STATUS
Single, no children
PERMANENT ADDRESS
Via Rossini 2
Carnago (VA), 21040
Italy
PHONE
+41 76 222 07 95
FAX
+39 0331 98 53 77
EMAIL
pauloref@mit.edu
paulo.reﬁnetti@gmail.com
paulo.reﬁnetti@epﬂ.ch
Publications
PEER-REVIEW JOURNALS
Reﬁnetti, P., Morgenthaler, S., & Ekstrom, P. O. (2016). Cycling temperature capillary 
electrophoresis: A quantitative, fast and inexpensive method to detect mutations in mixed 
populations of human mitochondrial DNA. Mitochondrion, 29, 65–74. http://doi.org/
10.1016/j.mito.2016.04.006
Arstad, C., Reﬁnetti, P., Warren, D., Giercksky, K.-E., & Ekstrøm, P. O. (2016). Scanning the 
mitochondrial genome for mutations by cycling temperature capillary electrophoresis. 
Mitochondrial DNA. Part a, DNA Mapping, Sequencing, and Analysis, 1–12. 
http://doi.org/10.1080/24701394.2016.1233532
Kini, L. G., Herrero-Jimenez, P., Kamath, T., Sanghvi, J., Gutierrez, E., Hensle, D., et al. 
(2013). Mutator/Hypermutable fetal/juvenile metakaryotic stem cells and human 
colorectal carcinogenesis. Frontiers in Oncology, 3, 267. http://doi.org/10.3389/fonc.
2013.00267
Reﬁnetti, P., Morgenthaler, S., Thilly, W.G. and Ekstrom, P.O., 2014. Mapping cell lineage 
growth in human tumors using somatic mitochondrial mutations. International Journal Of 
Molecular Medicine, 34, pp.S17-S17.
CONFERENCE PAPERS
Paulo Reﬁnetti, Stephan Morgenthaler, Per O. Ekstrom. 3D mapping of somatic 
mitochondrial mutations in human tumor. A matter of Life and Death, Mechanisms 
and Relevance of Cell Death for Cancer Biology and Treatment. EACR conference 
series 2016
Paulo Reﬁnetti, Stephan Morgenthaler, Per O. Ekstrom . 3D cell lineage tracing from 
tumor to metastasis . 8th Asian Oncology Summit held alongside the 12th Annual 
Conference of the OOTR and Kyoto Breast Cancer Consensus Conference 2016.
Paulo Reﬁnetti, Stephan Morgenthaler, Per O. Ekstrom. Cycling temperature capillary 
electrophoresis: Adopting an orphan method for 3 dimensional lineage tracing in human 
tumors. Global Summit on Rare Diseases & Orphan Drugs, 2016. 
Page 4
BIRTH 
Born 26/10/1988
in Paris, France
NATIONALITY
Italian, Brazilian
CIVIL STATUS
Single, no children
PERMANENT ADDRESS
Via Rossini 2
Carnago (VA), 21040
Italy
PHONE
+41 76 222 07 95
FAX
+39 0331 98 53 77
EMAIL
pauloref@mit.edu
paulo.reﬁnetti@gmail.com
paulo.reﬁnetti@epﬂ.ch

